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Specific and sensitive recognition of foreign agents is a critical attribute of the 
overall effective immune system required for maintaining host protection against 
challenge from pathogenic cells. In the humoral arm of the immune system, this 
recognition attribute is carried out by the cell surface bound immunoglobulin-like 
receptors (BCR) and its soluble forms i.e. antibodies. Over several million years of 
evolution, the immune system has adopted several strategies for diversifying the antibody 
sequence and thus its ability to recognize an astronomical variety of molecules through 
the combinatorial assembly of a small number of DNA segments or genes. Among these 
immunoglobulin gene diversification strategies, antibody somatic VDJ recombination 
and junctional diversity are the fundamental mechanisms in generating a broad range of 
antibody specificities. Understanding how the genetic diversity of antibodies is affected 
in health and disease is critical for a wide range of medical applications, from vaccine 
evaluation to diagnostics and therapeutics discovery. Because of the very large number of 
distinct antibodies encoded by the more than 10 billion B cells in humans, it is essential 
to use high throughput next generation sequencing technologies in order to obtain an 
adequate sampling of the sequences and relative abundance of different antibodies 
expressed by B cells in clinical samples. The process requires rigorous methods for first, 
 vii 
experimentally determining the sequences of antibodies in a sample and for second, 
informatics tools designed for distilling this information for practical purposes. This 
dissertation describes a variety of experimental approaches and informatics tools 
developed for the determination and mining of the antibody repertoire. The information 
from this work has not only led to major conclusions in efficient antibody discovery but 
also regarding the nature of the antibody repertoire in healthy individuals, in rabbits, in 
volunteers following vaccination, and in HIV-1 patients. 
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Chapter 1: Introduction 
The well-being of a multi-cellular organism is dependent upon the efficacy of its 
protection strategies against foreign pathogens and pathological agents. Such protection 
in higher-order organisms is orchestrated by the innate and the adaptive immune 
responses. Collectively regarded as the immune system, these protection strategies are 
undeniably one of the most complex molecular and cellular networks in maintaining 
health. Many medical interventions and remedies entail the restoration or the exploitation 
of the various facets of the immune system to sustain health [1], [2]. The immune system 
can be broadly categorized into four unique functionalities: immunological recognition, 
immune effector functions, immune regulation, and immunological memory [1]. This 
dissertation is focused on the use of next generation DNA sequencing technology to 
survey the antibody repertoire pertaining to immunological recognition. First, however, a 
brief overview of the major components of the immune system and their respective 
functions are included herein to help illustrate the significance of the studies presented in 
this dissertation.  
 
THERAPEUTIC SIGNIFICANCE OF ANTIBODY REPERTOIRE STUDIES AND ANTIBODY 
DISCOVERY TECHNOLOGIES 
Manipulation of the immune system has long historical records and has fortified 
its place in medicine. Pioneered by Edward Jenner in the late 18th century, smallpox 
vaccination was the first vaccination that made a significant impact on the greatest 
medical woe of that era and eventually led to the eradication of the smallpox virus [2]. A 
century later, Emil Adolf von Behring and Paul Ehrlich made a medical breakthrough 
using antiserum therapy to combat diphtheria and tetanus. As a result, both scientists 
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were awarded with Nobel Prize in the early 20th century [2]. In both medical 
breakthroughs, antibodies played an irreplaceable role in the success of the therapies 
(overview of antibody is provided in the following section). Throughout the ages, there 
have been unwavering efforts to develop monoclonal antibodies (mAbs) for the treatment 
of diseases such as cancers (leukemia, lymphoma, breast cancer, etc.), autoimmune 
diseases (Systemic Lupus Erythematosus, Rheumatoid Arthritis, etc.), viral infections 
(Influenza, HIV, etc.), Graft-versus-host diseases, and allergies. In fact, the significance 
of mAbs in tackling medical needs can be reflected in its expanding global market share. 
Monoclonal antibodies have maintained their leading role in the biotechnology industry 
for the past few decades [3], [4]. And, the worldwide market for mAbs has grown from 
$6.9 billion in 2003 to about $24.8 billion in 2007 with an annual growth rate estimated 
at about 38% [3]. In the US alone, mAbs have reached about $24.6 billion in sales 
reaping approximately 18.3% growth over the prior year [4]. The 2012 sales in mAbs is 
equivalent to the sales made by the next two classes of drugs combined, namely 
hormones and growth factors. 
 
One of the reasons for the huge success of mAbs is the proven clinical efficacy 
highlighted by several commercial blockbuster mAbs such as Rituxan (rituximab), 
Humira (adalimumab), and Avastin (bevacizumab). With advancement in the humanizing 
antibodies and Fc glycoengineering, the side-effects of mAbs can be further minimized. 
Another reason mAbs are the “weapon” of choice for combating diseases is their high 
specificity, hence, reducing undesired off-targets effects. For example, the trait of high 
specificity is also capitalized on the targeted delivery of chemotherapy. Antibody-drug 
conjugates such as Kadcyla (trastuzumab emtansine) is Herceptin (trastuzumab) 
conjugated to cytotoxic agent mertansine (DM1) where it can be used to specifically 
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deliver the toxic agent to HER2+ breast cancer cells [5]. As importantly, the Fc fragment 
(constant region of the antibody) can modulate different immune effector functions 
(discussed in subsequent section). And, this particular trait has also been capitalized to 
improve existing mAbs; for example, Gazyva (obinutuzumab) is the first mAbs approved 
by the Food and Drug Administration (FDA) through breakthrough therapy designation 
(BTD) and it is also the first approved glycoengineered and Fc-engineered antibody. The 
glycoengineered Fc portion of Gazyva has been shown to improve direct killing via 
antibody-dependent cell-mediated cytotoxicity (ADCC) by enhancing the engagement of 
the Fc receptors on effector cells [6]. Because antibodies possess such therapeutic 
benefits, gaining knowledge on the antibody repertoire during immune responses can 
help with the discovery of therapeutically relevant antibodies. Since antibody plays such 
a central role in this dissertation, it is important to review this molecule in more details in 
the next section. 
 
ANTIBODIES ARE IMPORTANT PROTEIN MEDIATORS OF EFFECTOR FUNCTIONS AND 
IMMUNOLOGICAL RECOGNITION 
The antibody molecule in its native form is a homodimer made of two 
heterodimeric units. Each heterodimeric unit consists of two different polypeptide chains: 
a light chain (shown in red and yellow regions in Figure 1) and a heavy chain (shown in 
blue and green regions in Figure 1) [7], [8]. Two identical heavy-light chain 
heterodimeric units are then bound together by disulfide bonds to form the full-length 
antibody. Considering just the heavy-light chain heterodimeric unit, the light chain 
contains two domains: a variable (VL) region (red regions in Figure 1) and a constant 
(CL) region (yellow regions in Figure 1). The heavy chain of an IgG isotype antibody 
contains four domains: a variable (VH) region (blue regions in Figure 1) and three 
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constant (CH1, CH2, CH3) regions (green regions in Figure 1). The different isotypes 
represent the different conserved constant region sequences encoded in the host’s genome 




Figure 1: Schematic diagram of a full-length Immunoglobulin G (IgG) 
 
Structurally, each region adopts a general tertiary organization folded by 
antiparallel β-sheets stabilized through disulfide bonds and a hydrophobic core. In terms 
of the modular domains, the arm consisting of the VL, VH, CL, and CH1 regions are 
known as the Fab fragment (50 kDa) and the stem consisting of the dimeric form of CH2 
and CH3 regions are known as the Fc fragment (50 kDa). Hence, a full-length IgG 
antibody molecule is about 150 kDa. The different fragments can be generated using the 




As mentioned before, the human genome encodes different conserved groups of 
antibody constant region sequences known as isotypes, each of which are associated with 
different immune response functions. In most mammals, there are generally five different 
isotypes: IgM, IgG, IgA, IgE, and IgD. The antibody most commonly found in the serum 
is IgG and its structure is one of the first to have been extensively studied and thus often 
referenced as the example of an antibody. The various antibody isotypes differ in their 
sequence composition in the CH1-CH3 domains. Additionally, IgM and IgE isotype 
antibodies contain an extra CH4 domain. Apart from the sequence composition of the Fc 
fragments, IgM and IgA form multimers as depicted in Figure 2. 
 
 
Figure 2: Schematic diagram of multimeric form of Immunoglobulin M (IgM) and 
Immunoglobulin A (IgA) 
 
Multimerization of IgM and IgA requires a small tail of 18 amino acids 
containing a cysteine residue that is critical for multimer formation. A separate 
polypeptide, the J chain (15 kDa), mediates multimer formation by linking the tail’s 
cysteine of each unit together [9], [10]. Multimer formation was found to have significant 
implication in enhancing binding strength against repeating epitopes via avidity effects 
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(i.e. an increase in the effective concentration of the binding sites) on bacterial pathogens 
and facilitating IgA transport through epithelia for mucosal secretion [1], [9], [10]. The 
Fc domain of the antibody fragment also affects the degree to which an antibody can 
engage various effector immune cells via interactions with their membrane-bound Fc 
receptors (FcRs) [11]. The role of FcRs is known to mediate antibody-induced immune 
response upon binding to the Fc fragment of an antibody. The interactions between the 
FcRs and the different isotypes are specific; therefore, there are usually as many different 
classes of FcRs as the isotypes. Depending on the cytoplasmic domain of an FcR, either 
containing the immunoreceptor tyrosine-based activation motifs (ITAM) or the 
immunoreceptor tyrosine-based inhibitory motifs (ITIM), an FcR can transduce either 
activation or inhibitory signals for a cellular response. Hence, effector cells (natural killer 
cells, T cells, B cells, granulocytes, dendritic cells, and macrophages) expressing 
different amounts and types of FcRs can respond differently to complexes of pathogens 
bound by antibodies of various isotypes. Although it is not within the scope of this 
chapter to further elaborate on the background of Fc modulation, it is noteworthy to at 
least mention that the Fc fragment can further modulate its interactions with effector cells 
through the nature of the glycan that is appended to a single Asn residue in the Fc 
polypeptide. For example, the presence of fucose, galactose, mannose, N-
acetylglucosamine, or sialic acid [11], and irregular levels of certain types of 
glycosylation are observed in patients with various autoimmune diseases [12]. Therefore, 
the Fc fragment of an antibody possesses important properties that can modulate the 
degree of immune effector functions. 
 
Without proper immunological recognition, immune effector functions would be 
modulated non-specifically. The Fab fragment of the antibody molecule is responsible for 
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immunological recognition. Both the heavy and light variable regions of the Fab 
fragment form the molecular interface that interacts and recognizes antigens. Interactions 
between the antigen and the variable regions are mediated by non-covalent forces and 
may vary in strength depending on the conformational fitting between the variable region 
and the antigen epitope. Each unique variable region that fits to a unique antigen epitope 
is called an idiotype. Since idiotype is a function of the structure of the variable regions 
and structure is dependent upon the amino acid sequence of the antibody polypeptide 
chain, mechanisms that can generate sequence diversity in antibodies are key to amassing 
a wide variety of idiotypes. This broad sequence/structure space is often sufficient for 
surmounting the molecular diversity of possible pathologic molecules. Such a high 
degree of diversity can only be achieved by recombination and rearrangement of multiple 
germline variable gene segments (VDJ for V-Heavy chain and VJ for V-Light chain) and 
the recombinantly joined segments form the naïve antibody repertoire. (A more detailed 
explanation of both the recombination and the B cell affinity maturation process is 
discussed in their respective sections.) Briefly, naïve antibodies bind to antigens with low 
affinity and are then optimized (with respect to affinity) by mutagenesis and a selection 
process that eventually results in antibodies of exquisite selectivity and affinity. This 
process is called somatic hypermutation (SHM) and targets predominantly the 
hypervariable regions of the variable domain that are directly involved in the active 
binding to the antigens, which can also be observed by antigen-antibody co-crystal 
structures [13]–[15]. The sequence variability within the hypervariable sections of the 
Variable Light chain and the Variable Heavy chain regions [16]–[18] in healthy adult 
peripheral blood B cell antibody sequences is shown in Figure 3. The regions of the 
variable domain where sequence variability is significantly higher (i.e. the hypervariable 
regions) relative to the neighboring conserved sequence segments are also called the 
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complementarity-determining regions (CDR) and they represent the contacting sites with 
the antigens as mentioned above [14], [15], [19]. Since variability is highly elevated in 
these sections, the uniqueness of an antibody sequence is usually found within the CDRs. 
On each of the Variable Light and Variable Heavy chain, the hypervariable regions are 
denoted as CDR1, CDR2, and CDR3 in Figure 3. 
 
 
Figure 3: Kabat-Wu variability coefficient plot for Heavy and Light (Lambda) chain 
variable region 
 Note: Variability = k/n*N where k is the different numbers of amino acids in 
the position; n is the number of occurrence for the prevalent amino acids in 
the position; N is the total number of sequences analyzed 
 
In particular, the CDR3, the section closest to the C terminus on both chains, 
contains the highest degree of variability and it has the potential to be as unique as a 
molecular barcode for an antibody sequence. Together, the six CDRs have been shown to 
be largely responsible for the antigen specificity of the antibodies [7], [8], [14], [15]; 
hence, knowledge of the sequence composition in the CDRs and its relationship to 
conformational structure is essential in immunological studies. The degree of recognition 
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is further refined with a second level of diversity via the combinatorial pairings of the 
Variable Light chain and the Variable Heavy chain [20]. Therefore, it is just as critical to 
be able to identify the native pairing of the Variable Heavy and the Variable Light chains 
in elucidating binding specificity and affinity. There are numerous technical advances 
that focus on identifying native VH/VL pairs and the topic is discussed in greater detail in 
a technical review by Georgiou et al. [21].  
 
OVERVIEW OF B CELL DEVELOPMENT AND ITS RELATIONSHIP TO ANTIBODY DIVERSITY 
The B cell (bursal or bone marrow derived cell) is one of the many hallmarks of 
humoral immunity and its main function is to produce a diverse antibody repertoire in 
response to external stimuli and challenges [22]. Each B cell at any given moment can 
theoretically only produce a single unique antibody, thus targeting a unique cognate 
epitope. After a B cell is activated through cognate antigen binding, its differentiation 
toward the plasma cell state commences. The rate of antibody production continues to 
increase as an activated B cell differentiates into a plasma cell, where an enlarged 
endoplasmic reticulum is developed to accommodate higher antibody production. 
However, before a B cell commits to terminal differentiation to become a plasma cell, it 
is still transient in some ways, including with the potential ability to still modify the 
antibody it is producing [23]. Therefore, one can expect different stages of B cells would 
perform differently in terms of affinity and specificity [22]–[27]. Given the significance 
of B cell development, the following overview is provided and a schematic diagram 




Figure 4: Brief schematic diagram of B cell development 
 Note: CLP = common lymphoid progenitor; FDC = follicular dendritic cell; 
SHM = somatic hyper mutation; CSR = class-switch recombination  
 
B cells are derived from the common lymphoid progenitor (CLP) lineage and the 
initial stages of development occur in the fetal liver and subsequently in the bone marrow 
in neonatals and throughout adulthoods. During the pro-B cell stage, the pro-B cell is still 
undergoing imprecise variable domain gene rearrangement (which will be explained in 
more details in the next section) [28], [29]; therefore, the immunoglobulin is not 
expressed on the cell surface yet. Expression of an immunoglobulin chain is seen during 
the large pre-B cell stage where immunoglobulin-like structure or pre-B cell receptor 
(pre-BCR) can be found. The pre-BCR consists of a rearranged heavy chain with the μ 
isotype and surrogate light chain (SLC). The SLC is a generic light chain heterodimer 
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consisting of the VpreB and Lambda 5 components [30]. Given the error-prone nature of 
gene rearrangement, not all pro-B cells can transition to the pre-B stage by successfully 
forming a pre-BCR; hence, this is the first checkpoint for ensuring proper expression of 
immunoglobulin heavy chain. During the small pre-B stage, light chain gene 
rearrangements that result in successful expression can replace the SLC to form the 
surface immunoglobulin or B cell receptor (BCR), which signifies the immature B cell 
stage. During the immature stage, the BCR (surface IgM) is tested for auto-reactivity via 
a well-established biological mechanism [31]. If autoreactivity is detected then it is either 
corrected by a process called receptor editing or results in B cell apoptosis [31]–[33]. 
This checkpoint is important in preventing self-targeting B cells from being released into 
circulation. Upon passing this checkpoint, the immature B cell expresses surface IgD and 
is released from the primary lymphoid organ, whereupon the B cell is then classified as a 
mature B cell. Mature B cells further develop along two different lineages: B-1 or B-2 
[34]. B-1 cells, after egressing from the bone marrow can mainly be found in pleural 
cavities and the peritoneum. They predominantly produce what are called “natural” 
antibodies (or innate antibodies), typically do not display SHM, are directed against T-
independent (meaning not requiring T-cell costimulatory signals) antigens and their 
repertoire is restricted to the post fetal stage [35]. On the other hand, B-2 cells are mainly 
found in secondary lymphoid organs, such as the spleen and lymph nodes, where they 
produce adaptive antibodies mainly targeting T-dependent antigens. In terms of renewal, 
the B-1 cell is self-renewing whereas B-2 cells cannot proliferate (unless they are 
stimulated by cognate antigen binding, see below) and thus are continuously replenished 
via the influx of new cells from the bone marrow. B-2 cells are the major contributor to 
the diversity of antibody repertoire and will be discussed in more details hereafter.  
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As mentioned above, distinct B cell developmental stages ensure the generation 
and maintenance of antibody producing B cells. Mature B cells are estimated to encode 
for an astronomical diversity of unique antibodies with more than 1012 diverse clones 
[36]. A majority of the diversity can be found in the B-2 cell lineage where a large 
number of these cells reside near the follicles inside the secondary lymphoid organs 
(more specifically referred to as follicular B cells). Upon cognate recognition between the 
BCR and the antigens, these follicular B cells located within the follicles in the lymph 
nodes or spleen that have bound antigen become activated. Activation entails a rapid 
burst of cell expansion and differentiation to generate a nascent wave of plasmablasts (an 
intermediate stage of B cells to become plasma cells) and short-lived plasma cells that 
produce antibodies for immediate protection as depicted in the lower branch in Figure 4.  
 
On the other hand, a portion of the activated B cells can refine their respective 
antibody’s affinity and specificity in the germinal center as depicted in Figure 4. It is still 
unclear how this decision is made but it has been implicated that factors such as toll-like 
receptors and the type of antigen might affect the decision [37]–[39]. Germinal centers 
are compartmentalized sites in the secondary lymphoid organs where activated B cells 
undergo affinity maturation. A single germinal center can be divided into a light and a 
dark zone. The light zone is where follicular helper T cells (cognate T cells providing 
costimulatory signals), follicular dendritic cells (antigen presentation), and cognate B 
cells congregate. Follicular dendritic cells act as antigen presenting cells for the purpose 
of bringing cognate B cells in close proximity to follicular helper T cells. Due to a limited 
number of follicular helper T cells in the germinal center, their availabilities to provide B 
cell proliferative signals are restricted to only highly affinity matured cognate B cells. 
Cognate B cells receiving the proliferative signals can migrate and proliferate in the dark 
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zone where activation induced cytidine deaminase (AID) will introduce SHM to the 
antibody sequence. Independently, the AID reaction can also change the antibody’s 
isotype through class-switch recombination (CSR) [25], [40] during this process. 
Through this cyclic selection process, only the B cells with affinity-refined antibody can 
be selected to remain in the germinal center for further refinement. These affinity-
matured B cells either differentiate into memory B cells or into plasmablasts, although 
the underlying mechanisms that dictate this decision are unclear [41]–[48]. It is important 
to point out that long-lived memory B cells can also be generated independent of the 
germinal center [49]. Antibody producing B cells that have differentiated into 
plasmablasts have a short lifespan of a few days unless they can home to survival niches, 
mainly found in the bone marrow. Although still debatable, some scientists believed that 
plasmablasts need to localize into the bone marrow before terminally differentiating to 
plasma cells and to become long-lived plasma cells (LLPCs) [50]. LLPCs can survive up 
to at least several decades [51]. Immunological memory in the B cell branch is therefore 
maintained in the form of the memory B cell and LLPC populations. 
 
It is well-studied that the bone marrow is the homing-destination for plasmablasts 
and that the bone marrow survival niches provide microenvironments for supporting 
long-term survival for non-dividing LLPCs [50]–[57]. Hence, the bone marrow LLPC 
pool is potentially an archival history of the antigenic specificities generated by the 
immune response; therefore, it plays a major role in immunological memory. Due to a 
limited number of survival niches [58], it is speculated that the diversity of the repertoire 
encoded by LLPCs is limited. Several studies reported that LLPCs can survive from as 
little as 60 days up until even the death of the host lasting decades [52], [56], [59]–[62]. 
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OVERVIEW OF THE HUMAN IMMUNOGLOBULIN VARIABLE HEAVY/VARIABLE LIGHT 
LOCI RECOMBINATION DIVERSITY 
The human immunoglobulin Variable Heavy chain gene locus is located on 
chromosome 14 (14q32.33) [63], while the Variable Light Kappa chain locus is located 
on chromosome 2 (2p11.2) [64], [65] and the Variable Light Lambda chain locus is 
located on chromosome 22 (22q11.2) [66]. It is necessary to join three gene segments (V-
, D-, J-) for a heavy chain or two gene segments (V-, J-) for a light chain to form a 
productive full-length variable coding region for expression. Depending on which 
annotation database is referenced, the number of V-, D-, and J-segments may vary 
slightly. Nonetheless, according to the commonly used Immunogenetics Tools (IMGT) 
database [17], [67], [68], the Variable Heavy chain consists of 56 V-, 23 D-, and 6-J 
segments. The Variable Light Kappa chain has 38 V- and 5 J-segments while the 
Variable Light Lambda chain has 35 V- and 7-J segments. These segments are the 
fundamental genetic units for generating proficient diversity in the antibody repertoire. 
Somatic recombination joining of the V(D)J segments encode for the Variable Heavy 
chain and recombination joining of the VJ segments encode for the Variable Light chain. 
A schematic diagram depicting the sequential steps involved is shown in Figure 5. 
 
Except for pseudo-gene segments, V-, (D- for heavy chain), J-, and constant gene 
segments are ordered as shown in Figure 5 on their corresponding chromosomal locus. 
With respect to the constant gene segments, in human the different isotypes are located 
neighboring the J-gene segments in the following order away from the centromere of the 




Figure 5: Schematic diagram of V(D)J rearrangement for Variable Heavy Chain  
 
The joining of the V(D)J segments is mediated predominantly by the 
recombination-activating gene (RAG) complex (RAG-1 & RAG-2) but also by the 
Ku70:80 complex, the DNA-PK/Artemis complex, and by the terminal deoxynucleotidyl 
transferase (TdT). Briefly, the complexes can recognize the recombination signal 
sequences (RSSs) flanking the gene segments and bring them to a juxtaposition where 
imprecise excision removes sections of the chromosome to bring the to-be-joined 
segments into close proximity. This process leaves behind palindromic overhangs for 
each segment. TdT then introduces non-templated nucleotides (N-nucleotides) to the 
overhang. Afterwards, DNA repair enzymes correct and complete the complementary 
strand, leaving behind palindromic sequences (P-nucleotides). This process of N/P 
nucleotide addition signifies the completion of a gene segment-joining event. For heavy 
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chain rearrangement, the DJ joining precedes the V- and the constant segment joining. 
Since the light chain lacks the D-segment, the VJ joining precedes the constant segment 
joining. 
 
If gene segment recombination were the only diversification strategy, the 
maximum theoretical number of Variable Heavy chain variants would only be around 
7728 unique combinations. However, junctional diversity provides an additional layer of 
sequence diversity via non-templated (N/P) nucleotide addition resulting in incorporation 
of various numbers of nucleotides to the joining junctions. Thus, in theory, a diversity of 
more than 1012 of antibody genes is generated [36]. Together with combinatorial pairing 
between Variable Heavy and Variable Light chains, the theoretical diversity increases 
even more. However, some evidence using high throughput sequencing of V genes has 
suggested that the actual or true sequence diversity of the repertoire is much smaller and 
estimated at only 1-10 million clones [69]–[71]. The veracity of these estimates needs to 
be validated further. Nonetheless, a repertoire comprising less than 107 antibody 
sequences can be determined in its entirety by next generation sequencing (NGS) 
technology. As the operational costs of NGS continues to decline, it would be relatively 
practical to sequence at greater depth with comprehensive coverage. 
 
NEXT GENERATION SEQUENCING TECHNOLOGY 
For decades, the Sanger chain termination DNA sequencing technology has been 
the workhorse for DNA sequence analysis [72]. However, throughput is limited and large 
scale sequencing of DNA samples comprising billions of base pairs, as is the case for the 
immune repertoire is extremely labor intensive [73]. The greater throughput of NGS can 
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be attributed to innovation in the template preparation strategy, sequencing reaction 
methodologies, detection and informatics analysis. These innovative strategies enable the 
multiplexing of hundreds of thousands of DNA templates to be sequenced simultaneously 
[74].  
 
Ever since the initial debut of NGS in 2005, the operational cost has continued to 
decline while the performance continues to improve rapidly. More importantly, 
substantial resources have been invested to improving accuracy, to provide longer read 
lengths, and for higher throughput [75]–[77]. Furthermore, with the huge potential market 
for personalized genome sequencing, there is additional incentive for the sequencer 
manufacturers to further reduce costs and to increase throughput making the products 
more enticing [74]. The emergence of many cutting-edge sequencing platforms, for 
example the Roche 454 pyrosequencing [78], [79], Ion Torrent PGM (Life 
Technologies), and Illumina MiSeq [80], have enabled high throughput analysis of 
several organisms’ genomes, including the human in a reasonable amount of time [74]. In 
particular, the two platforms that are the most relevant in terms of the work presented in 
this dissertation are: the Roche 454 pyrosequencing and Illumina MiSeq. The Roche 454 
pyrosequencing technology relies on emulsion PCR for template preparation [81] and 
pyrosequencing uses luciferase [78] as shown in Figure 6 top panel. Particularly, the 
Roche 454 pyrosequencing begins by clonal amplification in the oil-aqueous emulsion 
that isolates the PCR reaction of a primer conjugated bead with a single template 
molecule. The emulsion is disrupted after the clonal amplification resulting in each bead 
being covered with the monoclonal amplicon. These beads are then situated into plate 
with pico titer sized wells where the pyrosequencing steps will take place via the 
sequencing by synthesis method. Sequencing signals are generated when pre-defined 
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nucleotides are incorporated during the template polymerase reaction that will release 
pyrophosphate (PPi) stoichiometrically. The pyrophosphate together with adenosine 5’ 
phosphosulfate (APS) can be quantitatively converted to ATP by sulfurylase. The 
stoichiometrically generated ATP can then power luciferase to convert luciferin to 
oxyluciferin emitting an amount of light proportional to the number of nucleotides 
incorporated. The light signal from each well is captured with a charge-coupled device 
(CCD) camera. With repeated cycles of washing and the introduction of pre-defined 
nucleotides, the sequence on each bead can be identified.  
 
The Illumina MiSeq platform relies on solid-phase bridge PCR amplification and 
fluorescent-labeled reversible terminator to generate sequencing signals [80], [82] as 
shown in Figure 6 bottom panel. Briefly, common PCR primers are conjugated to a solid-
phase glass slide (flowcell) where one cycle of PCR transfers the template onto the 
immobilized primers. Then, about 35 cycles of bridge PCR are used to generate clonal 
amplification in the form of an amplicon cluster. The amplicon cluster is generated in 
order to have sufficient DNA so that upon sequencing a strong signal can be readily 
detected. Specific cleavage of the strand in the opposite orientation ensures that each 
cluster only contains unidirectional strands. The sequences are read during strand 
synthesis where nucleotides extended from the sequencing primer are reported by the 
unique fluorescent-label on each type of reversible terminator nucleotide. In order to 
ensure single nucleotide extension, the nucleotides are originally blocked from further 
polymerization and only after nucleotide signals are captured by a total internal reflection 
fluorescence (TIRF) detector are the incorporated nucleotides unblocked to allow further 
extension. After repeated rounds of nucleotide incorporation, signal detection, and 
nucleotide unblocking, the representative sequence from each cluster is revealed.  
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The Roche 454 pyrosequencing and Illumina sequencing platforms each have 
their own respective pros and cons. For example, the Roche 454 pyrosequencing platform 
offers single read-throughs of ~750 bps in length but has at maximum sequencing depth 
of only 1 million reads per run. On the other hand, Illumina MiSeq can generate up to 
about 25 million reads per run but the read length is restricted to only 300 bps on each 
pair end currently. In order to ascertain longer read lengths with the MiSeq system, pair-
end reads are required with sufficient overlap for in silico assembly algorithms to “stitch” 
together each end at the expense of half the sequencing depth. The turnaround time for 
Illumina MiSeq is also longer where a typical run requires about 40 hours whereas the 
turnaround time for the Roche 454 pyrosequencing is only 24 hours. In terms of 
sequencing errors, the Roche 454 pyrosequencing platform is prone to generate 
insertion/deletion errors in homopolymer regions whereas the Illumina MiSeq platform 
tends to generate substitution errors for bases after guanine. Regardless, both platforms 
are currently the best possible options for surveying antibody repertoires at a reasonably 
high depth and at relatively low cost. 
 
The applications of NGS ranges from genome assembly to transcriptome analysis 
to targeted amplicon sequencing, etc. In particular, NGS can simultaneously read 
antibody sequences in the range of millions resulting in a comprehensive measure of the 
repertoire. This ability has been capitalized to find antigen specific antibodies [83]–[85] 
and to identify repertoire signatures in healthy individuals or in individuals with immune 
malignancies [69], [70]. Moreover, it could be used to pin point self-reactive antibodies 
in rheumatoid arthritis patients [86]. Hence, NGS is utilized throughout the work 
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described in this dissertation to survey the antibody repertoire in ways that could lead to 
implications in antibody discovery or identification of other repertoire signatures. 
 
 
Figure 6: Schematic diagram for 454 pyrosequencing and Illumina MiSeq sequencing  
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BIOINFORMATICS AND EXPERIMENTAL TOOLS FOR ANTIBODY REPERTOIRE STUDIES 
As mentioned previously, the ability for NGS to measure the antibody repertoire 
can lead to medical implications for therapeutics or diagnostics. In order to 
comprehensively determine the sequences that comprise the antibody repertoire, it is 
necessary to use a multi-layer approach by combining NGS, bioinformatics tools, 
immunological assays, and recombinant antibody technology into an integrative pipeline. 
Bioinformatics tools and analysis remain a critical bottleneck to the extraction of 
important technical and biomedical information from NGS sequencing datasets, 
especially when the influx of data is far greater than any manual processes can handle. 
Moreover, it is essential to maintain a low computational skill barrier for widespread 
adoption of the approach. Therefore, many bioinformatics-centric groups have published 
various packages and analysis tools to lower the level of computational skill required for 
the analyzing of NGS data [87]–[96]. 
 
The bioinformatics tools related to antibody repertoire analysis that were made 
publicly available can be categorized into four groups: pre-processing tools, germline 
annotation tools, clustering tools, and visualization tools. The respective web locations 







Pre-processing tools   
FASTX toolkits http://hannonlab.cshl.edu/fastx_toolkit/ 
Ig-HTS tools http://immsilico2.lnx.biu.ac.il/Software.html 
Flash http://ccb.jhu.edu/software/FLASH/ 
PEAR http://sco.h-its.org/exelixis/web/software/pear/ 








Antibody mining toolbox http://sourceforge.net/projects/abmining/ 




Visualization tools  
IgTree http://immsilico2.lnx.biu.ac.il/Software.html 
Circos http://circos.ca/ 
Table 1: Summary of bioinformatics tools and their web locations 
 
 23 
Sequence quality could vary from read-to-read and it is common practice for 
researchers to first prune irrelevant and low-quality sequences. Pre-processing tools 
designed for this task are usually made available in a programming language such as 
PERL. Two commonly used tools in this area are FASTX Toolkit from the Hannon 
Laboratory and the Ig-HTS tool [97] by the Mehr Laboratory. These tools can automate 
multiplex tag trimming and the filtering of short/low-quality reads. In addition to 
sequence pruning, sequence merging is also necessary for analyzing antibody sequences 
identified through the Illumina MiSeq platform. Since the MiSeq run currently only 
supports up to 300 bps of read length from each end of a template molecule, recovery of 
the full-length variable region requires merging of the pair-end reads. Tools such as 
FLASH [98] and PEAR [99] are exceptionally efficient in the merging of paired-end 
reads. Briefly, on the one hand, FLASH’s algorithm is meant to minimize the overlap 
length to mismatch ratio and it requires mean DNA fragment size and standard deviation 
of fragment population as input parameters to generate merged reads that are almost 
identical in size. On the other hand, PEAR utilizes an overlap assembly score based on a 
tuned scoring matrix that heavily penalizes mismatches and rewards matches to generate 
merged reads. In our experience, both tools perform equally well in most cases but on 
rare occasions, PEAR can outperform FLASH in recovering more merged reads. 
 
Among the different tools, the germline annotation tools that can assign the V-, 
D-, J- gene segments are of great importance because such information can be used to 
intrinsically infer the ancestry of the B cells and identify certain gene usages that have 
been found to be associated with certain diseases [100]–[103]. There are various tools 
that automate the annotation process but IMGT/V-QUEST by far appears to be the one 
that has been the most widely adopted [89]. IMGT/V-QUEST offers a web-based 
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platform using a proprietary annotation scheme to report the annotations along with 
detailed periphery information such as somatic mutation levels and isoelectric points 
organized across multiple tab-delimited files. These files can then be subsequently 
processed and transformed by downstream programs such as the Immunoglobulin 
Analysis Tool (IgAT) [104] to extract repertoire information such as CDR3 spectra 
counts and N/P addition analysis. The downside of IMGT/V-QUEST is that it imposes a 
limit of 500,000 sequences per analysis making analysis in the tens of millions quite 
inconvenient. The next commonly used annotation tool is IgBlast [92] that is 
implemented using the National Center for Biotechnology Information (NCBI) C++ Blast 
toolkit and reports results in the GenBank alignment format. The information reported by 
IgBlast is not as easily extracted and, more importantly, it does not report the CDR3 
region which is often times a critical piece of information. SoDA2 [91] and iHMMune-
align [88] are both based on hidden Markov models for annotation and they are deployed 
under a JAVA standalone package. Their processing capabilities seemed to be limited to 
the range of 106 sequences. VDJsolver [105] is a combination of JointHMM (hidden 
Markov model) and JointML (maximum-likelihood) based methods to obtain the best fit 
to a typical antibody model. Ab-origin [90] optimized a scoring scheme based on a 
Monte Carlo simulation that minimizes effects from large length variations in the V(D)J 
joint. Lastly, the Antibody mining toolbox [93] uses regular expression pattern finding of 
conserved motifs to identify the CDRs within the variable gene sequence. As observed 
above, the underlying concept for the annotation tools is the ability to map the antibody 
sequence with a degree of flexibility to the germline database. Results generated by each 
tool can be affected by the alignment approach. Hence, until there is a standard set from 
which to benchmark the tools, there is still no clear consensus as to which tool is more 
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accurate. However, researchers tend to welcome the tool that provides the most periphery 
information; therefore, IMGT/V-QUEST is still popular among immunologists.  
 
In addition to annotation tools, tools that can cluster sequences into clonotypic 
units are also critical in determining antibody ancestry relationship. The ones that are 
commonly used are Usearch [94], CD-HIT [95], and ClonalRelate [96]. Last but not 
least, visualization tool like IgTree [106] that constructs phylogenetic trees can illustrate 
the maturation path of an antibody sequence while a Circos plot [107] can illustrate 
shared sequences in different sample populations.  
 
SUMMARY 
The dominance of mAbs as effective therapeutics is expected to remain in the 
coming decades. And, the NGS technology has presented us with unprecedented high 
throughput ability to mine the antibody repertoire in different disease states or during 
vaccination regime that can reveal great amount of information in advancing 
immunotherapy. By combining bioinformatics processing and analysis tools with NGS 
technology, we demonstrate in this dissertation the utility of such integrative approach in 
antibody discovery, immune traits identification in healthy adults, determination of new 
germline and gene conversion rates in rabbit, and finally the characterization of circle 




Chapter 2: Isolation of Monoclonal Antibodies without Screening by 
Mining the Variable Gene Repertoire of Plasma Cells 
 
Specifically for the work described in this chapter, K.H. Hoi performed the immunization 
and bone marrow sample collection together with S.T. Reddy. K.H. Hoi has also 
performed bacterial cloning and expression of the antibodies (scFvs and full-length), the 
reagents used in the experimental assays (Western blots, ELISAs and immune-
precipitation). In terms of bioinformatics analysis, K.H. Hoi has improved the initial 
script X. Ge created to increase performance and functionality for reporting additional 
information regarding the antibody sequencing data. 
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INTRODUCTION 
The ability of the mammalian humoral immune response to generate a vastly 
diverse antibody repertoire as a response to stimuli (i.e., immunization) has been 
substantially exploited for biotechnology applications, specifically, monoclonal antibody 
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(mAb) isolation [108]. Since the development of the hybridoma technology by Kohler 
and Milstein 35 years ago [109], a variety of methods for the generation of mAbs have 
been developed. Such methods include B cell immortalization by genetic reprogramming 
via Epstein-Barr Virus (EBV) [110] or retrovirus-mediated gene transfer [111], cloning 
of V genes by single cell PCR [112], [113], and methods for in vitro discovery via the 
display and screening of recombinant antibody libraries [114]–[121]. Both in vitro and in 
vivo methods for antibody discovery are critically dependent on high-throughput 
screening to determine antigen specificity. Recently, B cell analysis has been expedited 
by microengraving techniques that utilize soft lithography for the high-throughput 
identification of antigen-specific B cells [119], [120], however, this is at the cost of 
considerable technical complexity due to the need for antibody variable gene 
amplification and cell expansion. Similarly, the success of in vitro antibody discovery 
techniques is dependent on screening parameters including the nature of the display 
platform, antigen concentration, binding avidity during enrichment, multiple rounds of 
screening (e.g, panning or sorting), and importantly, on the design and diversity of 
synthetic antibody libraries [108], [121], [122]. 
 
In an effort to streamline the process, we developed a simple and rapid method for 
antibody isolation without the need for any laborious screening steps. We exploited high-
throughput DNA sequencing to analyze the variable light chain (VL) and variable heavy 
chain (VH) antibody gene repertoires derived from the mRNA transcripts of fully 
differentiated mature B cells, also known as antibody secreting plasma cells, found within 
the bone marrow of immunized mice. Following bioinformatics analysis, several 
abundant and unique antibody VL and VH gene sequences could be identified within the 
repertoire of each immunized mouse. By utilizing the automated liquid handling robots, 
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synthetic antibody genes were rapidly generated by oligonucleotide and PCR assembly. 
Antibodies were recombinantly expressed in bacterial and mammalian systems as single-
chain variable fragments (scFv) in the bacterial system and full-length IgG in the 
mammalian system (Figure 7). The pairing of VL and VH genes was accurately predicted 
by representation within the repertoire and it was confirmed that abundant and unique 
sequences corresponded to antigen-specific antibodies, thus providing a method for rapid 
and direct isolation of mAbs without screening. 
 
 
Figure 7: Schematic for isolation of monoclonal antibodies without screening by 




Moreover, B cell maturation culminates in the terminal, non-proliferative stage of 
B cell development - the formation of plasma cells that serve as immunoglobulin 
production factories. Plasma cells represent less than 1% of all lymphoid cells and yet are 
responsible for the overwhelming majority of antibodies in circulation [123], [124]. The 
bone marrow constitutes the major compartment where plasma cells take residency and 
produce antibodies for prolonged periods of time. In mice, a stable and highly-enriched 
antigen-specific BM-PC population of ~105 cells (10-20% of all BM-PCs) appears 7 days 
following secondary immunization and persists for prolonged periods [60]. In contrast, 
the splenic plasma cell population is highly transient, as it peaks at day 7 and rapidly 
declines to <104 cells by day 11. Importantly, BM-PCs are responsible for the synthesis 
of the most abundant circulating antibodies which in turn are likely to play a dominant 
role in pathogen neutralization and other protective humoral immune responses [123]. 
Hence, in order to examine the dynamics of the antibody V gene repertoires in BM-PCs, 
especially during the early phase post challenge (i.e., to mimic situations where mice 
exhibit weak immune responses), pairs of mice were immunized with chicken egg 
ovalbumin (OVA), human complement serine protease (C1s), human B cell regulator of 
IgH transcription (Bright), or adjuvant only as control to explore the differences in 
dynamics under different challenging antigens. 
 
MATERIALS AND METHODS 
Immunization 
Purified human complement protein C1s (CalBiochem), purified chicken egg 
ovalbumin (OVA, Sigma), or recombinant bacterially-expressed human B cell regulator 
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of IgH transcription (Bright) were resuspended in sterile-filtered phosphate buffered 
saline (PBS) at 1.0 mg/ml. On the day of primary immunization, 25 ul of antigen solution 
was thoroughly mixed with 25 ul of Complete Freund’s Adjuvant (CFA, Pierce 
Biotechnology) and 50 ul of sterile PBS and stored on ice. Female Balb/c mice (Charles 
Rivers Laboratories) 6-8 weeks old were housed in conventional barrier space and were 
maintained on a normal chow diet. Prior to injections, mice were bled from the tail vein 
and approximately 25 ul of blood was collected and stored at -20°C for later analysis. 
Day 1 was designated as the day primary immunizations were performed. 100 ul of the 
antigen-CFA mixture per mouse was injected with a 26-gauge needle subcutaneously into 
the backpad. Mice were monitored daily by animal housing staff and cages were changed 
twice per week. For secondary immunization, 25 ul of antigen solution was thoroughly 
mixed with 25 ul of Incomplete Freund’s Adjuvant (IFA, Pierce Biotechnology) and 50 
ul of sterile PBS and stored on ice. On day 21 mice were given the secondary 
immunization intraperitoneally at 100 ul of antigen-IFA mixture per mouse. On day 26 
mice were sacrificed by CO2 asphyxiation and blood, femurs and tibia were collected. All 
experiments were conducted following the guidelines provided by the university’s 
Institutional Animal Care and Use Committee (protocol number AUP-2009-00016). 
 
Isolation of bone marrow plasma cells 
Muscle and fat tissue was removed from the harvested tibias and femurs. The 
ends of both tibia and femurs were clipped with surgical scissors and bone marrow was 
flushed out with a 26-gauge insulin syringe (Becton Dickinson, BD). Bone marrow tissue 
was collected in sterile-filtered Buffer#1 (PBS with 0.1% bovine serum albumin (BSA)/2 
mM ethylenediaminetetracetic acid (EDTA)). Bone marrow cells were collected by 
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filtration through a 70-um cell strainer (BD) with mechanical disruption and washed with 
20 ml of PBS and collected in a 50 ml tube (Falcon, BD). Bone marrow cells were then 
centrifuged at 1200 RPM for 10 min at 4°C. Supernatant was decanted and the cell pellet 
was resuspended with 3.0 ml of red blood cell lysis buffer (eBioscience) and shaken 
gently at 25°C for 5 minutes. Cell suspension was then diluted with 20 ml of PBS and 
centrifuged at 1200 RPM for 10 minutes at 4°C. Supernatant was decanted and cell pellet 
was resuspended in 1.0 ml of Buffer#1. 
 
 
Each isolated bone marrow cell suspension was incubated with 2.5 ug and 1.5 ug 
of biotinylated rat anti-mouse CD45R(B220) and biotinylated rat anti-mouse CD49b 
(eBioscience), respectively. Cell suspension was rotated at 4°C for 20 minutes. Cell 
suspensions were then centrifuged at 2,000 RPM for 6 minutes at 4°C, supernatant was 
removed and the cell pellet was resuspended in 1.5 ml of Buffer#1. Streptavidin 
conjugated M280 magnetic beads (Invitrogen) were washed and resuspended according 
to manufacturer’s protocol. 50 ul of magnetic beads were added to each cell suspension 
and the mixture was rotated at 4°C for 20 min. Cell suspensions were then placed on 
Dynabead magnet (Invitrogen) and supernatants (negative fraction, cells unconjugated to 
beads) were collected and cells bound to beads were discarded.  
 
Pre-washed streptavidin M280 magnetic beads were incubated for 30 min at 4°C 
with biotinylated rat anti-mouse CD138 (BD Pharmingen) with 0.75 ug antibody per 25 
ul of magnetic beads. Beads were then washed according to manufacturer’s protocol and 
resuspended in Buffer#1. The negative cell fraction (depleted of CD45R+ and CD49b+ 
cells) collected as above was incubated with 50 ul of CD138 conjugated magnetic beads 
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and the suspension rotated at 4°C for 30 min. Beads with CD138+ bound cells were 
isolated by the magnet, washed 3 times with Buffer#1, the negative (CD138-) cells 
unbound to beads were discarded (or saved only for analysis). The positive CD138+ bead-
bound cells were collected and stored at 4°C until further processed. 
 
Preparation of variable light chain VL and variable heavy chain VH genes 
CD45R-CD138+ BM-PCs isolated as described herein were centrifuged at 2,000 
RPM at 4°C for 5 min. Cells were then lysed with TRI reagent and total RNA was 
isolated according to the manufacturer’s protocol in the Ribopure RNA isolation kit 
(Ambion). mRNA was isolated from total RNA with oligodT resin and the Poly(A) purist 
kit (Ambion) according to the manufacturer’s protocol. mRNA concentration was 
measured with an ND-1000 spectrophotometer (Nanodrop).  
 
The isolated mRNA was used for first strand cDNA synthesis by reverse 
transcription with the Maloney murine leukemia virus reverse transcriptase (MMLV-RT, 
Ambion). cDNA synthesis was performed by RT-PCR using 50 ng of mRNA template 
and oligo(dT) primers according to manufacturer protocol of Retroscript kit (Ambion). 
Following cDNA construction, PCR amplification was performed to amplify the VL and 
VH genes using 2 ul of unpurified cDNA product and standard VL and VH primer mixtures 
[125]. PCR products genes were gel purified and submitted to Genomic Sequencing and 
Analysis Center at the University of Texas Austin for 454 DNA sequencing.  
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High-throughput sequencing of VH and VL repertoires 
V gene repertoires isolated from BM-PC of eight mice were sequenced using 
high-throughput 454 FLX sequencing (University of Texas, Austin, TX; SeqWright, 
Houston, TX). In total, 415,018 sequences were generated, and 454 data quality control 
filtered and grouped >97% of the sequences into datasets for each mouse according to 
their Multiplex Identifiers (MID) usages. 
 
Bioinformatics analysis of V gene repertoires 
CDR3 sequences were identified based on homology to conserved flanking 
sequence motifs found upstream and downstream to CDR3s. Searching motifs for 
CDRH3 and CDRL3 were determined based on amino acids which occur with an average 
frequency of 99% at specific positions in V genes, based on the Kabat database [16]. VH 
sequences were identified by searching for DXXX(Y/F)(Y/F)C (Kabat # 86-92) and 
WGXG(T/S) (Kabat # 103-107) motifs at the N- and C- termini of CDRH3 respectively. 
Analogously, VL genes were found by searching for degenerate codon sequences 
encoding DXXXY[F/Y]C (Kabat # 82-88) and FGXGT (Kabat # 98-102). This approach 
correctly identifies over 94% of VH and 92% of full-length VL sequences in the Kabat 
database. Any sequences or reverse complements containing these motifs encoding in-
frame CDR3 sequences were extracted as putative VH or VL genes. For each sample, 
CDR3 sequence abundance and frequencies were calculated. V genes containing high 
frequency CDR3s were used for BLAST searches of the sequence database. Full-length 
V gene sequences were accepted if they covered all 3 CDRs. Subsequently, pairwise 
homologies among full-length sequences were determined using the multiple sequence 
alignment tools (Geneious Software). Analyses were performed using Perl scripts in a 
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Unix environment and converted into a graphical user interface using Matlab 7.1 for user-
friendly environment. 
 
Construction of synthetic antibody genes 
The coding sequences for the selected VL and VH genes were designed using the 
GeneFab software component of our in-house protein fabrication automation (PFA) 
platform [126]. After reverse translation of the primary amino acid sequences for each VL 
and VH using an E. coli class II codon table, the coding sequences for each VL and VH 
were paired based upon the rank abundances and relative frequency from the sequencing 
data (most abundant VL with the most abundant VH so and so forth). The antibody V 
region sequences were built in scFv format with a poly-glycine-serine linker (GGGGS)4 
between the VL and VH sequences. The rank ordered scFv sequences were then aligned 
using the common (GGGGS)4 linker sequence and a universal randomly generated stuffer 
sequence was applied to the ends of the scFv sequences to ensure that all of the 
synthesized constructs were the same length (808bp). This design format reduced the 
number of oligonucleotides needed for gene synthesis as oligonucleotides with identical 
sequences between the different scFv constructs could be reused. SfiI restriction 
endonuclease sites were added flanking each gene sequence to facilitate cloning of the 
synthetic gene constructs into compatible pMoPac vectors [127]. 
 
The scFv genes were synthesized from overlapping oligonucleotides using a 
modified thermodynamically balanced inside-out nucleation PCR protocol [128]. The 80-
mer oligonucleotides necessary for the construction of the various scFv genes were 
designed using the GeneFab software with a minimal overlap of 30 nucleotides between 
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oligonucleotide fragments. The oligonucleotides were synthesized using standard 
phosphoramidite chemistry at a 50nmol scale using a Mermade 192 oligonucleotide 
synthesizer (Bioautomation; Plano, TX) using synthesis reagents from EMD Chemical 
(Gibbstown, NJ) and phosphoramidites from Glen Research (Sterling, VA). All of the 
oligonucleotide liquid handling operations necessary for assembling the various genes 
were done on a Tecan Evo 200 workstation (Tecan; Mannedorf, Switzerland) with 
reagent management and instrument control done through the FabMgr software 
component of the PFA platform2. The gene assembly PCRs were performed using KOD-
Hotstart polymerase using buffers and reagents supplied with the enzyme (Novagen; San 
Diego, CA). To facilitate cloning of the VL and VH genes separately into vectors for IgG 
expression, the genes for the various VL and VH pairs were either built as gene fusions 
similar to the scFvs except without the (GGGGS)4 linker or as separate genes. These 
constructs contained sites for the restriction enzymes BssHII and BsiWI flanking the VL 
gene and the BssHII and NheI sites flanking the VH gene. 
 
Antibody expression and antigen binding analysis 
Antibody fragments were expressed as scFv fusions to the human light chain 
constant region Cκ (scAbs) [127], which possessed a by a C-terminal a polyhistidine 
(polyHis) tag. Cloning was accomplished by SfiI digestion of antibody genes and ligation 
into the expression vector pMoPac16 followed by electroporation transformation into 
E.coli Jude 1 cells, which were then plated on Luria Broth (LB, Miller) agar plates 
supplemented with 100 ug/ml ampicillin. Single colonies were used to inoculate cultures 
in microtiter 96 well plates with 200 ul/well of Terrific Broth (TB, Miller) supplemented 
with 2% glucose and 100 ug/ml ampicillin; plates were shaken for 16 h at 30°C. 10 ul of 
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each well was used to inoculate 200 ul/well of fresh 96 well plates containing TB media 
supplemented with 100 ug/ml ampicillin and 1 mM of Isopropyl-β-D-
thiogalactopyranoside (IPTG, Calbiochem).  
 
Following a 4h induction, plates were centrifuged at 4,000 RPM for 10 min at 
4°C, the supernatent was decanted and cell pellets were resuspended in 20% BugBuster 
HT (Novagen) in PBS at 150 ul/well. Plates were then shaken at 25°C for 30 min, and 
then centrifuged at 4,000 RPM for 15 min at 4°C. 50 ul/well of cell lysates were then 
added to an ELISA 96 well plate that was pre-coated with antigen (e.g., OVA, C1s, 
Bright) at 2 ug/ml in PBS and pre-blocked with 0.5% BSA or 1% Gelatin. A standard 
indirect ELISA protocol was followed with the detection anti-polyHis antibody (Sigma) 
conjugated to horseradish peroxidase (HRP) and developed with TMB substrate (Dako) 
for 15-45 minutes and stopped with 2N H2SO4. The absorbance was measured at 450 nm 
with a 96 well spectrophotometer (BioTek). Positive wells were identified when the 
absorbance value was at least 3-fold above background binding to BSA.  
 
For IgG expression, synthetic VL and VH genes were digeseted with BssHII/BsiWI 
and BssHII/NheI respectively and then ligated into the vectors pMAZ-IgL and pMAZ-
IgH, respectively [129]. pMAZ-IgL carries the constant human kappa light chain 
antibody region and pMAZ-IgH carries the constant human heavy chain antibody region 
of IgG1. Vectors were transformed into E.coli Jude 1 cells and plated on Luria Broth 
(LB, Miller) agar plates supplemented with 100 ug/ml ampicillin. Single colonies were 
selected and verified for correct V gene sequence. E.coli cells carrying pMAZ-IgL and 
pMAZ-IgH vectors were then grown in 2 ml TB supplemented with 100 ug/ml ampicillin 
isolated and DNA was purified. 20 ug each of purified pMAZ-IgL and pMAZ-IgH were 
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used for co-transfection and transient expression from HEK293F cells following the 
Freestyle MAX expression system (Invitrogen). HEK293F cells were grown for 96h 
following transfection and media was harvested and IgG was purified by a protein-A 
agarose chromatography column. 
 
Surface Plasmon Resonance (Biacore) 
C1s was covalently immobilized on a CM5 chip (GE healthcare, NJ) at a level of 
approximately 200 response units via standard amine coupling chemistry as described in 
manufacturer’s protocol. BSA was similarly coupled for baseline correction. All kinetic 
analyses were performed at 25℃ in HBS-EP (10mM HEPES, 150mM NaCl, 50μM 
EDTA, 0.005% P-20, pH 7.4) on a BIAcore 3000 (GE healthcare, NJ). Antibodies were 
injected over immobilized antigen at a flow rate of 50μl/min or 100μl/min and the chip 
was regenerated with a single 10s injection of 20mM NaOH. Each sensogram was run in 
duplicate. Kinetic and equilibrium constants were determined by global fitting to a 
bivalent model using BIAevaluation software (GE healthcare, NJ). 
 
RESULTS 
Unlike recent high-throughput sequencing analyses that explored V gene 
repertoire diversity in zebrafish, humans, or synthetic libraries [69], [70], [130], [131], 
our goals focused on: determining the relative V gene transcript abundance in the BM-PC 
repertoires of immunized mice and that highly abundance transcripts to be likely antigen 
specific. These tasks do not require exhaustive coverage of the V gene repertoire; we 
have found that obtaining >5k V gene sequences per BM-PC sample is sufficient to 
provide the information needed for antibody discovery, minimizing DNA sequencing 
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costs. 454 reads were first processed by multiple sequence filters, and then subjected to a 
simple and rapid bioinformatics analysis that relied on homologies to conserved 
framework regions within V genes to identify the most common complementarity 
determining region 3 (CDR3) sequences. This approach correctly identified ~94% of VH 
and ~92% of VL sequences in the Kabat database [16]. Out of a total of 415,018 reads, 
23.2% contained CDRH3 and 26.6% contained CDRL3 sequences (Table 2), 
representing 6,681-16,743 CDRH3 and 7,112-21,241 CDRL3 sequences read per mouse, 
respectively.  
 
Sample 454 GS-FLX 
Sequencing 
Size 

















Adjuvant-1 32066 6681 2706 1811 7112 1638 1053 
Adjuvant-2 86720 16743 4640 2890 21241 3136 1888 
Ova-1 63872 15350 4789 3010 13355 2251 1355 
Ova-2 72257 15751 3821 2401 17200 2786 1700 
C1s-1 43753 11595 2440 1443 13972 1706 1045 
C1s-2 39961 9071 1799 999 14664 1477 847 
Bright-1 36599 9453 2025 1178 12209 1383 632 
Bright-2 39790 11769 2530 1210 10441 1422 578 
Total 415018 96413 24750 14942 110194 15799 9098 
Unique Sequences Across All Samples  21271   8690  
Table 2: Reads summary for 454 DNA sequences containing CDR3 
V gene sequences containing a particular CDR3 were accepted as full-length if 
they covered all 3 CDRs. Pairwise identities and frequencies were calculated by multiple 
sequence alignments followed by germline analysis. Concurrently, a graphical user 
interface application was developed to enhance data analysis and visualization of the 
results. Analysis of the BM-PC repertoires led to several interesting observations. First, 
in all immunized mice, including those receiving the same antigen, >92% of the CDRH3 
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sequences were unique to an individual mouse. The CDRL3 repertoires were less diverse, 
and in some instances, BM-PCs from mice immunized with different antigens expressed 
high levels of the same CDRL3 (data not shown). A lower degree of VL diversity, 
especially in early responses (as was the case here) is logical, since CDRL3 is derived 
from a single V-J recombination as opposed to two recombination events (V-D-J) for 
CDRH3. Second, and most importantly ~10-20% of the total repertoire of all immunized 
mice were on average comprised of only 4 CDRH3 sequences (data not shown). For 
example, in the two mice receiving C1s, the frequencies of the most abundant CDRH3s 
were 7.93% and 10.99% of the total repertoire. Third, as expected for early responses, the 
most highly abundant CDR3s were assembled from a diverse array of germline V gene 
segments, with average somatic mutation rate of only 2 and 5 amino acid substitutions for 
VL and VH, respectively. Not surprisingly, certain germline V gene families were 
represented preferentially in mice responding to particular antigens. For example in mice 
immunized with C1s, between 15-30% of the entire VH gene repertoire utilized IGHV1 
family whereas the adjuvant only immunized mice were dominated by IGHV5 or IGHV6 
families.  
 
In most instances the V genes encoding a highly abundant CDR3 were dominated 
by one sequence with the second most abundant V gene sequence (somatic variant) being 
present at >10-fold lower level and differing from the dominant sequence by 1-2 amino 
acids (Table 3), where the first number after the antigen represents the animal number 








1st VH Freq 
(%)a 




OVA-1.1 GSSYYAMDY 7.11 60.0 1.7 96.1 
OVA-1.2 DYYGSSYWYFDV 1.10 47.1 5.8 89.9 
OVA-1.3 DNWDWYFDV 0.57 49.0 4.0 95.0 
OVA-1.4 LLWLYAMDY 0.54 54.7 4.7 97.3 
OVA-2.1 RTTVSRDWYFDV 7.61 15.3 5.6 92.3 
OVA-2.2 YYYGSSAMDY 3.23 26.0 10.8 96.0 
OVA-2.3 DGWYYFDY 2.22 22.7 4.1 89.1 
OVA-2.4 EDDYDLFAY 2.10 9.4 8.7 94.9 
      
C1s-1.1 GNYYYAMDY 7.93 68.8 1.1 97.9 
C1s-1.2 DDGYWYFDV 5.14 60.9 5.3 90.0 
C1s-1.3 YYYGSSAMDY 4.37 58.5 3.7 94.5 
C1s-1.4 DMISYWYFDV 2.64 70.9 1.1 90.0 
C1s-2.1 SDRYDGYFDY 10.99 11.1 9.4 95.7 
C1s-2.2 SDRFDGYFDY 9.93 12.5 4.2 94.7 
C1s-2.3 WLLLAY 3.30 26.3 7.7 88.8 
C1s-2.4 YGNYFDY 2.47 72.1 1.4 96.8 
      
Bright-1.1 HDYGNYVDY 7.20 66.2 2.6 98.7 
Bright-1.2 DGNYQEDYFDY 5.62 63.1 5.9 98.6 
Bright-1.3 EGYAYDVDY 1.91 27.4 23.9 95.6 
Bright-1.4 DDYDWYFDV 1.54 59.3 2.8 97.5 
Bright-2.1 RGDGNYFFDY 2.57 16.1 14.0 95.0 
Bright-2.2 GDEAWFAY 2.27 43.3 6.7 97.1 
Bright-2.3 EGDFDY 2.03 14.9 8.1 95.3 
Bright-2.4 YYYGSSYFDV 1.84 77.8 0.7 99.2 




1st VL Freq 
(%)a 




OVA-1.1 WQGTHFPLT 11.70 41.4 1.8 92.1 
OVA-1.2 QQSNSWYT 4.40 54.5 2.4 94.0 
OVA-1.3 QQYSSYPLT 3.38 46.2 1.9 93.9 
OVA-1.4 QHHYGTPPWT 2.20 49.7 2.1 93.7 
OVA-2.1 WQGTHFPLT 5.32 33.3 2.3 93.7 
OVA-2.2 QQYSSYPLT 4.05 43.6 1.1 94.3 
OVA-2.3 QQYNSYPLT 3.46 20.1 4.5 92.3 
OVA-2.4 QQHYSTPWT 2.01 50.2 2.6 95.3 
 
Table 3 continues to the next page  
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Table 3 continued from the previous page 




1st VL Freq 
(%)a 




      
C1s-1.1 WQGTHFPQT 12.95 68.8 1.1 97.9 
C1s-1.2 QQWSSYPQLT 6.94 60.9 5.3 90.0 
C1s-1.3 QNDHSYPLT 3.81 58.5 3.7 94.5 
C1s-1.4 QQGQSYPWT 3.16 70.8 1.1 98.5 
C1s-2.1 FQGSHVPLT 17.10 5.7 4.7 90.4 
C1s-2.2 QQSNEDPWT 2.62 65.7 2.8 97.4 
C1s-2.3 WQGTHFPH 2.20 36.1 18.5 96.5 
C1s-2.4 WQGTHFPT 2.15 39.2 15.6 96.9 
      
Bright-1.1 LQYASSPFT 6.64 74.0 1.0 98.3 
Bright-1.2 WQGTHFPRT 4.73 60.8 1.5 97.9 
Bright-1.3 QQNNEDPRT 4.51 61.8 3.7 97.8 
Bright-1.4 QQRSSYPLT 3.59 68.4 0.8 96.5 
Bright-2.1 WQGTHFPQT 7.24 44.5 5.7 95.8 
Bright-2.2 QQGQSYPWT 4.50 71.3 1.0 98.8 
Bright-2.3 LQYASSPYT 3.12 70.7 2.0 98.6 
Bright-2.4 FQGSHVPWT 2.58 47.3 3.8 95.0 
Table 3: The frequency and homology of highly ranked sequences from the different 
immunized animals 
 
Notably, the VH repertoires were quite distinct even among genetically identical 
littermates immunized with the same antigen on the same day. For mice immunized with 
C1s or Bright, each mouse developed a distinct and diverse set of abundant CDRH3 
sequences (Figure 8). This suggests that each mouse generates its own unique and highly 
expressed VH gene repertoire, which may allow for the discovery of a panel of diverse 
antibodies. One exception however was that in the cohort of OVA-immunized mice we 
observed that a few abundant CDRH3 sequences also present at high frequency in other 
mice, suggesting that the corresponding antibodies may be poly-specific. Not 
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surprisingly, some moderately represented CDRH3 sequences from animals that received 
adjuvant only, were also present in immunized mice (Figure 8).  
 
 
Figure 8: Comparison of high frequency CDRH3s reveals unique VH genes in each 
mouse 
 
Antibodies encoding these sequences were probably specific to adjuvant or to 
common natural antigens. CDRL3 diversity was lower with several promiscuous 
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sequences represented at high frequency in several mice (data not shown). Fourth, even 
though the BM-PC VH repertoires were largely comprised of sequences unique to each 
mouse, principal component analysis of CDRH3s shared between mice revealed distinct 
clustering of the data for each cohort (i.e., same cage and litter) immunized at the same 
time but with different antigens (Figure 9). This signature likely reflects environmental 
factors, such as the antigenic history of the animal groups, and suggests that V gene 
repertoire analysis may provide valuable diagnostic information. 
 
 
Figure 9: Principal component analysis (PCA) of CDRH3 sequences from the BM-PC 
repertoires of different mouse groups 
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It should be noted that a few copies (typically <5) of the most abundant CDRH3 
sequences raised to a given antigen were observed at very low levels (typically <0.1%) in 
the CDRH3 repertoires of mice receiving other antigens. Since several of the respective 
V genes were shown to encode antigen-specific antibodies, we believe that the presence 
of these sequences in mice immunized with other antigens might originate from low 
levels of cross-sample contamination, a conclusion supported by the biased distributions 
of common CDRH3 sequences within the same cohort. Because of the high sensitivity of 
454 DNA sequencing, even with the utmost care it is not possible to completely rule out 
low-level contamination (sequence noise) during library preparation/multiplex 
sequencing. Although an important consideration for studies aiming to compare unbiased 
repertoires [69], [130], sequence noise does not impact the methodology described 
herein, since the most abundant V genes in the BM-PC repertoire are represented at 
levels 20- to more than 100-fold higher than the sequence noise level. 
 
Manual screening of small combinatorial libraries of scFvs in E.coli using BM-PC 
V genes led to a low yield of antigen-specific clones (<4 positive clones per 96 well 
plate, data not shown). Upon further analysis, most of these scFvs displayed low apparent 
affinity by ELISA and/or poor expression and aggregation. We reasoned that this was a 
consequence of combinatorial pairing: even if a VL and a VH gene are represented at 5% 
of the cDNA pool, assuming no PCR biases in scFv assembly, the probability of correct 
pairing is only 0.25%, and therefore discovery of positive clones would require an 
extensive amount of screening. To overcome these problems, and to avoid screening 
altogether, we hypothesized that VL and VH genes represented at approximately the same 
abundance likely arise from the same plasma cell and hence, are naturally paired. To test 
this hypothesis, the top 4-5 most abundant full-length VL and VH genes from each mouse 
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(excluding VH sequences that were cross-represented in adjuvant-only mice), which 
accounted for a minimum of 0.5% of the repertoire, were gene synthesized as pairs, 
recombinantly expressed, and tested for antigen binding. Synthetic genes were 
constructed by robotically assisted, high-throughput DNA synthesis as described in the 
materials and methods section. Briefly, gene fragments (lengths from 200 to 500 
nucleotides) were generated using inside-out nucleation PCR reactions. The design of 
these fragments and relevant overlaps was automated using customized software to 
facilitate robotic synthesis and assembly. Alignment and "padding" of the sequences at 
either end yielded genes of identical length and permitted the use of a generic 
overlapping assembly strategy that ensured the greatest oligonucleotide re-use. In this 
manner, up to 48 VL and 48 VH genes could be synthesized and validated for correct ORF 
by one researcher within one week, at a reagent cost <$2,000. In most cases, VL and VH 
pairing was determined by rank ordering of CDR3 frequency within the repertoire. In 
cases where two VL or VH genes were found at very similar frequencies, we constructed 
multiple VL-VH combinations. Paired V genes were then expressed as scFv fragments in 
E.coli. ELISA analysis of bacterial lysates indicated that the resulting antibodies were 
overwhelmingly antigen-specific (~78%): we obtained 21/27 antigen specific antibodies 
from six mice immunized with three different protein antigens (Table 4). To further 
evaluate the utility of this simple pairing strategy, we constructed a combinatorial library 
of scFvs comprising the 4 most abundant VL and VH genes from each of the two mice 
immunized with C1s. scFv antibody fragments were expressed in E.coli; binding analysis 
by ELISA revealed that all of the highest antigen-binding clones possessed the same VL-




VL-VH pair % VL CDRL3 % VH CDRH3 
scFv 
binding 
α−OVA           
1.1L-1.1H 11.70 WQGTHFPLT 7.11 GSSYYAMDY + 
1.2L-1.2H 4.40 QQYNSYPLT 1.10 LLWLYAMDY + 
1.3L-1.3H 3.38 QQSNSWYT 0.57 DVYDGYAMDY + 
1.4L-1.4H 2.20 QHHYGTPPWT 0.54 NPYAMDY - 
2.1L-2.1H 5.32 WQGTHFPLT 7.61 RTTVSRDWYFDV + 
2.2L-2.2H 4.05 QQYNSYPLT 3.23 YYYGSSAMDY + 
2.3L-2.3H 3.46 QQYSSYPLT 2.22 DGWYYFDY + 
2.4L-2.4H 2.01 QQHYSTPWT 2.10 EDDYDLFAY + 
α−C1s           
1.1L-1.1H 12.95 WQGTHFPQT 7.93 GNYYYAMDY + 
1.2L-1.1H 6.94 QQWSSYPQLT 7.93 GNYYYAMDY + 
1.3L-1.2H 3.81 QNDHSYPLT 2.64 DMISYWYFDV + 
1.4L-1.3H 3.16 QQGQSYPFT 1.67 EDYGNYWYFDV + 
1.4L-1.4H 3.16 QQGQSYPFT 1.67 EGYYYGSSYFDY - 
2.1L-2.1HA 17.10 FQGSHVPLT 10.99 SDRYDGYFDY + 
2.1L-2.1HB 17.10 FQGSHVPLT 9.93 SDRFDGYFDY + 
2.2L-2.2H 2.62 QQSNEDPWT 3.30 WLLLAY + 
2.3L-2.2H 2.20 WQGTHFPH 3.30 WLLLAY + 
2.3L-2.3H 2.20 WQGTHFPH 1.65 SDGYYYFDY + 
2.4L-2.4H 1.64 QQHYSTPFT 1.15 YYDYDKAYYFDY - 
α−Br           
1.1L-1.1H 6.64 LQYASSPFT 7.20 HDYGNYVDY + 
1.2L-1.2H 4.73 WQGTHFPRT 5.62 DGNYQEDYFDY - 
1.3L-1.3H 4.51 QQNNEDPRT 1.91 EGYAYDVDY + 
1.4L-1.4H 3.59 QQRSSYPLT 1.20 YDYGKDFDY + 
2.1L-2.1H 7.24 WQGTHFPQT 2.57 RGDGNYFFDY + 
2.2L-2.2H 4.50 QQGQSYPWT 2.27 GDEAWFAY - 
2.3L-2.3H 3.12 LQYASSPYT 2.03 EGDFDY - 
2.4L-2.4H 2.58 FQGSHVPWT 1.63 GGNYDYAMDY + 
Table 4: Antigen binding of antibody single-chain variable fragments (scFvs) from 
high frequency VL and VH genes 
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Mouse C1s-2 displayed the highest serum titers and therefore, antibodies from 
this mouse were selected for biophysical characterization of antigen binding affinity by 
surface plasmon resonance (Biacore; data shown in subsequent paragraph) and sandwich 
ELISA (Figure 10).  
 
 
Figure 10: Sandwich ELISA by coated synthetic anti-C1s scAb 2.1L-2.1H-B capturing 
with C1s and detecting with characterized anti-C1s high-binder full-length 
IgG 
 
Antibodies were recombinantly expressed and purified as monomeric scFv 
fragments in E.coli and as full-length IgG antibodies in HEK 293F cells. Pairing of the 
most abundant light (2.1L) and heavy (2.1H-B) V genes (17.10% and 9.93% CDRL3 and 
CDRH3 frequencies, respectively) from mouse C1s-2 yielded an antibody with a KD of 
20 nM as a scFv (kon=2.3 x 104 M-1 sec-1; koff=5.0 x 10-4 sec-1) and unexpectedly, a slightly 
lower monovalent KD of 50 nM (kon=2.4 x 104 M-1 sec-1; koff=1.2 x 10-3 sec-1) as an IgG. 
From the same mouse, pairing of C1s 2.2L with 2.2H (2.62% and 3.30% CDRL3 and 
CDRH3 frequencies, respectively) resulted in an IgG that displayed low binding affinity 












C1s concentration (nM) 
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and 3.30% CDRL3 and CDRH3 frequency, respectively) yielded an IgG with sub-
nanomolar binding affinity (KD=0.43 nM, kon=4.5 x 105 M-1 sec-1; koff=1.9 x 10-4 sec-1, 
indicating that the natural pairing is likely 2.3L-2.2H (Table 5). Not surprisingly, the 
antibodies were suitable for functional assays, such as sandwich ELISA and 










% VL 17.10 17.10 2.20 
% VH 9.93 9.93 3.30 
CDRL3 FQGSHVPLT FQGSHVPLT WQGTHFPH 
CDRH3 SDRFDGYFDY SDRFDGYFDY WLLLAY 
Kon 2.35 x 104 2.38 x 104 4.51 x 105 
Koff 4.98 x10-4 1.21 x 10-3 1.92 x 10-4 
KD (nM) 20 50 0.43 
Table 5: Biophysical characterization of the different format of anti-C1s molecules 
derived from the BM-PC repertoires of mouse C1s-2 
 
DISCUSSION 
Our approach capitalizes on the mining of the repertoire of BM-PCs, a population 
of B cells that is responsible for the synthesis of the large majority of circulating 
immunoglobulins in animals [123]. While we have validated this methodology in mice 
there is no reason to believe that the same approach cannot be readily extended to 
primates including humans. Furthermore, it is possible that this technology could be 
extended for antibody discovery with more complex antigens such as viral and bacterial 
pathogens, as in these situations BM-PCs may still develop polarity to a single antigen. 
The mechanisms that dictate the selection of B cell differentiation into plasma cells and 
homing into the bone marrow are complex and appear to partially relate to high antigen 
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affinity [50], [132]. Since the highly abundant BM-PCs correspond to abundant 
circulating antibodies, it is plausible to hypothesize that these antibodies have been 
selected by the immune system (at least partly) because they display more potent 
pathogen neutralization. Therefore antibodies generated by the mining of the BM-PC 
repertoire may prove particularly useful for therapeutic purposes. The hybridoma 
technology and other B cell immortalization methods interrogate the antibody producing 
cells in pre-PC B cell populations, specifically in memory B cells, or in circulating short 
lived plasmablasts [112]; while, fully differentiated plasma cells are not amenable to 
most of these analyses since they do not survive outside their biological niches. Very 
recently, Jin et al. used microwell arrays and single cell cloning to isolate antibodies from 
spleen plasma cells [119]; however, despite the use of a sophisticated screening 
technology small numbers of antigen-specific clones could be isolated and consequently 
information on the repertoire and relative abundance of V genes could not be obtained by 
this method.  
 
Here we report on a simple, rapid, and fundamentally new approach for antibody 
isolation without screening that capitalizes on the mining of BM-PC antibody repertoires. 
The ability to take advantage of high-throughput DNA sequencing, bioinformatics 
analysis, and automated gene synthesis can lead to the isolation and expression of mAbs 
with minimal effort. In our hands, we have estimated that it takes about 10 man-hours for 
sample preparation for DNA sequencing. With automated bioinformatics processing of 
the 454 sequencing data, no extra effort is required to identify highly abundant VL and VH 
genes for DNA synthesis. Synthetic genes can be constructed either by an automated 
facility (as described herein) or through commercial gene synthesis vendors (such as 
IDT’s gBlock). Furthermore antibody genes can be codon optimized as desired for either 
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bacterial or mammalian expression and subsequent characterization studies. Thus, in 
terms of effort by dedicated personnel (not including DNA sequencing and synthesis, 
which are carried out by multi-user services) and timeline required for antibody 
discovery, our method compares very favorably to hybridomas, B cell immortalization, 
and B cell screening/single cell cloning methodologies. Currently, the most expensive 
part of our antibody discovery process is DNA sequencing followed by gene synthesis; 
however the cost for these technologies are declining at a rapid and exponential pace, 
resembling Moore’s law for microelectronics [76], [133]. Taken within this context, the 
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INTRODUCTION 
Immunoglobulin B cell receptor (BCR) diversity is an essential component of 
adaptive immunity for the recognition of a diverse constellation of foreign antigens. As a 
heterodimeric protein containing two heavy-chains and two light-chains, immunoglobulin 
is encoded by the rearrangement of variable (V), diversity (D), and joining (J) gene 
segments located in the immunoglobulin heavy locus (IGH) on chromosome 14 whereas 
the light chain is encoded by V-gene and J-gene rearrangements derived from either the 
immunoglobulin kappa locus (IGK) on chromosome 2 or the lambda locus (IGL) on 
chromosome 22. Genetic processes are a critical and fundamental step in the generation 
of extensive BCR diversity [29], [134]–[136]. A diversity of 1 x 1011 unique BCRs can be 
achieved in theory via random V(D)J recombination together with pairing of heavy and 
light chains. Additionally, due to imprecision in the V(D)J joining process itself, as well 
as enzyme-catalyzed reactions which can result in the addition of nontemplated (N/P) 
nucleotides and the introduction of somatic hypermutations (SHM), these mechanisms 
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together further expand the potential diversity of the immunoglobulin repertoire to more 
than one peta-BCRs (1x1015) [36]. Contrarily, the actual diversity in humans is likely to 
be several orders of magnitude lower, due in part to physiological limitations such as the 
number of B cells which can be derived during the finite lifespan of the organism. Actual 
diversity has been experimentally estimated to be on the order of 1-10 million [69]–[71]; 
hence, it seems implausible that random processes should be a primary constituent for 
BCR diversity, and thus selective mechanisms, be it genetic and/or somatic, must be in 
place to maintain the observed range of BCR diversity. 
 
In support of this view, characterization of heavy and light chain immune 
repertoires has revealed preferential, nonrandom usage of particular IGH genes [70], 
[137]–[141] as well as IGK genes [142]–[145]. One recent study of the human IGK 
repertoire [145], using next-generation deep sequencing of more than 60,000 IGK cDNA 
reads generated from peripheral blood B cells derived from four ethnically different 
individuals, showed a significantly biased use for particular IGK variable (IGKV) and 
IGK joining (IGKJ) genes; interestingly, the authors also reported that a surprisingly high 
percentage (up to 60.2%) of IGK protein sequences were shared, or so-called “public”, 
between any two of the four individuals examined, leading to the conclusion that the 
repertoire of unique κ chains is merely on the order of thousands as compared to prior 
theoretical repertoire estimates comprising 105 – 106 different IGK genes. This 
observation of frequent public sequences in the IGK repertoire differs from previous 
reports [142]–[144], presumably because at most only a total of a few hundred cells per 
individual were sequenced, and probably reflects the greater sensitivity and coverage 
made possible by the deep-sequencing techniques used in this study. Furthermore, the 
authors speculated that the existence of public IGK sequences might reflect: (i) a limited 
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number of rearrangements that do not introduce conformational clashes upon pairing with 
the heavy chain thus resulting in productive pairings; (ii) selection of light chains that do 
not interfere with antigen recognition, the latter being mediated near-exclusively by the 
IGH; or lastly, (iii) that certain IGK rearrangements are either counter-selected due to 
potential auto-reactivity or are positively selected as a response mechanism to 
superantigen-like molecules on microbes [145].  
 
In contrast with the more common studies of IGH and IGK repertoires, 
surprisingly little has been published regarding the IGL repertoire, whether in humans or 
various humanized mouse models [146]–[151]. Thirty-five functional IGLV segments 
have been classified within 10 gene families and 4 functional IGLJ segments [66], [152]–
[154]; CDR-L3 length is highly restricted while N/P nucleotide additions on average add 
only one new codon to the CDR-L3 [147], [149]. One prior theoretical calculation of the 
combined IGK plus IGL CDR3 repertoire has been estimated to be on the order of >1.6 x 
105 [70]. The CDR-L3 repertoire, specifically, has been estimated to comprise perhaps as 
many as 338,130 unique sequences [155]. Regarding its expression, preferential IGLV 
gene usage has been observed in humans as well as in transgenic mice engrafted with 
human lambda loci [146], [148]. Furthermore, Richl et al. [151] also reported preferential 
IGLV gene usage in human neonatal and adult B cells through the analysis of 236 
productive IGL sequences. These results suggested that the underlying gene 
recombination processes might be non-random yielding a preferred IGL repertoire.  
 
Here we have analyzed the IGL repertoire at great depth using next-generation 
sequencing (NGS) data from peripheral blood B cells obtained from two volunteers and 
compared it with the IGL repertoires derived from splenic B cells in NOD-scid-IL2Rγnull 
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mice (humanized mice) engrafted with human umbilical cord blood stem cells [18]. For 
additional comparison, deep sequencing data obtained independently by another research 
group and derived from two pairs of identical twins [138] were included in our analysis. 
As noted in the NGS study of the human IGK repertoire by Jackson et al. [145], we 
report here the frequent occurrence of public rearrangements within human and 
humanized mice IGL repertoires. Interestingly, public rearrangements include not only 
identical CDR-L3 peptide sequences but also identical full-length IGL protein sequences. 
Furthermore, we report that notable differences exist between public and private CDR-
L3s in terms of the degree of N/P nucleotide addition, somatic hypermutation, IGLV1 
gene family usage, and amino acid utilization. 
 
MATERIALS AND METHODS 
Humanized mice 
NOD.Cg-Prkdcscid IL2rgtm1Wjl (NOD-scid-IL2Rγnull) mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME). NOD-scid-IL2Rγnull mice were irradiated with 100 
cGy of gamma irradiation at 1-2 days of age. Upon irradiation, 50 µL of 3 x 104 human 
CD34+ hematopoietic cells derived from umbilical cord blood were injected via 
intracardiac route (Lonza, Cat. 2C-101B). HuMs1 and HuMs2 were both engrafted with 
the same donor, while HuMs3 was engrafted with a different donor. The humanized mice 
were housed at the Animal Resource Center of the University of Texas at Austin. All 
experiments were conducted following the guidelines provided by the university’s 





B cell preparation, RNA extraction, cDNA generation, and PCR amplification 
Detailed procedures have been described previously [18]. Briefly, mononuclear 
cells from two anonymous healthy donors, (both healthy females with one in her 30s and 
the other in her 50s), were prepared from whole blood using Histopaque-1077 density 
centrifugation and humanized mice spleens were harvested post euthanization. These 
single cell suspensions were used for total RNA preparations, and Oligo-dT cDNA was 
generated which was then used as template for an optimized PCR amplification of Vλ-Jλ 
recombinants. Samples were collected and prepared independently over a period of four 
months. 
 
Next generation sequencing of IGL repertoires 
Detailed procedures have been described previously [18]. Briefly, samples were 
serially acquired and PCR amplicons were gel-purified and prepared independently over 
a period of four months. Samples were then submitted to the University of Texas 
Genome Sequencing and Analysis Facility for library construction and Roche GS-FLX 
454 high-throughput sequencing.  
 
Bioinformatics analysis 
IGL repertoire sequences were obtained from two adults’ peripheral blood 
mononuclear cells (PBMCs), from splenic B cells isolated from three humanized mice, 
and from a pool of immature B cells isolated from three humanized mice [18]. Total RNA 
was isolated from the samples and library was generated with previously reported sets of 
primers [83]. Sequences were filtered to meet a minimum of 350 bps length requirements 
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and each had to contain an in-frame CDR-L3 region. These filtered sequences were 
submitted to IMGT/HighV-QUEST [89] for complete annotations, namely, Vλ and Jλ 
gene segment assignment, N- and P-nucleotide addition, and somatic hypermutation. 
Annotated information was parsed and extracted using Perl scripts for the analysis 
described in this manuscript. Public CDR-L3 was defined as CDR-L3 peptide sequences 
that can be found in two or more samples among the ten samples we examined. Only 
unique IGL nucleotide sequences were analyzed to avoid over-counting of duplicated 
sequences. All raw 454 sequences have been deposited to the NCBI Sequence Read 
Archive (Accession SRA049345). 
 
Rinat-Pfizer Twin Sequences 
Sequences from two pairs of adult monozygotic twins were kindly provided by 
the Rinat-Pfizer scientists [138]. Twin pair A [denoted in this manuscript as A1, A2] is of 
Western European and Mediterranean descent at the age of 54 years old. Twin pair B 
[denoted in this manuscript as B1, B2] is of Ashkenazi Jewish descent at the age of 57 
years old. Twin pair B was diagnosed with Multiple Sclerosis. These sequences were 
subjected to the same sequence analysis processing procedures and bioinformatics 
analysis as described in the bioinformatics analysis section of this manuscript. 
 
Statistical methods 
GraphPad Prism version 5.00 for windows was used to conduct statistical 
analysis. ANOVA (Kruskal-Wallis test) and Mann-Whitney test were used to determine 




B cells were sorted and IGL cDNAs were sequenced using Roche GS-FLX 454 
technology, as described previously [18]. Additionally, independently derived IGL cDNA 
sequences from two sets of identical twins were provided by the Rinat-Pfizer group [138] 
to corroborate our analysis. Only DNA sequences with more than 350bps and identified 
by IMGT/V-QUEST as “productive” were considered for further analysis. “Public” 
CDR-L3s were defined as CDR-L3 peptide sequences present in two or more samples 
whereas “private” CDR-L3s were unique to their single respective sample. In the work 
previously published by our group [18], under the same sample preparation and sequence 
analysis procedures as in this report, we found less than 0.001% of CDR-H3s to be 
shared among the human and humanized samples, which is consistent with the findings in 
other NGS studies [69], [71]. On the other hand, using the dataset derived from the same 
procedures, we analyzed the overlap of CDR-K3 between the human samples and found 
that about 19.7% of CDR-K3s were shared, which is similar to, although 3-fold less, than 
the degree of public sharing reported by Jackson et al. [145]. The frequency of public 
CDR3s found in our IGH library (<0.001%) and in our IGK library (~20%) agree with 
prior publications and, therefore, seem to indicate a minimal-to-zero introduction of 
sequencing artifacts and, furthermore, that our sample preparation and sequence analysis 
procedures faithfully preserved the integrity of the repertoires. Any artifacts which could 
have been introduced would have been expected to appear disproportionately, but this 
was not observed in the previous work nor in the CDR-L3 dataset analyzed here. 
 
Analysis of the human samples (HuPBC1, HuPBC2), humanized mice samples 
(HuMs1, HuMs2, HuMs3, HuMsImmB), and Rinat-Pfizer twin samples (A1, A2, B1, 
B2), revealed that any given individual sample shared at least 20% of its CDR-L3s with 
 58 
at least one other of the nine samples (Figure 11). IGL repertoires from humanized mice 
on average contained higher percentages of public CDR-L3s compared to the human 
counterparts (~57% versus ~30%) possibly due to an expanded compartment of naïve B 
cells in the humanized mice [18]. 
 
Figure 11: Percentage of public IGL CDR-L3s across all samples 
 
The human peripheral B-cell samples HuPBC1 and HuPBC2 (Figure 12b) 
exhibited a lower percentage of public CDR-L3s as compared to the complete 
comparison across all samples. The majority of the CDR-L3s in the two human samples 
were therefore distinct and hence private. Additionally, Rinat-Pfizer twin samples also 
indicated a lower percentage of public CDR-L3s as shown in Figure 12c. Both of these 
human datasets suggest that a greater number of naïve CDR-L3s were displaced to give 
rise to more “customized” CDR-L3s to cope with increased exposure to pathogenic 
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environments in both the human groups which was diminished in the specific pathogen-
free environment of the humanized mice. 
Figure 12: b-Percentage of public IGL CDR-L3s across in-house human samples c-
Percentage of public IGL CDR-L3s across Rinat-Pfizer twin samples 
 
On the other hand, as shown in Figure 13, the reverse was observed in the 
humanized mice samples where at least 40% of CDR-L3s were public. Nevertheless, 
frequent public CDR-L3s were still observed across all samples exposed to presumably 
different pathogenic environments; this includes public CDR-L3 repertoires shared 












Figure 14: Percentage of public IGL CDR-L3s across all human samples 
 
Additionally, these findings imply that preferential IGL gene rearrangements 
occur regardless of the repertoire’s developmental microenvironment. Therefore, there is 
a strong indication that preferential λ–chain gene rearrangement could be due to intrinsic 
genetic mechanisms independent of selective forces exerted at the cellular level. It is still 
unclear, however, as to the true cause of the difference in public CDR-L3 percentages 
between the human and the humanized mice samples. It is worthwhile to note that 
humanized mice tend to have impaired immune responses which suggests that many 
clones might not be significantly hypermutated or affinity-matured. 
 
Next, we separated full-length nucleotide sequences containing public or private 
CDR-L3 into individual FASTA files. These public/private-categorized sequences were 
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submitted independently to IMGT to ascertain N/P nucleotide addition, somatic 
hypermutation (SHM), CDR-L3 peptide sequence, V-J gene utilization, and full-length 
IGL protein sequence for each public/private group. Subsequently, we characterized the 
public and private IGL sequences in terms of V-J gene segment utilization and we found 
a decrease in the use of IGLV1 gene family in the public CDRL-3 sequences for the 
humanized mice group (Figure 15).  
 
Figure 15: IGLV1 family repertoire usage comparison 
 
This difference was not observed in the human group. Utilization of the remaining 
V and J gene segments did not show statistically significant differences across samples. 
CDR-L3 N/P nucleotide addition and IGL SHM were also examined, and the value for 
each sample was calculated as an average of all the SHM counts for the IGL sequences 
(FR1-FR4) derived from each sample. In terms of N/P nucleotide addition (Figure 16), 
there was a statistically significant difference between the public CDR-L3 sequences and 
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the private CDR-L3 sequences (p<0.001). In general, the private sequences demonstrated 
approximately two-fold more N/P nucleotide additions than the public CDR-L3 
sequences, indicating how preferential gene rearrangements are favored by fewer N/P 
additions, resulting in less diversity, enabled by unaltered joining of a germline IGLV 
gene segment to an IGLJ gene segment due perhaps in part to microhomology-mediated 
joining of the gene segments. 
 
Figure 16: N/P nucleotide additions comparison 
As a result, the likelihood of such unaltered CDR-L3 sequences occurring among 
individuals appears to be higher; however, it would require more evidence to conclude 
that the direct cause for public CDR-L3s can be solely attributed to fewer N/P nucleotide 
additions. Nevertheless, it was an unexpected observation that overall N/P nucleotide 




On the other hand, in Figure 17, no significant difference in SHM was observed 
between the public and private CDR-L3 groups for the humanized mice samples; 
however, the SHM difference between the public and private groups for the human 
samples, both the HuPBC and Rinat-Pfizer twin samples, were statistically significant 
(p<0.001).  
 
Figure 17: Nucleotide SHM comparison 
  
This difference could be due to the effects of antigenic selection augmenting the 
SHM numbers for the human samples. Since the humanized mice were housed in a 
specific pathogen-free environment and that no overt antigenic pressure was applied, 
germinal center reactions and hence SHM in the humanized mice should have been scant 
to nonexistent, as has been described generally for this mouse strain. This alone might 
explain the similarity of SHM observed in both the public and private humanized mice 
CDR-L3 groups. The significant difference between the public and private groups of 
 
 64 
CDR-L3s in the human samples, on the other hand, might reflect extensive past immune 
responses and the initiation of germinal center reactions, SHM, and selective mechanisms 
exerted upon antigen-specific B cells.  
 
We investigated the amino acid composition of length=11 CDR-L3s which were 
the most frequently observed across samples. We noticed, in general, that amino acid 
composition was similar between the public and private groups, except for arginine, 
proline, tryptophan, serine, and valine usage (p<0.001) as shown in Figure 18.  
 




Among those differences, the private groups utilized arginine, proline, and 
tryptophan ~1%-3% more than within the public groups. On the other hand, the public 
groups utilized ~6% more serine and valine. Serine was generally abundant in CDR-L3s 
across all samples overall, due primarily to the inherent serine-rich nature of IGL 
germline genes. The reduction of serine usage in the private group that we observed here 
could simply be due to the “customization” of the germline genes after various degrees of 
antigenic exposures. The enhanced use of arginine, proline, and tryptophan in the private 
group further support the notion of CDR-L3 “customization” as a result of antigenic 
challenge since these amino acids tend to promote recognition of pathogenic moieties. 
 
Lastly, upon further investigation of all the public CDR-L3 sequences, we 
observed that ~10.14% were part of otherwise identical full-length IGL protein sequences 
(Table 6). As noted in one prior study [150] where a frequency of ~15% identical IGL 
chains was observed within any single biologic sample assayed (fetal tissue or adult 
blood), the ~10% frequency in the present study is highly comparable—but striking in its 











Public CDR-L3 peptides appended with IMGT Vλ and Jλ assignments Count % 
Total 4169 - 
Non-exact match of CDRL-3+IMGT Vλ and Jλ assignments 1801 43.20 
Exact match of CDRL-3+IMGT Vλ and Jλ assignments 2368 56.80 
   
Full-length IGL protein sequences from the public CDR-L3 group Count % 
Total 26013 - 
Non-exact match of the Full-length IGL protein sequences 23375 89.86 
Exact match of the Full-length IGL protein sequences 2638 10.14 
Top panel: IMGT Vλ and Jλ assignments along with CDR-L3 were considered among the public CDR-L3 
group 
Bottom panel: Full-length IGL protein sequences were considered among the public CDR-L3 group 
Table 6: Enumeration of public CDR-L3s in all samples 
 
DISCUSSION 
Public CDR-L3s across individuals can be observed in IGL repertoires similar to 
that reported for IGK repertoires [145] but in stark contrast to the unique diversity and 
“privacy” of IGH repertoires [18], [69], [71]. Public CDR-K3s do occur at a very high 
frequency [145] and at a rate surpassing what we have observed for CDR-L3s. The IGL 
preferential gene rearrangements we observed do not seem to be affected by the 
microenvironment suggesting that intrinsic genetic mechanisms of recombination may 
contribute to this phenomenon. An associated phenomenon in the public CDR-L3 group 
was found to be suppressed N/P nucleotide addition that could potentially increase the 
likelihood of public CDR-L3s due to microhomology-mediated, unaltered joining of 
IGLV and IGLJ gene segments. As a result, the likelihood of public CDR-L3 would be 
increased. On the other hand, SHM trends observed in our study were inconsistent and 
did not indicate a clear correlate between SHM and the occurrence of public CDR-L3s. 
Nonetheless, a high percentage of public CDR-L3s having identical full-length IGL 
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protein sequences seems to support the naïve newly-formed nature of the IGL public 
repertoires. That naïve peripheral B cells were specifically sorted in the humanized mice, 
and that these samples exhibit the most extensively public CDR-L3 repertoire, further 
supports the notion that it is the primary IGL repertoire which can be publicly shared. 
 
Our findings indicate that the IGL repertoire is significantly constrained in the 
expression of CDR-L3 peptide sequence and suggests that a considerable fraction of 
these CDR-L3s is evolutionarily conserved and is expressed “publicly” by the species. 
By extension, limited λ-chain diversity implies that the combinatorial pairing of IGL light 
chains with IGH heavy chains might also be constrained. In most resolved antibody 
structures, the CDR3 loops of IGH and IGL are nearly always in contact at or near the 
center of the antibody binding pocket [156], [157]. Furthermore, unlike the considerable 
structural variation and sequence diversity of the CDR-H3, CDR-L3s adopt only a very 
limited set of distinct “canonical” conformations [14], [158]. The sequence restriction 
and public sharing of CDR-L3 protein sequences we report here seemingly correlates 
with the previously appreciated restriction of canonical structures. Even though one 
previous report did suggest the role of intrinsic genetic factors in the generation of the 
human IGL repertoire and, moreover, proposed this as a chief mechanism for ensuring 
the overrepresentation of particular IGLV segments [148], the extent of sequence analysis 
was insufficient to fully extrapolate their observation specifically to the CDR-L3, as we 
have done here using NGS deep-sequencing technology.  
 
Previous studies from the Lipsky laboratory using single-cell analysis of IGL 
repertoires in human fetal and adult tissues have suggested the positive selection of 
immunoglobulin light chain which is independent of the immunoglobulin heavy chain 
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[149], [150]. Although based upon a limited number (~100) of single-cell-derived 
sequences, the repeated occurrence of identical IGL chains was firmly established; 
however, these identical IGL chains were observed only within any one single sample 
assayed, contrary to our observation of public occurrences across multiple samples, 
which we attribute to marked differences in the depth of sequencing coverage between 
their study and ours. Moreover, these prior single-cell studies documented how identical 
IGL chains could pair with multiple IGH chains [150]. A more recent analysis by Weigert 
and colleagues indirectly supports this same observation and similarly concludes the 
existence of an IGH-independent mode of IGL selection [159]. Using microarray 
profiling rather than deep sequencing, a set of IGL genes was observed to be uniformly 
highly expressed without IGH chain restriction (i.e., IGH exhibiting a normally 
distributed CDR-H3 length spectratype), which they conclude is consistent with the 
positive selection of particular IGL chains, rather than clonal selection, independent of 
the IGH chain. Their results suggest that multiple overexpressed IGL chains might pair 
promiscuously with IGH chains. Indirectly, these results imply the possibility that some 
of the highly overexpressed IGL chains are in fact identical.  
 
It might be proposed, therefore, that certain CDR-L3s are optimal for binding a 
range of antigens and therefore have been selected and maintained throughout human 
evolution. An immediate corollary to this proposal is that certain classes of public CDR-
L3s pair preferentially with IGH chains. To address these possibilities and to gain further 
insight into the human antibody repertoire, we have developed a high-throughput 
methodology for NGS deep sequencing of natively paired H-L immunoglobulin chains 
isolated from single B lymphocytes [20]. The nature of this technique will allow for 
robust statistical analysis and the determination as to whether particular light chains, and 
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moreover, particular CDR-L3s, pair preferentially with particular heavy chains --- either 
the particular IGHV segment or even a particular class of CDR-H3. A specific analysis of 
the primary antibody repertoire of IgM+ naïve B cells in peripheral blood is predicted to 
reveal identical, public CDR-L3s, and even identical full-length IGL chains, but paired 
with multiple distinct IGH chains; thus, indicating non-clonally related sequences which 
have arisen independently in the primary repertoire. Imminent evidence that such must be 
the case is the very fact that the IGH repertoire is documented to be extensively 
diversified [18], [71] and, therefore, the restriction of IGL diversity we observe here can 
only be accommodated if it pairs promiscuously with multiple IGH chains and their 
CDR-H3s. Such a striking observation would immediately imply an unexpected IGL-
mediated mode of selection, independent of the IGH chain, which recruits IgM+ naïve B 
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INTRODUCTION 
B cell development and repertoire diversification vary significantly among 
vertebrate species [160]. Diversification of the Ig repertoire occurs through the 
combinatorial joining of numerous V, D, and J gene segments for the Ig heavy chain (or 
just V and J gene segments in the case of Ig light chains) through several mechanisms 
collectively referred to as VDJ recombination, followed by somatic mutagenesis upon 
subsequent B-cell encounter with foreign antigen. Compared to humans and mice, which 
use a diverse assortment of germline VH gene segments during VDJ recombination of the 
 71 
heavy chain, the rabbit IgH repertoire displays highly restricted VH gene segment usage. 
Earlier studies had indicated that the majority of B cells in the rabbit utilize the VH1 
gene, the most D-proximal VH locus [161]. VH1 Igs are serotypically VHa-positive, and 
there are three distinct VHa allotypic lineages (a1, a2, and a3) [162], [163]. In addition, 
approximately 10-20% of expressed Ig in rabbits are serotypically VHa-negative (VHn) 
[163], [164]. The VHn Ig genes that have been annotated in rabbits (VHx, VHy, and 
VHz) are encoded by loci significantly upstream (>100 kb) of the VH1 gene locus [165]. 
Recently, sequencing of the rabbit genome has enabled the identification of germline Ig 
elements in a Thorbecke inbred rabbit [166]. Overall, >300 VH-like gene sequences were 
identified within 79 unplaced genomic scaffolds (i.e. unknown chromosomal locations). 
The large number of previously unannotated VH-like sequences identified within the 
a1/a2 Thorbecke rabbit, as well as previously identified sequences from latent heavy 
chain allotypes [161], [167], clearly demonstrate the complexity of the germline Ig 
repertoire. However, because the sequenced Thorbecke rabbit was heterozygous at the 
IgH locus (a1/a2 based on mapping of the VH1 gene), the actual number of distinct VH 
gene elements in the haploid genome is unclear. 
 
Another major source of Ig repertoire diversity derives from the somatic 
introduction of non-templated nucleotides into the imprecise junctions formed by the 
variable ligation of recombining V-D and D-J gene segments—a process known as N-
nucleotide addition. This hypervariable V-N-D-N-J interval defines CDR3 of the heavy 
chain (CDRH3). Species such as cattle have extremely long CDRH3s [168] as a result of 
increased levels of N-nucleotide addition. Longer CDRH3s not only create a more 
expansive and diverse sequence space in the Ig repertoire, but may also hold unique 
functional relevance in protection against disease [169]. For most mammalian species, N-
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nucleotide addition during VJ recombination of the light chain is limited and therefore 
junctional diversity in the light chain is much less pronounced compared to the heavy 
chain; however, rabbits have been shown to have light chain CDR3s (CDRL3s) that are 
unusually longer and more diverse, indicating significant N-nucleotide addition during 
light chain VJ recombination [170]. 
 
After VDJ recombination, the naïve Ig repertoire in rabbits is further diversified 
in the first 2 months of age by extensive somatic mutagenesis in the gut-associated 
lymphoid tissue (GALT) [171], through both somatic hypermutation (SHM) and gene 
conversion events [172], both of which have been shown to be dependent upon the 
exposure of the naïve B cell repertoire to the gut microflora [173]. Ig gene conversion is 
employed not only by rabbits, but also by other species including chickens and involves 
the non-reciprocal homologous recombination of upstream donor V gene loci into the 
recombined VDJ (and VJ) locus. Like SHM, Ig gene conversion is mediated through the 
enzyme activation induced cytidine deaminase (AID) [174] and thus is often found to 
occur proximal to hotspot AID motifs conserved within germline V genes. In chickens, 
gene conversion has been shown to be the dominant mechanism of AID-mediated 
mutagenesis [175] and involves a single functional VH and VL gene undergoing gene 
conversion with numerous upstream VH and VL pseudogenes, respectively [176]. In 
rabbits, however, the upstream loci are a mix of functional V genes and pseudogenes that 
can serve as potential donor sequences in gene conversion events. The fundamental 
properties of gene conversion events and the relative extent to which gene conversion 
plays a role in rabbit Ig diversification is not entirely clear, mostly due to limitations in 
sampling and difficulty in precise, automated identification of gene conversion events in 
highly mutated Ig sequences. 
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Here, we present a thorough characterization of the expressed rabbit IgG 
repertoire. We identify several unannotated functional rabbit germline VH and VL 
germline gene sequences and provide a comprehensive survey of the salient features of 
the rabbit Ig repertoire. We estimate the gene conversion frequency in the rabbit and 
demonstrate that it is significantly less than that observed in the chicken repertoire and, 
not surprisingly, much greater than that observed in humans and mice. 
 
MATERIALS AND METHODS 
Ethics Statement 
Three New Zealand white (NZW) rabbits and one white leghorn chicken were 
used for this work, as approved through the Institutional Animal Care and Use 
Committee (IACUC) of the University of Texas at Austin (protocol AUP-2011-00016). 
All efforts were made to ensure animal welfare and minimize suffering in accordance 
with the United States Department of Agriculture (USDA) Animal and Plant Health 
Inspection Service (APHIS) Guidelines for animal care and husbandry. 
 
Isolation of B cells from immunized rabbits, chicken, mouse, and human 
At sacrifice, rabbit femoral bone marrow (BM) cells were isolated and 
approximately 100 ml blood was collected into heparin tubes. Blood aliquots of 20 ml 
were gently layered over 20 ml of Histopaque 1077 (Sigma, MO, USA) and centrifuged 
in a swinging bucket rotor at 400g, 45 min at 25°C (Beckman Coulter). The serum was 
removed from the top of the gradient and stored at -20° C. PBMCs were isolated from the 
intermediate layer. Each collected tissue (BM and PBMC) was processed as previously 
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described [83], with the exception that the PBMCs did not require red blood cell lysis 
after gradient centrifugation. CD138+ cells were isolated as previously described [84]. 
PBMCs or CD138+ BM plasma cells (PCs) were centrifuged at 930xg, 5 min at 4°C. Cells 
were then lysed with TRI reagent (Ambion, TX, USA) and total RNA was isolated 
according to the manufacturer's protocol in the Ribopure RNA isolation kit (Ambion). 
RNA concentrations were measured with an ND-1000 spectrophotometer (Nanodrop, 
DE, USA). 
 
For the chicken, total RNA was prepared from splenic tissue of a white leghorn 
chicken using TRIzol reagent (Life technologies) and purified with RNeasy Micro Kit 
(Qiagen, CA). cDNA was generated from total RNA using oligo(dt) according to the 
manufacturer’s protocol (Superscript II First strand Synthesis kit, Life Technologies), 
PCR-amplified as described previously [177] using chicken IgY-specific primers listed in 
Table 7, and sequenced using the 2 × 250 paired end MiSeq Next Generation Sequencing 
(NGS) platform (Illumina, San Diego, CA, USA). The two IIlumina 2x250 output files 
were aligned using FLASH [98] and CDRH3 and full-length VH sequences were 
determined using in-house probabilistic model [83] for delimiting the CDRH3 regions 
based on Gallus gallus Ig sequences found in NCBI Genbank. 
 
Amplification and high-throughput sequencing of rabbit VH and VL gene 
repertoires 
Approximately 0.5 µg of ethanol precipitated RNA was used for first-strand 
cDNA synthesis according to the manufacturer’s protocol for 5’ RACE using the 
SMARTer RACE cDNA Amplification kit (Clontech, CA, USA). The cDNA reaction 
was diluted into 100 µl of Tris-EDTA buffer and stored at -20°C. 5’ RACE PCR 
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amplification was performed on the first strand cDNA to amplify the VH repertoire with 
the kit-provided, 5’ primer mix and 3’ rabbit IgG-specific primers RIGHC1 and RIGHC2 
(Table 7). The rabbit VL repertoire was amplified via 5’ RACE, using a 3’ primer mix 
specific for both the Vκ and Vλ rabbit constant regions. The VL primers comprised 90% 
RIGκC mix and 10% RIGλC mix (Table 7) to approximate known ratios of light chain 
isotypes in rabbits. Reactions were carried out in a 50 µl volume by mixing 35.25 µl H2O, 
5 µl 10X Advantage-2 PCR buffer (Clontech), 5 µl 10X Universal Primer A mix 
(Clontech), 0.75 µl Advantage-2 polymerase mix (Clontech), 2 µl cDNA, 200 nM VH or 
VL primer mix, and 200 µM dNTP mix. PCR conditions were: 95 °C for 5 min, followed 
by 30 cycles of amplification (95 °C for 30 sec, 60 °C for 30 sec, 72 °C for 2 min), and a 
final 72 °C extension for 7 min. The PCR products were gel-purified to isolate the 
amplified VH or VL DNA (~500 bp). 100 ng of each 5’ RACE amplified VH or VL DNA 





Sequence Description of use 
RIGHC1 CAGTGGGAAGACTGACGGAGCCTTAG Rabbit IgG CH1 reverse VH primer mix 
(equimolar) 
RIGHC2 CAGTGGGAAGACTGATGGAGCCTTAG Rabbit IgG CH1 reverse VH primer mix 
(equimolar) 
RIGκC1 TGGTGGGAAGAKGAGGACAGTAGG Rabbit Igκ reverse primer mix (90% of mix) 
RIGκC2 TGGTGGGAAGAKGAGGACACTAGG Rabbit Igκ reverse primer mix (5% of mix) 
RIGκC3 TGGTGGGAAGAKGAGGACAGAAGG Rabbit Igκ reverse primer mix (5% of mix) 
RIGλC1 CAAGGGGGCGACCACAGGCTGAC Rabbit Igλ reverse primer mix (equimolar) 
RIGλC2 GTGAAGGAGTGACTACGGGTTGACC Rabbit Igλ reverse primer mix (equimolar) 
RIGλC3 GAGGGGGTCACCGCGGGCTGAC Rabbit Igλ reverse primer mix (equimolar) 
Chicken VH1 GCCGTGACGTTGGACGAGTCC Chicken VH1 forward primer 
Chicken IgY GGAGGAGACGATGACTTCGGTCCC Chicken IgY reverse primer 
Table 7: Primers used to amplify IgH and IgK/Igλ repertoire 
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All 454 data were first processed using the sequence quality and signal filters of 
the 454 Roche pipeline and then subjected to bioinformatics analysis that relied on 
homologies to conserved framework regions using IMGT/HighV-Quest Tool [68]. 
Additional filters were applied for full repertoire database construction as follows: (i) 
Length cutoff: full-length sequences were filtered by aligned amino acid lengths > 70 
residues and aligned framework 4 region lengths > 2 residues; (ii) Stop codons: aligned 
amino acid sequences containing stop codons were removed. 
 
IgBLAST alignment, Multidimensional scaling (MDS), and k-means analysis 
An IgBLAST database for germline annotation of the rabbit IgG sequences was 
constructed using the following sequences: the IMGT rabbit V germline reference set that 
includes the allotypic a2 sequences in BAC clones AY386694 and AY386697 [178], 
allotypic a2 sequences from an Alicia rabbit (AF176997 through AF177016) [179], 
potentially latent IGHV (M12180, M60121, M60336) [167], [180], [181], allotypic a1 
sequences VH1-a1 (M93171), VH3-a1 (M93177), and VH4-a1 (M93181) [182], and the 
allotypic a3 sequences VH1-a3 through VH7-a3 (M93173, M93176, M93179, M93183, 
M93184, M93185, M93186) [172], [182]. In addition to the IMGT rabbit reference set, 
initial IgBLAST database included VH8-a3 through VH11-a3 (L27311, L27312, L27313, 
L27314) [183], VHx (L03846) [184], and VHy (L03890) [184]. For light chain, the 
IMGT database was used without addition. IgBLAST alignments against the database 
were analyzed by bit score (and equivalently the number of called nucleotide mutations 
per sequence). Aligned (annotated to a certain germline) sequences with greater than 30 
called mutations were extracted from this initial IgBLAST alignment and these poorly 
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aligned sequences were aligned using MUSCLE [185] multiple sequence alignment 
(BLOSUM80 substitution matrix, gap open penalty -15, gap extend penalty -3). For 
calculating distance matrices and performing MDS, the package bios2mds [186] in the R 
environment was used. The MUSCLE alignment was imported into R and the pairwise 
distance matrix calculation using the ‘mat.dif’ function, which computes a distance 
matrix based on pairwise differences between each sequence was performed. Metric 
MDS analysis of the pairwise distance matrix was performed using the function ‘mmds’, 
which reduces the dimensionality of the distance matrix into Euclidean space. These 
Euclidean values are analyzed by k-means silhouette scoring (function ‘sil.score) and k-
mean clustering (function ‘Kmeans’) to identify distinct sets of sequences that each 
derived from an unannotated germline Ig sequence. The sequences from each cluster are 
extracted and aligned in MUSCLE. For each derived cluster alignment, the consensus 
sequence was searched by BLASTn against the non-redundant nucleotide collection and 
the rabbit genome. 
 
IMGT and IgBLAST repertoire analyses 
Germline V gene assignments were derived from IgBLAST alignments against 
the database described above. Germline J gene assignments and CDR3 sequences (rabbit, 
mouse, and human) were derived from IMGT HighV-Quest alignments. Chicken CDR3 
sequences were derived from a position weight matrix motif search of the FR3 and J 
region in chickens. 
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Gene conversion analysis 
For rabbits, IgBLAST alignments of the NGS data sets was performed using 
custom BLAST databases for rabbit, as detailed above. For the chicken, the IgBLAST 
database included the functional VH1 sequence, along with 18 known VH pseudogenes 
[176]. For mouse and human, the IgBLAST-provided database was used. IgBLAST was 
used to assign the best-scoring germline VH reference sequence for each query sequence. 
To detect gene conversion events in the query, the assigned germline reference sequence 
was then scored against all other germline reference sequences in the IgBLAST 
alignment as follows (an example is shown in Figure 19): 1) For each VH germline in the 
alignment (each a possible donor VH sequence) except the assigned one, we used a 
scoring function that assigns a ‘1’ at each position only if the putative donor VH matches 
and the assigned reference VH germline mismatches, a ‘0’ at each position that both 
references either match or both mismatch, and a ‘-1’ at each position that the assigned 
reference VH matches and the putative donor VH mismatches. 2) Search each scored 
putative donor VH for stretches of positions that score as ‘1’, with a putative gene 
conversion event called only if three positions scoring ‘1’ are uninterrupted by positions 
scoring ‘-1’. The gene conversion event boundaries were defined by positions scoring ‘-
1’ (long tract boundary) or by the most distal positions of the tract that score ‘1’ (short 
tract boundary). Adjacent long tracts from the same donor VH are automatically 
combined by allowing long tracts with a shared boundary to connect. Positions of the 
alignment that have gaps in the query are scored as ‘0’ in all putative donor VH scored 
positions. To exclude PCR crossover products or gene replacement events (single 
crossover events), all gene conversion events that start within the first 15 positions or end 
with the last 15 positions of the aligned VH gene are excluded (e.g. the gene conversion 
must be an internal double crossover event with sufficient sequence from the assigned 
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VH on each side). The donor VH selected represents the germline VH with the highest 
scoring tract (sum of the tract positional scores). P-values for the gene conversion events 
are scored as described [187], with the exception that all polymorphic sites are permuted 
during the permutation test. The p-values described here are local p-values calculated via 
1000 iterations of positional permutation of the assigned and donor VH germlines. Only 
gene conversion events with a p-value below 0.05 (95% confidence interval) and a 
minimum tract score > 4 (to avoid effects of high SHM) are considered as high 
confidence events.  
 
 
Figure 19: An example summarizing the scoring system. 




Identification of putative rabbit VH germline elements using multidimensional 
scaling of high throughput sequencing data 
Total RNA was isolated from BM PCs and total PBMCs of three adult NZW 
rabbits. IgG heavy chain and Igκ/Igλ light chain cDNAs were amplified by 5’ RACE 
using primers that annealed respectively to the CH1 or CK/Cλ constant region directly 3’ 
of the J segment (detailed procedures in materials and methods section), and the resulting 
amplicons were sequenced by Roche 454 sequencing. 172,126 high quality reads 
corresponding to 88,830 unique heavy chain sequences across the three rabbits were 
obtained (Table 8).  
 
Sample reads 




Rabbit rab1 PBMC VH 16102 9447 5525 
Rabbit rab1 Bone marrow PC VH 31136 19044 5954 
Rabbit rab2 PBMC VH 24251 13459 7220 
Rabbit rab2 Bone marrow PC VH 76510 34762 11564 
Rabbit rab3 Bone marrow PC VH 24127 12118 5958 
Rabbit rab1 Bone marrow PC VL 24489 10446 5629 
Rabbit rab2 Bone marrow PC VL 17155 7487 4465 
Rabbit rab3 Bone marrow PC VL 23761 12581 7139 
Table 8: Summary of sequencing reads from 454 DNA sequencing 
 
Germline VH usage was determined with IgBLAST [92] alignments using a 
custom database that included NZW rabbit germline sequences compiled from a number 
of sources [167], [172], [178]–[184] (see Materials and Methods). For the VHa sequences 
in all three rabbits, >99% were of the a3 allotype, strongly indicating that the cohort of 
NZW rabbits examined here is homozygous a3/a3 at the IgH locus. However, the 
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IgBLAST alignments revealed a non-normal distribution of VH germline alignment 
scores (Figure 20).  
 
 
Figure 20: Comparison of IgBlast alignment before and after the addition of the 
putative sequences identified via MDS and k-means clustering 
 Note: before is v.1 in figure while after is v.2 in figure 
 
Based on an analysis by Gertz et al. [166] revealing a number of unannotated 
germline elements in an a1/a2 Thorbecke rabbit, we hypothesized that the NZW rabbit 
germline database may be incomplete and thus lack the germline V gene sequences for 
these poorly scoring Ig alignments. MDS [188], a space-based method that has been used 
to identify patterns in distance matrices derived from multiple sequence alignments 
(MSAs) of large biological sequence data sets [186], [189], [190], was employed to 
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deduce putative germline V gene segments. MDS allows MSA distance matrices to be 
analyzed in Euclidean space, facilitating k-means clustering [191] of the sequences. In 
the case of somatically mutated Ig V gene sequences, the consensus sequence of each of 
these k-means defined clusters represents a putative germline V gene sequence. Figure 21 
shows the MDS and k-means clustering of the poorly aligned VH gene sequences (higher 
than 30 nt differences from the nearest VH germline) in the NZW CCH1 immunized 
rabbit (CCH1 BMPC) repertoire as an example. For each of the other rabbits, the same 
pattern of four distinct VH clusters was identified. Each cluster of VH sequences was 
extracted and aligned, and the consensus sequence for each of the four clusters was 
compared across the three rabbits. Each of the four VH consensus sequences matched 
identically across all three rabbits, strongly supporting our hypothesis that the poorly 
aligned sequences are derived from unannotated germline VH elements encoded in the 
NZW rabbit genome.  
 
 
Figure 21: MDS and k-means clustering of low scoring alignments for CCH1 rabbit  
Note: BMPC VH sequences: the left panel is PC1 vs PC2 and the right panel 
is PC1 vs PC3 while each colored groups is determined by k-means 
clustering of the Euclidean MDS-derived values 
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 The four putative germline sequences identified by MDS and k-means clustering 
were searched by BLASTn to identify homology to publicly available rabbit genomic and 






total	  (nt)	   Source	  




(1)	  liver	  genomic	  DNA	  putative	  VH,	  (2)	  Thorbecke	  rabbit	  








(1)	  imm-­‐B	  cell	  genomic	  VDJ,	  (2)	  PBC	  mRNA	  LigApx	  rabbit,	  








(1,2)	  PBC	  mRNA	  LigApx	  rabbit,	  (3)	  Thorbecke	  rabbit	  
unplaced	  genomic	  scaffold	  
VHn2	   AF245499	   10/288	   mRNA	  from	  rabbit	  bone	  marrow	  and	  spleen	  
Table 9: Blastn results of the four putative VH germline sequences identified by MS 
and k-means clustering 
 
For three of the four putative VH germline sequences, NZW rabbit genomic or 
transcript sequence matches were found that were identical or within 1-3 nucleotide 
differences. The closely matching transcript sequences (AY676808, AF264452, and 
AF264440) were derived from rabbits that have a ligated appendix (LigApx) [173], 
[192], which effectively eliminates SHM and gene conversion. Three of the four putative 
germline sequences contained a 70WVN72 motif, consistent with VHa-negative (VHn) 
immunoglobulins (VHa sequences have a 70WAK72 motif), while one sequence (VHs1) 
had a 70SVK72 motif, which is predominant in VHs immunoglobulins (which are also 
VHa-negative) and ancestral to hares [193]. VHx2 was highly identical (281/288 nt) to 
the VHx32 allele previously annotated [184] and may represent a distinct VHx allele 
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(hence its designated ID). These four new putative germline sequences in the NZW rabbit 
were added to our existing NZW rabbit germline database (see Materials and Methods for 
full description) and using this updated database, IgBLAST was used to assign VH and 
JH germline usage (Figure 22). Consistent with earlier observations [84], [161], the VH1 
gene is heavily utilized in all three rabbits, as is the VH4 gene, which is >97% identical 
to VH1. The VHa-negative sequences (combined) account for 12%, 22%, and 11% of the 
total IgG sequences in CCH1 BMPC, CCH1 PBMC and CCH2 BMPC rabbit 
respectively. All three rabbits also exhibit highly restricted JH usage, with JH4 




Figure 22: Heavy chain germline gene usage 
Note: the left panel is the VH usage and the right panel is the JH usage  
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Vκ and Jκ usage in the rabbit 
Similar to mice, rabbits utilize the kappa light chain isotype at a much higher 
frequency than the lambda isotype [194]. We amplified the light chain repertoire from 
BM PCs in all three rabbits using 5’ RACE and sequenced the VL region using Cκ and 
Cλ specific primers. A total of 65,405 high quality reads and 30,514 unique sequences 
across the three rabbits were obtained (Table 8). As expected, the utilization of lambda 
light chain sequences sets was very low (<1%). Rabbit immunoglobulin kappa light 
chains have four allotypes: b4, b5, b6, and b9 [195]. For each of the three rabbits 
examined here, more than 98% of the unique VL sequences were of the b4 allotype, 
indicating this cohort of NZW rabbits was b4/b4 homozygous. Similar to the results of 
the VH IgBLAST alignments, Vκ gene alignment scores also revealed a non-normal 
distribution, with a group of sequences exhibiting significantly lower alignment scores as 
compared to the bulk of the Vκ sequences (data not shown). These poorly aligned 
sequences were examined more closely by MDS and k-means clustering as described 
above and in the Materials and Methods, and four new Vκ clusters were identified (data 
not shown). Two of the four putative Vκ germline sequences (NZWk57r and 
NZWk155g) were utilized in all three rabbits. NZWk57r and NZWk155g has also been 
detected in non-functional light chain sequences (VJ junction out-of-frame) in the bone 
marrow of a 1 day old b5/b5 NZW rabbit (i.e. early development when naive, unmutated 
Ig sequences are common in the rabbit) [170]. For the other two putative Vκ germlines, 
one was identified only in the CCH1 PBMC and CCH2 BMPC rabbit samples 
(NZWk807y), while the other was identified only in the CCH1 PBMC rabbit sample 
(NZWk529g). Nonetheless, all four cluster consensus sequences were also found by 
BLASTn analysis as either exact matches or differing by only 1 nt (NZWk807y) from 
previously identified germline genes in the Thorbecke inbred rabbit. 
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The four putative Vκ sequences were added to our existing NZW IgBLAST 
database, which was then used to assign germline Vκ usage (Figure 23). Contrary to the 
sharp germline restriction seen in the VH gene repertoire, Vκ gene usage is very diverse, 
with the top germline gene segment used at ~10-20% and 30 Vκ germlines utilized at 
least >1% (of total unique Vκ sequences) across the three rabbits. Jκ germline usage, on 
the other hand, is mostly restricted to the IGHK1_2 gene (~90%) and to a very small 
extent IGHK1_1 and IGHK2_2. 
 
 
Figure 23: Light chain germline gene usage 




Characterization of the CDRH3 and CDRL3 in the rabbit IgG repertoire as 
compared to other species 
In addition to the rabbit NGS data set, we also analyzed human [85], mouse [83], 
and chicken NGS data sets to compare and contrast repertoire characteristics across 
species. For the chicken, we obtained 320,468 high quality VH sequence reads (231,165 
unique VH amino acid sequences) from the splenic B cell repertoire of a white leghorn 
chicken using the Illumina MiSeq 2x250 NGS platform. A comparison of the CDRH3 
length distribution is shown in Figure 24. Rabbit IgG CDRH3 lengths are intermediate 
(mean = 14.8±3.6 aa, mode = 13 aa) relative to mice (mean = 11.1±2.0 aa, mode = 10 aa), 
humans (mean = 15.3±4.0 aa, mode = 15 aa), and chickens (mean = 17.9±2.8 aa, mode = 
16 aa). The length distribution of the CDRH3 for all unique IgG sequences was similar 
across all three rabbits (Figure S3). For CDRL3, mice and humans both exhibit very little 
junctional diversity and are severely restricted in length, with the vast majority of 
CDRL3s for both species being 9 ±1 amino acids (Figure 24); However, the rabbit 
exhibits significant junctional diversity in the CDRL3, with a wide distribution of 
CDRL3 lengths (range: 5aa – 16aa) and a much greater mean length, equal to 12 ±1.6 aa. 
The amino acid composition of the rabbit Ig CDRH3 is dominated by tyrosine (Y), 
glycine (G), and aspartate (D) which together represent half (49%) of the amino acid 
usage in the CDRH3 loop (Figure 24), while the top five amino acids used (GYDAS) 
represent a full two-thirds (66%) of the amino acid usage. In that regard, the overall 
amino acid utilization in the rabbit is highly similar to the other species, consistent with 
earlier observations [196] that the average hydrophobicity of CDRH3—and, hence, the 
center of the antigen binding site—is conserved across evolution to be slightly 




Figure 24: Cross species difference in the characterization of the CDRH3 and CDRL3  
Note: the top panel is CDRH3 lengths, middle panel is the CDRL3 lengths, 
and the bottom panel is amino acids composition 
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Nevertheless, when compared to other species, the CDRH3 amino acid 
composition in rabbits does show some distinct features. Human CDRH3s use glycine 
and tyrosine at a much lower frequency than that seen in rabbits. Chicken CDRH3s have 
less tyrosine (~ 2-fold less than rabbits) but utilize much higher cysteine content (~ 5–10-
fold higher than humans or rabbits). The higher utilization of cysteine residues in the 
chicken CDRH3 repertoire has previously been shown to be important for stabilizing (by 
disulfide bonds) the longer CDRH3 loops seen in chickens [197]. 
 
Diversification of the rabbit IgG repertoire by SHM and gene conversion 
The rabbit Ig repertoire is known to undergo extensive AID-mediated 
mutagenesis (via both SHM and gene conversion) early on in development when the 
antigen-inexperienced naïve B cell repertoire migrates from the bone marrow to the 
GALT [165]. Earlier studies with rabbits lacking an established gut microflora 
demonstrated significantly reduced levels of AID-mediated diversification of the 
repertoire, with most Ig having sequences that approximate the germline elements from 
which they are derived [173], [192]. 
 
We compared the overall level of mutation (combined SHM and gene conversion) 
within the IgG repertoires of rabbits, chicken, mice and humans (Figure 25). The 
mutational load varied as follows: chicken>rabbit ≈ human>mouse. It should be noted 
that the reported mutational load is a combination of both biological processes mediated 
by AID and inherent PCR/sequencing error, which has been reported to be approximately 




Figure 25: Comparison of overall nucleotide deviations in the VH sequences across 
species 
 
To determine the relative contribution of gene conversion to the diversification of 
the primary repertoire, we developed a script that searches Ig sequences for tracts of 
putative gene conversion events (see Appendix). Gene conversion tracts are detected as a 
contiguous block of nucleotides within a query Ig sequence that closely matches a 
different germline element (e.g. not the query’s assigned germline element) in the 
IgBLAST database. Additionally, to rule out possible PCR template switching artifacts, 
the gene conversion tracts were required to be bound on each end by positions (tracts) 
that match the query’s assigned VH germline sequence (i.e. the gene conversion event 
was not contiguous with the 5’ or 3’ ends of the sequence). Additionally, minimum 
scoring and p-value thresholds were applied as described in the methods. Strict statistical 
thresholds were set to ensure that the identified gene conversion events were highly 
significant and not attributed to high loads of point mutation. For these reasons, the 
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reported frequencies of gene conversion events should be considered as a lower bound of 











CCH1	  rabbit	  BMPC	  IgG	  VH1	   10680	   23	   17	   59	  
Chicken	  Spleen	  IgY	  VH1	   10000	   70	   23	   79	  
Mouse	  BMPC	  IgG	  VH1	   946	   0.1	   5	   6	  
Human	  PBMC	  IgG	  VH3	   1028	   2.5	   7	   39	  
Table 10: Gene conversion comparative analysis across species 
 
The vast majority of unique chicken IgY sequences examined (70%) display 
evidence of gene conversion events. In rabbits, 23% of IgG sequences were the products 
of gene conversion. There have been previous, although somewhat controversial, 
indications suggesting gene conversion occurs in humans and mice as well, albeit at a 
much lower frequency [199]–[201]. We find that, in the mouse, putative gene conversion 
events are nearly absent, with an estimated frequency of 0.1% of all unique IgG 
sequences. Whereas an earlier analysis of gene conversion in a small set of human IgG 
sequences indicated that ~7% (8 out of 121) display evidence of having undergone gene 
conversion [201], our present analysis of a much larger data set revealed a lower 
frequency of 2.5%. We note that, in humans and mice, the low p-values (p<0.05) in the 
detection of gene conversion events suggest that these are high confidence identifications 
despite the fact that the average tract lengths detected were significantly lower than those 
in the rabbit and chicken (Table 10). 
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The frequencies of donor germline VH usage for gene conversion in the rabbit are 
largely unknown. Figure 26 shows the donor germline VH usage for query sequences that 
were assigned by IgBLAST to one of three heavily utilized germline VH gene segments 
in the rabbit (VH1, VHs1, and VHn3). Because gene conversion occurs through 
homologous recombination, the frequency is heavily dependent on donor VH sequence 
homology and proximity. High homology donor VH genes directly upstream of the 
assigned VH reference (e.g. the VH germline originally used during VDJ recombination) 
are expected to be used in gene conversion more frequently than donor genes that are 
more distal or less homologous. The donor germline usage for VH1 is consistent with this 
expectation, with the genes directly upstream being used as donors for gene conversion 
more frequently than those more distal to VH1. The two VHa-negative sequences (VHs1 
and VHn3) have very different patterns of germline VH donor usage. The genomic 
location and organization of these two VHa-negative elements are not known, but it is 
clear that VHs1 must be downstream of VHn3 as it heavily utilizes VHn3 as a donor 
sequence for gene conversion. 
 
The tract lengths and start/end residue numbers of the gene conversion events for 
assigned VH1 sequences are shown in Figure 26 middle panel and 26 bottom panel. The 
majority of gene conversion tracts in rabbit IgG are under 30 bp in length, although some 
identified tracts are much longer (>120 bp). As expected for AID-mediated events, the 
gene conversion tracts have start and end positions that mostly localize to the CDRH1 
and CDRH2 regions of the V genes, where a number of conserved AID hotspot motifs 
are located. These CDRs, along with CDRH3, constitute a large amount of the paratope 





Figure 26: Gene conversion analysis 
Note: top panel describes donor genes utilization in gene conversion, middle 
panel describes gene conversion tract length, and bottom panel describes the 
nucleotide positions along the VH gene sequence where the gene conversion 




The vertebrate adaptive immune system is unparalleled in its ability to sample the 
depths of protein sequence space for the production of high-affinity antibodies endowed 
with exquisite specificity. Not only are antibodies extremely useful in the lab as affinity 
reagents, but they also represent the fastest growing sector of the biologics drug market, 
with annual global sales for monoclonal antibodies approaching $50 billion [202]. This 
has resulted in an increased interest for mining the antibody repertoires within vertebrates 
in a systematic, high resolution manner, something afforded by increasingly economical 
NGS technologies that enable the collection of thousands to millions of DNA sequences 
in a single sequencing run. Several species’ Ig repertoires have been characterized by 
NGS to date [20], [69], [83], [130], [168], [203]. In this report, we used 5’ RACE-
amplification of rabbit IgG and Igκ/Igλ transcripts, followed by NGS and bioinformatics 
analyses, to elucidate key features of the repertoire. We provide evidence that the existing 
rabbit germline VH gene database, as annotated from a number of sources [167], [172], 
[178]–[184] (see Materials and Methods), is incomplete. This was not surprising based on 
previous estimations of the number of Ig germline elements in the rabbit and also a very 
recent survey of Ig germline elements detected in the genome of a Thorbecke inbred 
rabbit [166]. 
 
There are typically two types of approaches for examining sequence relationships 
in the multiple alignments of homologous sequences: (1) tree-based methods (e.g. 
phylogenetics) and (2) space-based methods that, unlike phylogenetics, do not infer a 
hierarchical or a specific structure within the sequence alignment. For the assignment of 
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germline sequences, space-based methods provide a statistical framework for comparing 
and clustering the sequences based on pairwise identities or similarities. MDS is a space-
based method that allows the pairwise distances in the multiple sequence alignment to be 
reduced to a small number of principle components that aid in clustering the data within 
Euclidean space. This type of analysis applied to large Ig sequence data sets allows 
accurate genotyping of the germline elements within the species simply based upon the 
detection of highly frequent shared polymorphisms observed across individuals [142]. 
We show that MDS combined with k-means clustering provides an efficient approach 
towards discovery of new Ig germline elements in NGS data sets, even with repertoires 
that exhibit high loads of mutations, as is the case with the rabbit IgG repertoire where a 
large fraction of Ig sequences deviate significantly from the germline due to gene 
conversion events. MDS combined with k-means clustering could be successfully applied 
to a multitude of species for which the germline Ig loci are poorly annotated. 
 
The large sample size provided by NGS also allows the diversification 
mechanism of Ig repertoires to be analyzed in great detail. We show that in the rabbit, the 
frequency of gene conversion is significantly lower than in the chicken. Consistent with 
this finding, it had been previously reported that chickens depend on gene conversion as 
the primary mechanism of Ig diversification and that SHM play a smaller role [204]. In 
rabbits, the chromosomal organization of VH gene elements is quite complex, with many 
VH germline genes located in genomic regions far removed from the commonly utilized 
VH1 germline gene. This may effectually limit the relative frequency of gene conversion, 
as gene conversion of VH1 is limited mostly to those donor genes directly upstream. 
Further, several of these upstream donor genes are functional, whereas in chickens there 
exists a single functional germline VH and a pool of upstream pseudogenes that are used 
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exclusively as donor genes for gene conversion. Interestingly, and consistent with earlier 
data [199], we report a detectable amount of gene conversion in the human IgG 
repertoire, but not in the mouse. The gene conversion tract lengths are significantly lower 
in the expressed human IgG repertoire as compared to the rabbit and chicken, but 
nonetheless are of high statistical confidence (p<0.05). This finding argues that gene 






Chapter 5: Assessment of the circle sequencing technology in detecting 
true sequence variants 
 
INTRODUCTION 
The innate immunity, usually provoked in the early phase of pathogen exposure, 
is the “first responder” in host protection. However, this immediate response is usually 
short-term and non-specific in nature. Adaptive immunity, on the other hand, is usually 
long-term and specific against pathogen re-exposure albeit the need of an incubation 
period for protection development. Hence, adaptive immunity is a critical arm of 
immunity, providing effective long-term immune protection as well as immunological 
memory. Chapter 1 provides a detailed description of numerous mechanisms employed 
by adaptive immunity to ensure that antibody-producing cells (B cells) can accommodate 
specificity for a large diversity of potential pathogens. The diversity of the antibody 
repertoire or the B cell repertoire is reflective of the immune status; hence, measuring the 
antibody repertoire or the B cell repertoire enables the evaluation of the immunological 
landscape. For example, researchers can identify unique antibody repertoire signatures 
associated with the various dysfunctional or infectious diseases, such as chronic 
lymphocytic leukemia, rheumatoid arthritis, influenza, and dengue, etc. [69], [86], [101], 
[205]–[210]. Particularly, due to its uniqueness in amino acid sequence, the evaluation of 
the 3rd complementarity-determining region on the heavy chain (CDRH3) has shown to 
be most versatile for studying the immunological landscape; therefore, it can be utilized 
as a measure of the clonal cell population [211], [212]. Furthermore, CDRH3 sequence is 
referenced as a unique marker to deconvolute the serological antibody repertoire [84], 
[85]. Therefore, in order to accurately characterize the repertoire, it is essential to develop 
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methods which separate true sequence variation in the CDRH3 from sequence artifacts 
caused by sequencing errors. 
 
Variation due to sequence artifacts can be introduced at multiple stages of library 
preparation: (1) error can be introduced in reverse transcription, (2) error can be 
introduced during PCR amplification, and (3) error is introduced during next generation 
sequencing. A commonly accepted mutation rate for the commercially available reverse 
transcriptase (MMLV-RT or Invitrogen SuperScript) is around 10-4 to 10-5 error per base 
[213], [214] and the DNA polymerase commonly used has similar range of error rates 
[215]. As for the sequencing platform, the rate and the type of error differ respectively. 
The Roche 454 pyrosequencing and Life Technologies Ion Torrent are both prone to 
insertion/deletion in the homopolymeric region while the Illumina HiSeq/MiSeq are 
prone to substitution [216], [217]. The error rates for each sequencing platform has been 
reported to be 1.4% for 454, 1.2% for Ion Torrent, and 3.2% for Illumina [217], [218]. 
Although the Illumina platform tends to incur higher error rates, its costs and sequencing 
depth have provided the most balanced option suitable for many studies. 
 
One advantage of great sequencing depth is substantiated by improved sequencing 
reads fidelity through redundant confirmation [219]. Redundant reads can be especially 
effective at subsiding random mutation introduced during the sequencing process. The 
mutation reduction is achieved by negating the relatively few and scattered sequencing 
mutations from the consensus read where the correct bases are usually dominant. Due to 
the unavailability of a well-defined reference template in the CDR3 region of an 
antibody, an independent identifier must be used to trace redundant read products to its 
originating template sequence. Various groups have used barcoded primers to tag the 
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sequencing library or the first strand cDNA. This barcode can be used to group related-
redundant reads identified in the bioinformatics process post sequencing [220]–[223]. To 
obtain a sufficient number of redundant reads per unique barcode, barcoding library 
templates requires a good balance between barcode primers, amount of input materials, 
and the number of amplification cycles. For example, in the study by Shugay et al. [223], 
only 2 cycles of amplification were performed prior to sequencing. After sequencing 2 
million reads, the group was able to recover about 11,000 good unique barcodes. The 
barcoding method is direct but it might require individual optimization for each separate 
sequencing experiment and the cost-barrier might still be too rigid for wide-adoption. 
Alternatively, a method called circle sequencing [224], can generate tandem repeats of a 
template, and therefore, bypass the need to generate a sufficient library of independent 
sequences carrying the same barcodes. Moreover, even in the case of rare read instances, 
physically-linked tandem repeats can still ensure redundancy confirmation instead of 
being unaccounted for due to low redundancy recovery rate in the barcoded case. Due to 
the low barrier of sequencing depth requirement in obtaining redundant reads, circle 
sequencing appears to be a good methodology for detecting true variants in the CDRH3 
sequences. Thus, this project herein will characterize circle sequencing comparing to the 
baseline conventional sequencing to identify differences in sensitivity for detecting true 
CDRH3 variant from the artifactual one. 
 
MATERIALS AND METHODS 
Blood sample collection 
Blood samples from each healthy donor were collected no more than twice a 
month. For each venipuncture blood draw, less than 50 mL of blood was collected. The 
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blood collection protocol has been approved by the Institutional Review Board (IRB) at 
the University of Texas at Austin (protocol number 2012-08-0031). Additionally, sourced 
leukocytes pooled from anonymous healthy donors were acquired through the Gulf Coast 
Regional Blood Center (Houston, TX, USA). 
 
Naïve B cells enrichment using magnetic activated cell sorting 
Peripheral blood mononuclear cells (PBMC) were isolated from blood as 
described previously [18]. Briefly, whole blood was mixed in a 1:1 ratio with DPBS; 
30mL of the mixture was then added slowly to a falcon tube containing 15 mL of 
Histopaque-1077 (Sigma-Aldrich, MO, USA) at room temperature. Separation by 
centrifugation at 800 xg was performed at room temperature for 15 minutes with the 
brake turned off. After centrifugation, whole blood was separated into four distinct 
layers. These layers from top to bottom are: Plasma, PBMC, Histopaque-1077, and 
pelleted Erythrocytes. The top plasma layer was decanted to allow convenient access to 
the PBMC layer and the PBMC layer was collected using Pasteur pipette. Freshly 
collected PBMCs were split and stored in 50 mL Falcon tubes, diluted to 50 mL using 
DPBS, and spun at 300 xg with brake for 10 minutes at room temperature. After 
centrifugation, the supernatant was discarded and pelleted PBMCs were resuspended 
with DPBS and combined. The combined PBMCs were then adjusted to a cell density of 
about 5x107 cells/mL in 1 mL aliquots. For each aliquot, the cells were placed in a 5 mL 
polystyrene tube and 50 uL of EasySep Human Naïve B cell Enrichment Cocktail 
(STEMCELL TECHNOLOGIES INC, BC, Canada) was added. The cells/cocktail 
mixture was well-mixed and incubated at room temperature for 10 minutes. Then, 250 uL 
of well-suspended EasySep D Magnetic Particles was added to the cells/cocktail mixture 
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and incubated at room temperature for 5 minutes. Afterwards, the cell suspension was 
brought up to a total volume of 2.5 mL with DPBS and mixed well. The tube was then 
placed in the EasySep magnetic holder and set-aside for 5 minutes. In one continuous 
motion, the enriched naïve B cells were poured off into fresh tube leaving behind non-B 
cells labeled with magnetic particles. The enriched B cells were then added to TRI 
Reagent (Ambion, TX, USA) in a 1:2 ratio to make final volume to about 1 mL. 
 
Total RNA purification 
The enriched naïve B cell/TRI Reagent suspensions were used for total RNA 
purification with the RNeasy MinElute Cleanup Kit (Qiagen, MD, USA). The protocol 
provided in the kit was as follows. Briefly, 200 uL of chloroform was added to the 1 mL 
cell/TRI Reagent mixture and vortexed for 15 seconds. The samples were then set-aside 
at room temperature for 5 minutes. The samples were centrifuged at 12,000 xg at 4 oC for 
10 minutes. The supernatant layer of about 400uL was transferred to a fresh tube and one 
volume of 70% ethanol was added to the transferred supernatant and mixed thoroughly. 
The supernatant/ethanol mixture was then added to the RNeasy MinElute spin column 
placed in a 2 mL collection tube. After closing the tube gently, the column was spun at 
8000 xg for 30 seconds and the flow-through was discarded. The column was washed 
with 700 uL of the RWI buffer and spun at 10,000 xg for 15 seconds and the flow-
through was discarded. The column was then placed in a fresh 2 mL collection tube and 
500 uL of RPE buffer was added. The column was then centrifuged at 10,000 xg for 15 
seconds. After discarding the flow-through, 500 uL of 80% ethanol was added to the 
column. The column was subsequently spun for 2 minutes at 10,000 xg. After discarding 
the flow-through, the column was spun with the cap open at full speed for 5 minutes. The 
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column was then transferred to a 1.5 mL eppendorf collection tube and 25 uL of DI water 
was added to the column for elution. The column was allowed to incubate for about 1 
minute before being spun at full speed for 1 minute for the total RNA elution. The eluted 
25 uL total RNA was then ready for subsequent steps or for storage at -80 oC freezer. 
 
The generation of cDNA amplicon with reverse transcription and PCR 
amplification 
The isolated total RNA was reverse transcribed using the Super Script III reverse 
transcriptase (Invitrogen, USA) to generate the first strand cDNA. An initial mixture was 
prepared with following components: total RNA template at a concentration of 
approximately 250 ng per 10 uL solution, 1 uM of IgM reverse primer (5’-
AACGGGGAATTCTCACAGGAGAC-3’) in 2 uL, 10 mM dNTP in 1uL, and DI water 
to make up final volume to 13 uL. The mixture was heated to 65 oC for 5 minutes and 
subsequently cooled on ice for at least 1 minute. The following components were added 
while the mixture was still on ice: 5x First-strand buffer in 4 uL, 0.1M DTT in 1 uL, 
RNaseOUT (Invitrogen, USA) in 1 uL, and Invitrogen Super Script III (Invitrogen, USA) 
in 1 uL. The final mixture in 20 uL total volume was then subjected to thermocycling 
with the following temperature profile: 55 oC for 60 minutes, 70 oC for 15 minutes, and 4 
oC until samples were removed. Finally, 1 uL of RNase H (Invitrogen, USA) was added 
for incubation at 37 oC for 20 minutes to remove RNA. The sample could be stored at -20 
oC before subsequent steps. 
 
The cDNA amplicon generation was performed with Phusion polymerase (NEB, 
USA). The 50 uL reaction mixture was prepared with the following components: 5x 
High-Fidelity buffer in 10 uL, 10mM dNTP in 1 uL, 10 uM FR3 degenerate forward 
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primer (5’-AAGMRGACAYRGCYRTSTATTACTG-3’) in 5 uL, 10 uM IgM reverse 
primer (5’-AACGGGGAATTCTCACAGGAGAC-3’) in 5 uL, first-strand cDNA 
template in 10 uL, 2 units/uL of Phusion polymerase in 1 uL, and DI water to top off final 
volume to 50 uL. The reaction mixture was then subjected to thermocycling with the 
following temperature profile: 1 cycle (98 oC, 30 seconds), 4 cycles (98 oC, 10 seconds; 
55 oC, 30 seconds; 72 oC, 30 seconds), 4 cycles (98 oC, 10 seconds; 50 oC, 30 seconds; 72 
oC, 30 seconds), 4 cycles (98 oC, 10 seconds; 45 oC, 30 seconds; 72 oC, 30 seconds), 6 
cycles (98 oC, 10 seconds; 50 oC, 30 seconds; 72 oC, 30 seconds), 1 cycle (72 oC, 5 
minutes), 4 oC until samples were removed. The reaction products could then be size 
selected using either common gel extraction method or Agencourt AMPure XP beads size 
selection described below. The samples could be stored at -20 oC until subsequent steps. 
 
Agencourt AMPure XP beads size selection 
Agencourt AMPure XP beads (Beckman Coulter, IN, USA) are solid phase 
reversible immobilized beads that retain various sizes of DNA based on the flocculation 
condition. By increasing the volume ratio between the AMPure XP beads to the DNA 
samples, the DNA size retention can be extended to shorter fragments. In general, the 
following beads to sample ratio can provide the corresponding size retention: 0.4X for 
>1.2kbps; 0.6X for >900bps; 0.8X for >300bps; 1.2X for >100bps, etc. The experiments 
conducted in this manuscript used the ratio ranges from 0.5X to 0.85X to cover sizes of 
250bps to about 1kbps. The beads should be allowed to reach room temperature before 
use. The room temperature beads were vortexed with the samples and allowed to incubate 
at room temperature for 15 minutes and then magnetized for 5 minutes in MagneSphere 
magnetic stand (Promega, WI, USA). While placing the tube in the magnetic stand, the 
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supernatant was removed and the remaining beads were washed twice with 80% ethanol. 
The tube was removed from the stand and allowed to air-dry for about 10 minutes. Then, 
33 uL of Tris-EDTA (TE) was added to the beads and vortexed for about 15 seconds. The 
tube was incubated at room temperature for 5 minutes and then magnetized for another 5 
minutes. About 30 uL of the supernatant was transferred to fresh tube and these size-
selected samples were ready for subsequent steps or storage at -20 oC.  
 
Overview of circle sequencing 
An overview of the circle sequencing process is summarized in Figure 27. The 
process mainly consisted of four main modules: Template circularization, Rolling circle 
amplification, Next generation sequencing and Bioinformatics analysis. 
 
 




The amplicon should be phosphorylated at the 5’ end before circularization. 
Details of phosphorylation can be found in most kits. Briefly, first, the amplicon was 
made into ssDNA by denaturation at 95 oC for 15 minutes. Denatured amplicon was 
snap-freezed in liquid nitrogen for 5 minutes and subsequently allowed to thaw on ice. 
While thawing, the following CircLigase II (Epicentre, WI, USA) reaction mixture was 
prepared: 10x CircLigase II reaction buffer in 2 uL, 50mM MnCl2 in 1 uL, 5 pmol 
ssDNA in <16 uL, 100U CircLigase II in 1uL, where the final reaction volume was at 20 
uL. The reaction mixture was incubated at 60 oC for 1 hour. Removal of non-circularized 
ssDNA or dsDNA was completed by adding 1 uL of Exonuclease I (NEB, USA) and 0.5 
uL of Exonuclease III (NEB, USA) to each reaction and incubated at 37 oC for 1 hour. 
PCR cleanup was performed and circularized products were eluted with 20 uL DI water. 
The products could then be stored at -20 oC. 
 
Rolling circle amplification 
The ability for Bacteriophage Phi29 DNA polymerase (NEB, USA) to strand 
displace facilitated the generation of tandem repeats from the same circularized template. 
However, due to its 3’-to-5’ exonuclease activity, exonuclease-resistant primer 
containing phosphorothioate bonds are necessary to maintain the efficiency. First, the 
primers described in the cDNA generation step with phosphorothioate bonds were 
allowed to anneal to the circularized template in a 20 uL mixture. The mixture contained 
the followings: 2X Annealing buffer in 10 uL [10 mM Tris pH 8, 50 mM NaCl, 1mM 
EDTA], 10uM of both forward and reverse exo-resistant primers in 1 uL, circularized 
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template (1-100 ng) in <9 uL, and finally, DI water diluting the mixture to a 20 uL total 
volume. The mixture was allowed to incubate at 95 oC for 5 minutes and cooled to 4 oC. 
Then, the following components were added to the 20 uL mixture: 5 uL of 10x Phi29 
DNA polymerase reaction buffer, 1 uL of 100x BSA, 1 uL of 10mM dNTP, 0.2 Units of 
Inorganic pyrophosphate (NEB, USA), 10 Units of Uracil-DNA glycosylase (NEB, 
USA), 16 Units of Formamidopyrimidine-DNA Glycosylase (NEB, USA), 2 uL of Phi29 
polymerase (NEB, USA), and finally, DI water added to a final reaction volume of 50 uL. 
The reaction mixture was allowed to incubate at 30 oC for 3 hours and then heat-




The rolling circle products were mixed with a 1/10 volume of 3 M pH 5.2 sodium 
acetate. After thoroughly mixing, 3X volume of 100% ethanol was added and the mixture 
was placed at -80 oC freezer overnight. The mixture was then spun at max speed for 30 
minutes at 4 oC to pellet the DNA. The supernatant was discarded and 500 uL of fresh 
70% ethanol was added and vortexed for about 5 seconds. The resuspended mixture was 
then spun at max speed for 15 minutes at 4 oC. The supernatant was carefully removed 
and the DNA pellet was allowed to air-dry for about 10 minutes. Then, the DNA pellet 
was resuspended with 130 uL of Tris-EDTA (TE). The resuspended DNA products were 
then ready either for storage at -20 oC or subsequent steps.  
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Shearing of the rolling circle products 
Covaris S2 sonicator (Covaris, MA, USA) was used to shear the rolling circle to a 
range of predefined sizes. The sonicator preparation procedure can be referred on the 
manufacturer’s website and the settings used in the manuscript were as follows. For 
fragment size of about 1kbps, duty cycle at 2%, intensity at 4, cycle per burst at 200, time 
at 22 seconds, and mode is Freq Sweeping. For a desired fragment size of about 800bps, 
duty cycle at 5%, intensity at 3, cycle per burst at 200, time at 25 seconds, and mode is 
Freq Sweeping. After sonication, the sheared products could be purified with PCR 
cleanup kit and eluted in 25 uL of DI water. This purified product would be ready for 
sequencing preparation. 
 
TruSeq sequencing sample preparation 
This step was conducted by the Genomic Sequencing and Analysis Facility 
(GSAF) at the University of Texas at Austin. Briefly, the procedure entails end repair of 
sheared products, addition of adenine to repaired products, ligation of the TruSeq 
adaptors, 10 cycles of amplification to amplify successfully ligated products, AMPure XP 
beads size selection. The end products of the procedure would then be ready for Illumina 
MiSeq sequencing. 
 
Synthetic IgM control construction  
Plasmid containing pre-defined heavy chain IgM sequence was constructed using 
the Gibson assembly cloning method as described in the manufacturer’s manual (NEB, 
USA). The backbone of the plasmid was derived from the pMAZ360 vector [225] and the 
IgM sequence construct was generated with synthetic DNA sequences (IDT gBlock, 
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USA). The plasmid contains an origin of replication from pBR322 as well as an 
ampicillin selection marker. The synthetic heavy chain IgM is under a T7 promoter 
allowing generation of the synthetic IgM mRNA. The variable region and the CH1 of the 




Figure 28: Synthetic IgM construct sequence from variable region to CH1 
Note: The orange bar highlights the variable region; the green bars highlight 
the primers used for amplicon generation; the purple bar highlights the 
amplicon region; the blue bar highlights the CDRH3 region 
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Synthetic concatemer IgM control construction 
In addition to the synthetic IgM construct, six constructs containing different 
repeating numbers of the amplicon region (purple-highlight region in Figure 28) were 
constructed using overlap PCR extension and Gibson assembly cloning method. These 
additional constructs included amplicon region containing between 2-repeats (two-mer) 
to 7-repeats (seven-mer). The purpose of these specific constructs was to produce tightly 
length-restricted sequencing templates for identifying an optimal shear length that would 
be the least affected by PCR-mediated recombination event. PCR-mediated 
recombination as explained in Lou et al.’s study [224]. It is largely believed to be due to 
incompletion of PCR extension in each cycle of the cluster generation step for the 
Illumina sequencing platform. Due to the highly repeating nature of the sequencing 
template, the incomplete product from the previous cycle could complement with another 
template producing a much shorter product. After cluster generation in Illumina 
procedure, a cluster would contain a mix of completely extended products as well as 
shorter products. Thus, after the first repeat read-through of the cluster, some members of 
the cluster would signal the next correct repeat while some members of the cluster would 
signal the adaptor sequence. This mixed signal could occur in any subsequent repeats 
stochastically resulting to reduction of read base quality score for the duration of the 
length of the sequencing adaptor.  
 
Transcription of the synthetic IgM construct 
AmpliScribe T7 High Yield Transcription Kit (Epicentre, WI, USA) was used to 
generate the RNA from the synthetic IgM construct plasmid. Briefly, the following 
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reaction mixture was prepared at room temperature: about 200 ng of the IgM plasmid, 
10x AmpliScribe T7 reaction buffer in 2 uL, 100mM ATP, CTP, GTP, UTP in 1.5 uL 
each, 100mM DTT in 2uL, RiboGuard RNase Inhibitor in 0.5 uL, AmpliScribe T7 
Enzyme Solution in 2 uL, and top off with RNase-free water to 20 uL total volume. The 
reaction mixture was incubated at 37 oC for 2 hours and 2 uL of DNaseI was added to the 
mixture for another incubation at 37 oC for 15 minutes. The reaction product was then 
purified following the total RNA purification process described above. This IgM RNA 
product was used as the control for assessing the errors generated during the sequencing 
process.  
  
Bioinformatics analysis: oriented reads processing 
Tandem repeats from the circle sequencing are processed in silico to assemble the 
“oriented” read containing the consensus sequence. The bioinformatics pipeline described 
in the Lou et al.’s study [224] was used to process the sequencing data in this manuscript 
initially to generate oriented reads without filtering of the PCR-mediated recombination 
contaminated regions. Briefly, the pipeline first removed the read pairs that mapped to 
the PhiX genome. Then, the read pairs that contained premature adapter sequences were 
removed. After these filtering steps, an optimal periodicity was determined by scanning 
the sequence for the fraction of base-match in a range of fixed distances. Since tandem 
repeats should be theoretically a 1:1 copy of each other, the fixed distance that yielded 
the best fraction of base-match would be the optimal periodicity. Once the periodicity 
was determined for each pair-end reads, the optimal offset between the reads was 
determined similarly by finding the best-fixed distance that could yield the best base-
match fraction. Any pair-end reads without strong periodicity was discarded. With the 
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periodicity and offset, alignment of the repeats could yield consensus read assembled 
from independent sequencing events. Thus, the quality score was extended beyond the 
limit of phred-score Q40. The consensus reads that were adjusted to reflect the primer 
positions were referred as the oriented reads. 
 
Bioinformatics analysis: seed-based processing 
As cautioned by Lou et al. [224] that PCR-mediated recombination has significant 
impact on the quality of the repeated region of the reads; hence, in order to rescue usable 
repeats from regions “polluted” with PCR-mediated recombination events, a seed-based 
processing method was utilized to filter problematic region while reconstructing 
consensus reads only based on high quality repeating regions. The algorithm for seed-
based processing is similar to the Inchworm algorithm in the Trinity de novo 
transcriptome assembly method [226]. A schematic diagram summarizing the process 




Figure 29: Overview of seed-based processing with an example of size 4 k-mer  
 
Briefly, both the R1 and the reverse complemented R2 reads were broken into a 
collection of k-mers where k = 9 bases. The k-mers were identified by scanning the 
window a base apart with width of 9 bases across the whole R1 or reverse complemented 
R2 reads and the k-mers were quality checked to ensure 80% of the bases contained Q30 
or above. Any k-mers that could not satisfy the quality check would not be included in 
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the collection. When the same satisfactory k-mer was identified, their quality scores per 
base were expanded by first converting scores back to probability and then the 
probabilities were multiplied before converting back to the quality score. After ranking 
the k-mers by abundance, the most abundant k-mer was used as the seed for rebuilding 
the consensus sequence. Sequence extension to the right began with using the right most 
k-1 bases from the seed or the extended read. To form k-mer for the extension, the k-1 
bases were extended with four possibilities of A, T, G, or, C. By identifying from the 
collection table the most abundant k-mer among these four possibilities, the read was 
extended with the base that made the k-mer the most abundant from the collection table. 
The used k-mer was removed from the collection table preventing it from later 
consideration. In case of tie abundance, branching off events occurred and the tied counts 
were added in the next extension until a global maximum abundance was resolved 
leading to the respective branch kept as the extension result. When the sequence could no 
longer be extended to the right, the same exercise was repeated to the left until no k-mer 
could be identified to the left. The resulting extended sequence would have by now 
removed PCR-mediated recombination events as well as reconstructed the consensus. 
 
Bioinformatics analysis: error rate measurement 
The error rate was measured after aligning the determined consensus sequence to 
the known sequence of the synthetic IgM control construct using Biopython global 
alignment default settings. Since the sequence of the input was known a priori, error rate 
could then be measured by aligning the sequencing results to the known input sequence. 
The error rate was calculated by counting the total number of mismatch bases from the 
control over the total number of bases read.  
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Bioinformatics analysis: quality score threshold determination 
Receiver operating characteristics (ROC) analysis was used to determine the 
optimal expanded quality score that balances sensitivity and specificity for reliable base 
detection. Data generated from the synthetic IgM control experiment was used to perform 
this analysis. Briefly, a list of truly matching bases with their quality scores and a list of 
truly mismatching bases with their quality scores were collected from each sample (10 
for conventional and 10 for circle sequencing-filtered). Quality score threshold ranging 
from 1 to 93 was used to specify reliable base. Contingency table for each quality score 
could be constructed to calculate the True Positive Rate (number of truly matching base 
specified as reliable base over all truly matching bases) and the False Positive Rate 
(number of truly mismatching base specified as reliable base over all truly mismatching 
bases). These pairs of FPR and TPR were plotted as scattered plot. The quality score that 
maintained the FPR below 10% was used to analyze the human naïve B cells samples.  
 
Bioinformatics analysis: CDRH3 identification 
Identification of the CDRH3 was done by extracting sequences in between the 
following motifs: 
TATTACTG[ACTG] (…) TGGGG[ATCG][AC][AG][ACTG]GG[ACTG] where 
bases in the square brackets represent degenerate bases for that position in the motif and 
the parenthesis represent the CDRH3 sequences to be extracted. Upon extraction of the 
CDRH3 sequences, its minimum quality score was checked to meet the quality score 
threshold identified by the ROC analysis (Q30 or Q70). Sequences with at least one base 




Error rates for conventional sequencing and circle sequencing 
The synthetically constructed IgM control template was used in 20 samples. 10 of 
the 20 samples were prepared using conventional sequencing (no tandem repeats 
generated) while the second half were prepared using the circle sequencing method 
described above. All samples were prepared and submitted for NGS MiSeq 2x250 in 5 
independent sequencing runs. A total of about 9 million sequencing reads were generated 
across all runs. The erroneous bases introduced by each method were measured by 
aligning the consensus reads to the known IgM control sequence. For each sample, an 
error rate was calculated by finding the fraction of total number of erroneous bases over 
total number of bases being analyzed. Unlike the conventional sequencing samples, the 
circle sequencing samples required bioinformatics processing to reconstruct the 
consensus reads as described in the method section. Two different bioinformatics 
processing methods were used on the circle sequencing samples where the first method 
followed the Lou et al.’s scheme [224] without filtering out problematic region caused by 
PCR recombination (denoted as CircleSeq samples); the second method followed the 
seed-based processing where the problematic region is filtered (denoted as CircleSeq-
filtered samples). The error rates for each sequencing methods and each bioinformatics 




Figure 30:  Error rate for the different sequencing and bioinformatics processing 
methods 
Note: CircleSeq is the circle sequencing samples without PCR-mediated 
recombination filtering. CircleSeq-filtered is the circle sequencing samples 
with PCR-mediated recombination filtering. Conventional is the 
conventional sequencing samples. The figure inset has an appropriately 
scaled y-axis to better show the lower error rate samples. 
 
As seen in Figure 30, without proper filtering of problematic region, the circle 
sequencing method reported a median error rate of about 1.7x10-3 error/base. More 
importantly, non-filtered reads resulted in a wide variation between sequencing runs; the 
later sequencing runs of the circle sequencing samples reported lower variation and error 
rates. On the other hand, the conventional sequencing method and the circle sequencing 
method with filtering both obtained a median error rate of about 8x10-5 error/base. 
Specifically, the conventional sequencing was a more robust process in that the samples 
were consistently obtaining an error rate of 8x10-5 error/base while the circle sequencing 
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with filtering samples contained a wider spread. This again could be due to the batch-
dependent variation observed from the circle sequencing samples. Additional 
characterization of the types of mutation revealed that transversion was the predominant 
cause of mismatches while there appeared to be mutational hotspots throughout the 




Figure 31: Distribution of transition and transversion mutation 
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In a separate experiment, we used only 2 (as opposed to 18) cycles of PCR 
amplification of the synthetic IgM control template. This minimally amplified sequence 
was prepared and submitted for sequencing. The error rate was also found to be around 
8x10-5 error/base indicating that the lower bound error rate of the process was most likely 
reached. This assumption is further supported by the fact that cluster generation requires 
35 cycles of amplification with Bst polymerase (error rate 1.5x10-5 error/base) [215] and 
the reverse transcriptase error rate is at about 4.5x10-5 error/base [227] during the first 
strand synthesis process. 
 
The severity of the PCR-mediated recombination can be visualized using a 
complexity plot similar to the one described in the Lou et al.’s study. A complexity plot 
generated with a synthetically constructed concatamer two-mer sample is shown in 
Figure 32 to illustrate the problematic region issue that pertains to tandem repeats 
samples in MiSeq sequencing. 
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Figure 32: Complexity plot for the R1 and R2 reads of one circle sequencing sample 
Note: the left panel is R1 read and the right panel is R2 read; payload is the 
region of interest as well as the repeating unit; the left y-axis is fraction; the 
right y-axis is quality score; for each position, the dots represent the fraction 
of the bases reported from the sequencing run, the shaded background 
represent the supposed base for that position; the split shading represent 
degeneracy or sequencing adaptor region 
 121 
The complexity plot is reporting the relationship between quality score of a 
sequence to the different distribution of bases reported for each position of the 250 bps 
from each of R1 and R2 reads in a run. The sequenced samples were the two-mer 
samples containing exactly one forward degenerate primer region, two payload regions 
(IgM CDRH3-FR4 contorl sequence), and one reverse primer region. The samples were 
prepared using the conventional method of synthetically designed two-mer tandem 
repeats of the IgM control sequence (Gibson assembly cloning described above). Hence, 
this sample should have the least amount of extra confounding preparation steps. The plot 
indicates that the read quality remained high until the first repeat was encountered. 
Moreover, during the first repeat, a large portion of the bases reported matched the 
control sequence. However, the error rate significantly increased once the second tandem 
repeat was encoutered. With respect to this repeat, the quality score dropped to as low as 
15 (equivalent to 0.032 error/base). It was apparent that within the tandem repeat, there 
was a strong emergence of sequencing adaptor sequences denoted in the splitted shading 
background within the tandem repeat section in Figure 32. This drop in quality and 
emergence of adaptor sequences was due to PCR-mediated recombination cautioned by 
Lou et al. Incomplete extension during cluster generation and homologous repeats 
facilitated shorter reads within a cluster. Hence, in extreme severtity, a cluster might be 
hijacked with reads containing less repeats while in moderate case, the read quality would 
drop drastically during the repeats. Therefore, it is necessary to filter the circle 
sequencing reads to prune unconfident sections of the reads caused by PCR-medaited 
recombination as evidence in Figure 30 confirmed the case.  
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Effects of PCR-mediated recombination on different template lengths 
As mentioned above, circle sequencing is prone to PCR-mediated recombination 
leading to a degradation of high quality reads. In order to find an optimal template length, 
containing tandem repeats, that is the least affected by PCR-mediated recombination we 
created synthetic control sequences. Each control contained different numbers of tandem 
repeat of the known IgM CDR3-FR4 control sequence (payload). These concatemers 
were prepared using the conventional sequencing method. The sequencing reads were 
then processed using Lou et al.’s bioinformatics processing scheme to recover the 
consensus reads. These consensus reads were then aligned to the known IgM CDR3-FR4 
control sequence to determine the error rate as an indirect measure of PCR-mediated 
recombination effects.  
 
 
Figure 33: Error rate for the different concatemers  
 
Theorectically, the longer template containing more repeats (i.e. 7-mer) should be 
more prone to PCR-mediated recombination as there are more “entry points” for 
homologous binding. The longer length should also favor incomplete cluster generation. 
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Despite these speculations, as seen in Figure 33 except for the outlier 6-mer sample, the 
longer concatemers (5-mer and 7-mer) have similar error rate around 1x10-3 error/base to 
that of 2-mer. Based on this evidence alone, it is still unclear whether there is an optimal 
length that is the least affected by PCR-mediated recombination. However, at the very 
least, it is obvious that PCR-mediated recombination will affect any tandem repeat 
containing template as the error rate for these samples were about an order of magnitude 
higher than those without tandem repeats (i.e. conventional sequencing sample in Figure 
30). 
 
Determination of quality score threshold for improved sensitivity to true variant 
Although circle sequencing cannot outperform conventional sequencing in terms 
of the overall error rate, it does maintain its advantage where bases that are confirmed by 
redundancy have an expanded quality score. This expanded quality score allows for a 
greater confidence in the detection of a true variant at a specific position. The sensitivity 
of a method in detecting true variant is best visualized using a receiver operating 
characteristic (ROC) curve. This curve is originally used to illustrate the performance of a 
binary screening system where it plots the sensitivity against the non-specificity as the 
screening threshold changes. In this case, the match and mismatch information together 
with its respective quality score from all the synthetic IgM control sequencing 
experiments were collected accumulatively to determine the sensitivity and the non-
specificity. The sensitivity (or True Positive Rate) is the fraction of matching bases above 
the quality score threshold from all the matching bases. The non-specificity (or False 
Positive Rate) is the fraction of mismatching bases above the quality score threshold from 
all the mismatching bases. These pairs of values are plotted over the range of the 
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expanded quality score (i.e. Q1 to Q93). The ROC plot for sequencing samples derived 




Figure 34: Receiver operating characteristic (ROC) curve for the conventional 
sequencing and the circle sequencing PCR-mediated recombination filtered 
methods  
Note: TPR stands for True Positive Rate and FPR stands for False Positive 
Rate; Several quality score threshold points were annotated to illustrate 
quality scores for normal practice and the optimal quality score for the 
filtered circle sequencing process 
 
As important reference on a ROC curve, the diagonal line and the upper-left hand 
corner represent two extreme cases. The diagonal line reflects that the varying threshold 
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parameter has random sensitivity/specificity perfomance whereas the corner reflects 
perfect sensitivity/specificity performance. As seen in Figure 34, the filtered circle 
sequencing method outperformed the conventional sequencing method in its improved 
sensitvity/specificity performance. More specifically, the highest possible quality score 
(Q40) in the conventional sequencing gave about 0.52 TPR and 0.18 FPR. This means 
that using >Q40 threshold, one can expect to confidently retain 52% sequencing-error-
free bases while bearing 18% risk of mistrusting a base as error-free. On the other hand, 
with the expanded quality score in the filtered circle sequencing method, Q70 threshold 
gave about 0.95 TPR and 0.13 FPR which is optimally balanced to yield the highest 
possible sensitivity while managing the non-specificity. After obtaining this important 
threshold parameter, detection of true variant becomes much more trustworthy, especially 
when incorporated into a clustering algorithm. 
 
Measurement of human naïve B cells with the different sequencing methods 
In the absence of a diverse pre-defined repertoire standard, it is quite difficult to 
quantify the true variant detection performance from each sequencing method. However, 
as an approximation, measurement of a pre-defined number of human naïve B cells could 
still provide indicative benchmark to judge relative performance. It is empirically 
estimated that the naïve B cell diversity is about 1-10 million clones [69]–[71]. 
Therefore, sampling a small fraction of this vast diversity, say 200,000, should give rise 
to a maximum clonal diversity of 200,000. Using this hypothesis, any acceptable 
sequencing method should reports clonal diversity within reasonable range of 200,000.  
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To test this hypothesis, 200,000 naïve B cells from the same individual were 
collected, counted, and extracted for the total RNA. After 18 cycles of cDNA 
amplification, half of the amplified library, the conventional sequencing sample, was 
submitted for MiSeq 2x250. The remaining half was prepared with the circle sequencing 
method. Generated tandem repeat products were sheared at length of about 1 kbps prior 
to MiSeq 2x250 sequencing. After applying the seed-based processing step on the circle 
sequencing reads, the recovered sequences were about 4 million reads. The conventional 
sequencing yielded about 7.4 million reads. In order to normalize the number of reads 
between the samples, 4 million reads were randomly drawn from the conventional 
sequencing set for the analysis. As mentioned previously, applying a quality score 
threshold to prune unconfident bases can be an effective way to remove artifactual 
variants. A Q70 threshold was established to be optimal for the filtered circle sequencing 
sample. The same threshold is not possible for the conventional sequencing sample; in 
addition, using a Q40 would filter out most sequences from a conventional sequencing 
sample. Since Q30 is frequently used as a common quality cutoff, it will be used as 
threshold here to represent a normal practice. 
 
The unique numbers of CDRH3s generated by both of the sequencing method 
were higher than the maximum of 200,000 clones. This increased diversity suggests that 
both methods contained artifactual variants. From the conventional sequencing sample 
(Q30), there were 1,226,653 unique CDRH3s. On the other hand, the filtered circle 
sequencing sample (Q70) was analyzed to report 254,287 unique CDRH3s. The inflated 
diversity seemed more severe in the sample prepared with conventional sequencing 
method even with the commonly used quality score cutoff. Applying the circle 
sequencing method and the Q70 cutoff seemed to have mitigated the issue better than the 
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conventional sequencing method. Table 11 presents the top 30th abundant CDRH3s from 
each sequencing method sample.  
 
Conventional	   Frequency	   	  	   CircleSeq-­‐filtered	   Frequency	  
ARDETSVGPITGTTPSYYFDY	   0.00043	  
	  
ARAYSTGPQESYFAY	   0.000743	  
ARAYSTGPQESYFAY	   0.000325	  
	  
AKGYDSSGYYFDY	   0.000254	  
ARAWGYDSRESFYSY	   0.000183	  
	  
ARAWGYDSRESFYSY	   0.000212	  
ARGLLSAASLNWFDP	   0.000144	  
	  
ARGLLSAASLNWFDP	   0.000198	  
AREDGAVAGPYTGGMDV	   0.000118	  
	  
ARDETSVGPITGTTPSYYFDY	   0.000129	  
ARGLYCGGDCYPGSLGPDYYYDMDV	   0.000108	  
	  
ARGGRLITMLRGVRNYFDY	   0.000122	  
ASEGGDYYGAGRMLGGDY	   0.000103	  
	  
VKDDTPLLYYYGSGSYYSY	   0.000118	  
ARGRVGRLRVAVAGTGQGPRYFDY	   0.000103	  
	  
AKDGPDYGGNPFDY	   0.000115	  
ARGAYYYDTSGYSGAFDI	   0.000098	  
	  
ARDLGYYDSSGYNL	   0.000104	  
ARGTLEGLKKASWRRLWSHGFDP	   0.000097	  
	  
ARDAHSSGLDAFDI	   0.000101	  
ARGRSEYCSGGSCYSGRKNYYFDY	   0.000096	  
	  
AKEGIVLIVYATSFDL	   0.000097	  
ARESHDTGWFDY	   0.000082	  
	  
AKVNIVLIIYASGFDY	   0.000094	  
ARGAPSSITMVRGVYYYLDY	   0.00008	  
	  
ARNYDTSAYYYYF	   0.000094	  
ARGAYCGGDCYPGLIPHWNFDL	   0.000078	  
	  
ARGPDSSNFYYFY	   0.00009	  
ASAGYYYDSSGYYWIAAFDY	   0.000077	  
	  
ARVAYIYYDFWSGYYYFDY	   0.000087	  
ARVRDGSGSYSWYGMDV	   0.000076	  
	  
ARSGYDSSGYGRADVN	   0.000087	  
AGGIAAAGTSLNWFDP	   0.000075	  
	  
ARVGPVLGSYRYIDY	   0.000083	  
ARVFGSGFPPPSDAFDI	   0.000072	  
	  
ARDYYDSNA	   0.00008	  
ARDATIIYSGSYLANYYYGMDV	   0.000071	  
	  
TSPHYDSSDINDY	   0.00008	  
TTDGPGLRFLEWLSYYYYYYGMDV	   0.000069	  
	  
AKDALVDKYSGSYSDY	   0.00008	  
ARGSGDQILTAFYYYY	   0.000064	  
	  
ARATGILTGYYD	   0.00008	  
AKDGPDYGGNPFDY	   0.000064	  
	  
ASWYYYDSSGYYLFY	   0.00008	  
ARIKFRGLIGTTKYYYYGMDV	   0.000062	  
	  
ARDFDY	   0.00008	  
ARDDIAADGEWFDP	   0.00006	  
	  
ARSTSSWEDWLDS	   0.000076	  
ARGLIAAAGISYYYYAMDV	   0.000057	  
	  
VREFVRGVIISYFDS	   0.000076	  
ARGLVAAAGISYYYYGMDV	   0.000057	  
	  
ARDSTTFGAFDI	   0.000073	  
ARDPGSGYYYVSRWRAFDI	   0.000057	  
	  
ARDWHDISGYFEY	   0.000073	  
AKEGIVLIVYATSFDL	   0.000056	  
	  
ARHSSTNFFDY	   0.000073	  
ARGPDSSNFYYFY	   0.000056	  
	  
ARATVETNWLDP	   0.000073	  
ARGGRLITMLRGVRNYFDY	   0.000056	  
	  
ARIKFRGLIGTTKYYYGMDV	   0.000069	  
Table 11: Top 30th abundant CDRH3s amino acids sequences from the conventional 
sequencing and the filtered circle sequencing method 
Note: the shaded CDRH3s are the ones shared in both samples 
 128 
 
As observed in Table 11, not all highly abundant CDRH3s were shared between 
the samples. Only 8 out of 30 CDRH3s were shared indicating the additional steps 
involved in the circle sequencing method might have imposed bias affecting the 
abundance. This was expected by reasons that circularization efficiency was reported to 
be length dependent [228], [229]. This could explain why there was a descrepancy in the 
members of the top 30th abundant CDRH3s between the two samples. This trend persists 
for the total length distribution as seen in Figure 35. The CDRH3s in the filtered circle 
sequencing sample (Q70) were shorter (mean at 14.5 a.a.) as compared to the 
conventional sequencing sample (Q30) (mean at 17.5 a.a.). It is important to note that the 
results generated by the filtered circle sequencing process (Q70) followed more closely to 
the healthy human CDRH3 length distribution with mean near 14 a.a. 
 
 
Figure 35: CDRH3 amino acids length distribution between the conventional 
sequencing and the filtered circle sequencing sample 
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On the other hand, there appeared to be no difference for the hydrophobicity 
index [230] across the two methods as shown in Figure 36. The distribution also follows 
similarly to healthy individual in other reports [18], [210], where the mean is around the 
neutral (index of zero) and there is a long tail towards the hydrophilic end (negative 
index). This implied that biases towards base composition might be minimal and not as 
influencial as the length to the individual method.  
 
 
Figure 36: CDRH3 average hydrophobicity between the conventional sequencing and 
the filtered circle sequencing sample 
 
DISCUSSION 
The ability to detect a true sequence variant is entirely dependent on the ability to 
reduce sequence noise introduced by sequencing error. Thus, there is a great demand for 
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a silver lining solution that mitigates the overall error rate imparted by next generation 
sequencing to the antibody repertoires. The circle sequencing method described in Lou et 
al.’s study [224] provided an alternative approach to barcoding method for improving the 
sensitivity and detection of true sequence variants. We have adopted and characterized 
the circle sequencing method to analyzing the diversity of the CDRH3 sequence found 
within the naïve B cell antibody repertoire. Although the overall error rate for the circle 
sequencing method cannot outperform the conventional sequencing method, it did 
perform equivalently for an error rate at about 10-5 error/base given proper filtering of 
problematic sequence regions. In theory, the circle sequencing method should warrant 
ultra-low error rate but the negative impact by PCR-mediated recombination might have 
overshadowed the performance. To prevent PCR-mediated recombination issue, it would 
be necessary to modify the proprietary cluster generation process of Illumina sequencing. 
Particularly, to guarantee completion of partial sequence extension, we would need to 
change the polymerase or lengthen the extension time. Also, although not yet optimized 
for this current project, the initial number of cDNA amplification cycles should be 
minimized to still allow sufficient circularization. This could minimize early-on 
mutations from propagating to the circularization step. 
 
Despite the issues affecting the performance of circle sequencing, the unique 
benefit provided by circle sequencing is the increase in confidence for each base it 
sequenced. The ability to expand the quality score from Q40 to Q93 is extremely useful 
for robust screening of true variants from artifactual variants. Providing the expanded 
quality score, the circle sequencing method greatly improved the sensitivity of true 
variant detection. As proof of concept example, 200,000 human naïve B cells CDRH3s 
were sequenced with the two sequencing methods. Combined with the commonly used 
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quality cutoff (Q30) and the expanded quality score cutoff (Q70), the results were 
indicating that both methods reported inflated diversity. However, the circle sequencing 
method is the least affected and reported the number of unique CDRH3s as closely to the 
theoretical clonal numbers. Hence, the circle sequencing method with the expanded 
quality threshold was more effective at removing artifactual CDRH3 variants. Moreover, 
the CDRH3 repertoire reported by the circle sequencing method resembled closely with 
publicly reported values. Thus, the benefit of expanded quality score as a method for 
screening true variant outweighs the moderate error rate of 10-5 error/base. It would be 
recommended to adopt the circle sequencing method along-side the conventional method 
where one can take advantage of the full-length information in the conventional method 







Chapter 6: Conclusion and future work 
NGS has presented us with an unprecedented opportunity to systematically survey 
an immunolglobulin repertoire that could lead to discoveries not possible before. For 
antibody discovery, the use of NGS has helped to circumvent the need for labor intensive 
and time-consuming hybridoma screening process. Putting the NGS antibody discovery 
into perspective, it effectively cut down the time for the process from about 8 months to 
around a month. In addition to the improvement in antibody discovery process, the 
survey of the antibody repertoire using NGS has also revealed several interesting 
biological traits in human, rabbit, and other organisms. Given the high throughput nature 
supported by the NGS technology, we could plausibly confirm the commonly believed 
public Vλ clone (CDRL3) across different individuals. We also reported that about 20% 
of the Vλ repertoire from our healthy donors and humanized mice samples were public 
clone. After some characterizations of the public repertoire found in the samples, we 
observed in the public clones that about 5 or less nucleotide SHM and lower N/P 
nucleotide addition could have contributed to a limited diversity leading to better 
likelihood for public clones to be independently generated in different individuals. 
Similarly, high throughput survey of the antibody repertoire in rabbit revealed other 
interesting aspects including the discovery of new rabbit germline genes and the 
observation of about 23% gene conversion frequency in rabbit. 
 
As with any great technology, NGS brings forth great throughput and depth to 
systematic DNA analysis but it has shortcoming as well. Random sequencing errors can 
be implanted to the sequencing reads leading to artifactual variants obscuring the true 
landscape of an antibody repertoire. We have adopted and characterized the circle 
 133 
sequencing method to seek its utility in sensitivity improvement for the detection of true 
antibody variants in a repertoire. We have demonstrated that the advantage of the circle 
sequencing method is the capability of expanded quality score that extends beyond Q40 
up to a maximum of Q93. The expanded quality score allows for a higher resolution 
screening of the quality for sequences prepared with the circle sequencing method. By 
applying a Q70 threshold screening, the circle sequencing method was shown to 
effectively reduce the artifactual variants, of which the conventional sequencing method 
could not achieve due to its limited quality score capping at Q40. 
 
The NGS technology has thus far paved a great foundation for the advent and 
throughput in antibody repertoire study. In my opinion, there are several future directions 
that might be worthwhile to pursue. First, as NGS technology becomes more cost 
effective, it should be used as common practice to apply NGS on directed evolution 
experiment like the one described in Ravn et al.’s study [231]. By analyzing the 
repertoire derived from each round of enrichment, one could potentially identify the 
enrichment pattern and thus be able to understand the relationship between the ligand and 
the enrichment pattern. A database of these enrichment patterns might help train the next 
generation of molecular dynamics prediction software to improve rational design for 
binding interaction. Secondly, the finding of public clones could be further explored for 
their practical utility. For example, we could test for the ability of the public Vλ clone to 
pair with unrelated heavy chains that can still retain specificity. If these widely “pair-
able” Vλ clones were identified, they might prove to be good “structural stabilizer” that 
can pair with any heavy chains lacking native pairing information. Finally, having a more 
precise quantification and correlation of the antibody transcript abundance to clonal cell 
count can enhance the practical reach of the antibody repertoire data. This would be 
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particularly useful for diagnosis or cancerous cell tracking for leukemia and other B cell 
diseases. However, cell quantification relies on the elucidation of the relationship 
between transcript level and cell numbers. To obtain a solution with the current NGS 
technology, a standard calibrator that can report a run-to-run amplification difference 
might be a critical first step. The calibrator should be spiked-in to each sequencing 
sample such that a reference of transcript-to-cell ratio can be reliably obtained from each 
sequencing experiment. Two pieces of information is necessary for the construction of a 
standard calibrator: a. the relationship between cell numbers and the antibody transcripts; 
b. careful calibrator sequence design to minimize amplification bias. We have started 
some preliminary works on identifying the amount of IgM transcripts generated by 
human naïve B cells using quantitative PCR (qPCR). And, the regression line associating 
the naïve B cell number to qPCR cycle number (Ct) is shown in Figure 37. Together with 
the regression line associating the IgM transcript amount in ng to qPCR cycle number 
(Ct) as shown in Figure 38, we were able to derive a preliminary relationship between the 
cell numbers to the amount of IgM transcript the cells produce. The equation is: log(RNA 
in ng) = 0.892 x log(Cell numbers) – 8.07. As a result, it is estimated that 100 human 
naïve B cells can generate about 1 fg (1x10-12 g) of IgM transcript. There is still more 
work needed to better characterize amplification bias for the construction of the calibrator 
sequence. Once this critical piece of information is ascertained, the absolute 
quantification of clonal cells could be adjusted and normalized based on the spiked-in 
standard calibrator. Despite the many directions that can expand the reach of NGS 
technology, all in all, NGS technology has thus far granted us an unprecedented ability to 




Figure 37: Regression line for Human naïve B cell number to qPCR cycle number (Ct) 




Figure 38: Regression line for IgM transcript in ng to qPCR cycle number (Ct) 








HUMAN IGM CDNA CONSTRUCT  
 1 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
 61 tcctgtacag cctctggatt cacctttagc acctatggca tgagctgggt ccgccaggct 
 121 ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag cacatattac 
 181 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 
 241 ctgcaaatga acagcctgag agccgaggac acggccgtct attactgtgc tgcagcccca 
 301 agacatgcgg ggagtccacc ttatgactac tggggccaag gaacccttgt caccgtctcc 
 361 tcagggagtg catccgcccc aacccttttc cccctcgtct cctgtgagaa ttccccgtcg 
 421 gatacgagca gcgtggccgt tggctgcctc gcacaggact tccttcccga ctccatcact 
 481 ttctcctgga aatacaagaa caactctgac atcagcagca cccggggctt cccatcagtc 
 541 ctgagagggg gcaagtacgc agccacctca caggtgctgc tgccttccaa ggacgtcatg 
 601 cagggcacag acgaacacgt ggtgtgcaaa gtccagcacc ccaacggcaa caaagaaaag 
 661 aacgtgcctc ttccagtgat tgccgagctg cctcccaaag tgagcgtctt cgtcccaccc 
 721 cgcgacggct tcttcggcaa cccccgcaag tccaagctca tctgccaggc cacgggtttc 
 781 agtccccggc agattcaggt gtcctggctg cgcgagggga agcaggtggg gtctggcgtc 
 841 accacggacc aggtgcaggc tgaggccaaa gagtctgggc ccacgaccta caaggtgacc 
 901 agcacactga ccatcaaaga gagcgactgg ctcagccaga gcatgttcac ctgccgcgtg 
 961 gatcacaggg gcctgacctt ccagcagaat gcgtcctcca tgtgtgtccc cgatcaagac 
 1021 acagccatcc gggtcttcgc catcccccca tcctttgcca gcatcttcct caccaagtcc 
 1081 accaagttga cctgcctggt cacagacctg accacctatg acagcgtgac catctcctgg 
 1141 acccgccaga atggcgaagc tgtgaaaacc cacaccaaca tctccgagag ccaccccaat 
 1201 gccactttca gcgccgtggg tgaggccagc atctgcgagg atgactggaa ttccggggag 
 1261 aggttcacgt gcaccgtgac ccacacagac ctgccctcgc cactgaagca gaccatctcc 
 1321 cggcccaagg gggtggccct gcacaggccc gatgtctact tgctgccacc agcccgggag 
 1381 cagctgaacc tgcgggagtc ggccaccatc acgtgcctgg tgacgggctt ctctcccgcg 
 1441 gacgtcttcg tgcagtggat gcagaggggg cagcccttgt ccccggagaa gtatgtgacc 
 1501 agcgccccaa tgcctgagcc ccaggcccca ggccggtact tcgcccacag catcctgacc 
 1561 gtgtccgaag aggaatggaa cacgggggag acctacacct gcgtggtggc ccatgaggcc 
 1621 ctgcccaaca gggtcaccga gaggaccgtg gacaagtcca ccggtaaacc caccctgtac 
 1681 aacgtgtccc tggtcatgtc cgacacagct ggcacctgct actgaccctg ctggcctgcc 
 1741 cacaggctcg gggcggctgg ccgctctgtg tgtgcatgca aactaacccg tgtcaacggg 







CDR3 MOTIF SEARCH (PERL)  
#! /usr/bin/perl 
# This scripts can extract from antibody FASTA file for CDR3 stats, generate top 
specified number of CDR3 FASTA for candidate selection 
 
## ask how many top ranked sequences to be reported  
print "Enter the number of top ranked FASTA files needed (for consensus): "; 
chomp($topnum = <STDIN>); 
 
## Extract FASTA file 
$infile=$ARGV[0]; 
open (InFile, $infile) or die "Error opening $infile !\n";  




$i = -1; 
while ($line=<InFile>) { 
 if (($line =~ m/^>/)||($line =~ m/^#/)){  
 $newcheck = 1; $i++; $label[$i]=$line;}  
 else { 
 $line =~ s{[\W\d_]}{}g; chomp($line);  
 if ($newcheck == 1) {$SEQ[$i] = $line;} 
 else {$SEQ[$i] = $SEQ[$i].$line;} 




$size = @SEQ; 
$num50 = 0; $num100 = 0; $num150 = 0; $num200 = 0; 
$num250 = 0; $num300 = 0; $num350 = 0; $num400 = 0;  
$num401 = 0; 
$j = 0; 
$lenmax = 0; 
$sum = 0; 
foreach (@SEQ) { 
 $len=length($_);  
 if ($len>$lenmax) {$lenmax=$len;} 
 $sum=$sum+$len;  
 $j++;  
 if ($len<=50) {$num50++;} 




 elsif ($len<=150) {$num150++;} 
 elsif ($len<=200) {$num200++;} 
 elsif ($len<=250) {$num250++;} 
 elsif ($len<=300) {$num300++;} 
 elsif ($len<=350) {$num350++;} 
 elsif ($len<=400) {$num400++;} 
 else {$num401++;} 
 }  
 
print OutFileDist "sum = $sum, \t average = ",$sum/$size, "\n";  
print OutFileDist "total no. of seq = ", 
$num50+$num100+$num150+$num200+$num250+$num300+$num350+$num400+$nu
m401, "\n";  
print OutFileDist "Max length = $lenmax \n"; 
print OutFileDist "\nSeq length\tCount\tPercentage\n"; 
print OutFileDist "\n 1- 50:\t", $num50, "\t", $num50/$size*100;  
print OutFileDist "\n 51-100:\t", $num100, "\t", $num100/$size*100;  
print OutFileDist "\n100-150:\t", $num150, "\t", $num150/$size*100;  
print OutFileDist "\n151-200:\t", $num200, "\t", $num200/$size*100;  
print OutFileDist "\n201-250:\t", $num250, "\t", $num250/$size*100;  
print OutFileDist "\n251-300:\t", $num300, "\t", $num300/$size*100;  
print OutFileDist "\n300-350:\t", $num350, "\t", $num350/$size*100;  
print OutFileDist "\n351-400:\t", $num400, "\t", $num400/$size*100;  





## motif search 
## Note: Z means stop 
%base2aa = ("AAA" => "K", "AAC" => "N", "AAG" => "K", "AAT" => "N", "ACA" 
=> "T", "ACC" => "T", "ACG" => "T", "ACT" => "T", "AGA" => "R", "AGC" => "S", 
"AGG" => "R", "AGT" => "S", "ATA" => "I", "ATC" => "I", "ATG" => "M", "ATT" 
=> "I", "CAA" => "Q", "CAC" => "H", "CAG" => "Q", "CAT" => "H", "CCA" => "P", 
"CCC" => "P", "CCG" => "P", "CCT" => "P", "CGA" => "R", "CGC" => "R", "CGG" 
=> "R", "CGT" => "R", "CTA" => "L", "CTC" => "L", "CTG" => "L", "CTT" => "L", 
"GAA" => "E", "GAC" => "D", "GAG" => "E", "GAT" => "D", "GCA" => "A", "GCC" 
=> "A", "GCG" => "A", "GCT" => "A", "GGA" => "G", "GGC" => "G", "GGG" => 
"G", "GGT" => "G", "GTA" => "V", "GTC" => "V", "GTG" => "V", "GTT" => "V", 
"TAA" => "Z", "TAC" => "Y", "TAG" => "Z", "TAT" => "Y", "TCA" => "S", "TCC" 
=> "S", "TCG" => "S", "TCT" => "S", "TGA" => "Z", "TGC" => "C", "TGG" => "W", 





open OutFile_CDRH3, ">$infile".'_CDR3H.txt' or die $!;  
open OutFile_VHFNA, ">$infile-VH.fna" or die $!; 
open OutFile_CDRL3, ">$infile".'_CDR3L.txt' or die $!; 
open OutFile_VLFNA, ">$infile-VL.fna" or die $!; 
 
for ($i=0 ; $i<$size; $i++) { 
 $current = $SEQ[$i]; chomp $current; 
 $current_r = $current;  
 $current_r =~ tr/ACGT[]/TGCA][/; $current_r = reverse($current_r); 
 $len=length($current);  
 
 @cdna[1]=""; @cdna[2]=""; @cdna[3]=""; @cdna[4]=""; @cdna[5]=""; @cdna[6]=""; 
 @AA[1]=""; $cdna[1] = substr ($current, 0); for ($j=0; $j<$len; $j=$j+3) {$triplet = 
substr ($current, $j, 3); if ($triplet =~ "N") {$aa="X";} else {$aa=$base2aa{$triplet};} 
@AA[1]=@AA[1].$aa;} 
 @AA[2]=""; $cdna[2] = substr ($current, 1); for ($j=1; $j<$len; $j=$j+3) {$triplet = 
substr ($current, $j, 3); if ($triplet =~ "N") {$aa="X";} else {$aa=$base2aa{$triplet};} 
@AA[2]=@AA[2].$aa;} 
 @AA[3]=""; $cdna[3] = substr ($current, 2); for ($j=2; $j<$len; $j=$j+3) {$triplet = 
substr ($current, $j, 3); if ($triplet =~ "N") {$aa="X";} else {$aa=$base2aa{$triplet};} 
@AA[3]=@AA[3].$aa;} 
 @AA[4]=""; $cdna[4] = substr ($current_r, 0); for ($j=0; $j<$len; $j=$j+3) {$triplet = 
substr ($current_r, $j, 3); if ($triplet =~ "N") {$aa="X";} else {$aa=$base2aa{$triplet};} 
@AA[4]=@AA[4].$aa;} 
 @AA[5]=""; $cdna[5] = substr ($current_r, 1); for ($j=1; $j<$len; $j=$j+3) {$triplet = 
substr ($current_r, $j, 3); if ($triplet =~ "N") {$aa="X";} else {$aa=$base2aa{$triplet};} 
@AA[5]=@AA[5].$aa;} 
 @AA[6]=""; $cdna[6] = substr ($current_r, 2); for ($j=2; $j<$len; $j=$j+3) {$triplet = 
substr ($current_r, $j, 3); if ($triplet =~ "N") {$aa="X";} else {$aa=$base2aa{$triplet};} 
@AA[6]=@AA[6].$aa;} 
 
## setting the motif for the motif probability  
 $max_P_H1=1e-99; $max_P_L1=1e-99; $max_P_H2=1e-99; $max_P_L2=1e-99;  
 for ($j=1; $j<=6; $j++) 
 {$current_AA=@AA[$j]; $len_AA=length ($current_AA); 
if ($len_AA <10) 
{$best_segment_H1="BLANK";$best_segment_L1="BLANK";$best_segment_H2="BL
ANK";$best_segment_L2="BLANK";} 
else {for ($k=0; $k<($len_AA-10); $k++)   





  for ($kk=0; $kk<10; $kk++) {$m[$kk+1] = substr ($segment,$kk,1);} 
    
  if ($m[1] eq "E") {$p_H=0.85;} elsif ($m[1] eq "D") {$p_H=0.08;} else 
{$p_H=0.07/18;}  
  if ($m[1] eq "E") {$p_L=0.90;} elsif ($m[1] eq "D") {$p_L=0.05;} else 
{$p_L=0.05/18;}   
  
  if ($m[2] eq "D") {$p_H=$p_H*0.98;} else {$p_H=$p_H*0.02/19;}  
  if ($m[2] eq "D") {$p_L=$p_L*0.98;} else {$p_L=$p_L*0.02/19;}  
 
  if ($m[6] eq "Y") {$p_H=$p_H*0.97;} elsif ($m[6] eq "F") 
{$p_H=$p_H*0.01;} else {$p_H=$p_H*0.02/18;}  
  if ($m[6] eq "Y") {$p_L=$p_L*0.95;} else {$p_L=$p_L*0.05/19;}  
 
  if ($m[7] eq "Y") {$p_H=$p_H*0.80;} elsif ($m[7] eq "F") 
{$p_H=$p_H*0.18;} else {$p_H=$p_H*0.02/18;}  
  if ($m[7] eq "Y") {$p_L=$p_L*0.70;} elsif ($m[7] eq "F") 
{$p_L=$p_L*0.25;} else {$p_L=$p_L*0.05/18;}  
   
  if ($m[8] eq "C") {$p_H=$p_H*0.99;} else {$p_H=$p_H*0.01/19;}  
  if ($m[8] eq "C") {$p_L=$p_L*0.98;} else {$p_L=$p_L*0.02/19;}  
 
  if ($m[9] eq "A") {$p_H=$p_H*0.80;} elsif ($m[9] eq "T") 
{$p_H=$p_H*0.08;} elsif ($m[9] eq "V") {$p_H=$p_H*0.04;} else 
{$p_H=$p_H*0.08/17;}  
  if ($m[9] eq "Q") {$p_L=$p_L*0.50;} elsif ($m[9] eq "H") 
{$p_L=$p_L*0.10;} elsif (($m[9] eq "A") or ($m[9] eq "L") or ($m[9] eq "F") or ($m[9] 
eq "S")) {$p_L=$p_L*0.05;} else {$p_L=$p_L*0.20/14;}  
  
  if ($m[10] eq "R") {$p_H=$p_H*0.80;} else {$p_H=$p_H*0.20/19;}  
  if ($m[10] eq "Q") {$p_L=$p_L*0.80;} elsif ($m[10] eq "H") 




  if ($p_H>$max_P_H1) {$max_P_H1=$p_H; 
$best_segment_H1=$segment; $loc1_H1=$j; $loc2_H1=$k; }  
  if ($p_L>$max_P_L1) {$max_P_L1=$p_L; 
$best_segment_L1=$segment; $loc1_L1=$j; $loc2_L1=$k; }  
   }  
 




for ($k=0; $k<($len_AA-6); $k++)   
   {$segment = substr ($current_AA, $k, 6); $p_H=1e-99; $p_L=1e-99; 
  
  for ($kk=0; $kk<6; $kk++) {$m[$kk+1] = substr ($segment,$kk,1);} 
    
  if ($m[1] eq "Y") {$p_H=0.75;} elsif ($m[1] eq "V") {$p_H=0.10;} else 
{$p_H=0.15/18;} 
  if ($m[1] eq "T") {$p_L=0.92;} elsif ($m[1] eq "V") {$p_L=0.05;} else 
{$p_L=0.03/18;} 
  
  if ($m[2] eq "W") {$p_H=$p_H*0.99;} else {$p_H=$p_H*0.01/19;}  
  if ($m[2] eq "F") {$p_L=$p_L*0.99;} else {$p_L=$p_L*0.01/19;} 
 
  if ($m[3] eq "G") {$p_H=$p_H*0.98;$p_L=$p_L*0.99;} else 
{$p_H=$p_H*0.02/19;$p_L=$p_L*0.01/19;}  
 
  if ($m[4] eq "Q") {$p_H=$p_H*0.80;} elsif ($m[4] eq "A") 
{$p_H=$p_H*0.08;} elsif ($m[4] eq "T") {$p_H=$p_H*0.04;} else 
{$p_H=$p_H*0.08/17;}  
  if ($m[4] eq "G") {$p_L=$p_L*0.55;} elsif ($m[4] eq "A") 
{$p_L=$p_L*0.25;} elsif ($m[4] eq "S") {$p_L=$p_L*0.10;} else 
{$p_L=$p_L*0.10/17;}   
  
  if ($m[5] eq "G") {$p_H=$p_H*0.99;$p_L=$p_L*0.98;} else 
{$p_H=$p_H*0.01/19;$p_L=$p_L*0.02/19;}  
 
  if ($m[6] eq "T") {$p_H=$p_H*0.98; $p_L=$p_L*0.98;} else 
{$p_H=$p_H*0.02/19;$p_L=$p_L*0.02/19;}  
  
  if ($p_H>$max_P_H2) {$max_P_H2=$p_H; 
$best_segment_H2=$segment; $loc1_H2=$j; $loc2_H2=$k; }  
  if ($p_L>$max_P_L2) {$max_P_L2=$p_L; 
$best_segment_L2=$segment; $loc1_L2=$j; $loc2_L2=$k; }  






if ((($max_P_L1*$max_P_L2>1e-10) or ($max_P_L1>1e-3) or (($max_P_L1>1e-7) and 





 {print OutFile_CDRL3 substr(@AA[$loc1_L1], $loc2_L1+8, $loc2_L2-
$loc2_L1-8+1), "\t", @cdna[$loc1_L1], "\n";  
 #print OutFile_L $best_segment_L1, "\t", $best_segment_L2, "\t", 
@AA[$loc1_L1], "\n";  
 print $i, "\t\t", $best_segment_L1, "\t", $best_segment_L2, "\n";  
 $flag++; 
 print OutFile_VLFNA "$label[$i]$SEQ[$i]\n";} 
elsif ((($max_P_H1*$max_P_H2>1e-11) or ($max_P_H1>1e-4) or (($max_P_H1>1e-7) 
and ($max_P_H2>1e-5))) and ($max_P_L2<1e-5) and ($loc1_H1 == $loc1_H2) and 
($loc2_H1<$loc2_H2))  
 {print OutFile_CDRH3 substr(@AA[$loc1_H1], $loc2_H1+8, $loc2_H2-
$loc2_H1-8+1), "\t", @cdna[$loc1_H1], "\n";  
 #print OutFile_H $best_segment_H1, "\t", $best_segment_H2, "\t", 
@AA[$loc1_H1], "\n";  
 print $i, "\t", $best_segment_H1, "\t", $best_segment_H2, "\n";  
 $flag++; 
 print OutFile_VHFNA "$label[$i]$SEQ[$i]\n";}  
#if ($flag==0) {print OutFile_Junk $current, "\n";} 















open(InFile3L, $infile3L) or die $!; 
open(InFile3H, $infile3H) or die $!;  
open OutFile3L, ">$infile".'_CDR3L_UNIQUE.txt' or die $!; 
open OutFile3H, ">$infile".'_CDR3H_UNIQUE.txt' or die $!; 
 
while (my $line=<InFile3L>)  
{ 
chomp($line); 






while (my $line=<InFile3H>)  
{ 
chomp($line); 




map {$count3L{$_}++} @CDR3L; 




map {$count3H{$_}++} @CDR3H; 







@a=`sort -t $\'\t\' -k2 -nr $uniqueLfile`; 
open OutFile3L, ">$infile".'_CDR3L_UNIQUE.txt' or die $!; 
print OutFile3L @a; 
$uniqueHfile="$infile".'_CDR3H_UNIQUE.txt'; 
@b=`sort -t $\'\t\' -k2 -nr $uniqueHfile`; 
open OutFile3H, ">$infile".'_CDR3H_UNIQUE.txt' or die $!; 








## Generate FASTA files for the top specified ranked sequences on VL and VH 
## These files can be used for multiple sequence alignments 











open(InFile3L1, "$infile".'_CDR3L_UNIQUE.txt') or die $!; 
open(InFile3L2, "$infile".'_CDR3L.txt') or die $!; 
open(InFile3H1, "$infile".'_CDR3H_UNIQUE.txt') or die $!; 
open(InFile3H2, "$infile".'_CDR3H.txt') or die $!; 
 
for (my $i=0; $i<$topnum; $i++) 
{ 
 my $line1=<InFile3L1>; 
 chomp($line1); 
 if ($line1 =~ m/^(.*)\s\t/) {push(@topL,$1);} 
} 
 
while (my $line2=<InFile3L2>)  
{ 
 chomp($line2); 




for (my $i=0; $i<$topnum; $i++) 
{ 
my $n=$i+1; 
open OutFileL, ">$n-$infile-VL-$topL[$i].fna" or die $!; 
my $num=0; 
for (my $j=0; $j<=$size; $j++) 
{ 








for (my $i=0; $i<$topnum; $i++) 
{ 





 if ($line1 =~ m/^(.*)\s\t/) {push(@topH,$1);} 
} 
 
while (my $line2=<InFile3H2>)  
{ 
 chomp($line2); 




for (my $i=0; $i<$topnum; $i++) 
{ 
my $n=$i+1; 
open OutFileH, ">$n-$infile-VH-$topH[$i].fna" or die $!; 
my $num=0; 
for (my $j=0; $j<=$size; $j++) 
{ 















GENE CONVERSION (PERL) 
#! /usr/bin/perl 
# This is a script for identifying the best stretch of a query sequence that is of gene 
conversion in rabbit (comparing sequences between IGHV1S40 vs other GC reference 
donors) 
# Note: please update the reference name to match your IgBlast reference gene name in 
the results file. i.e. replace IGHV1S40 with any name that is your base reference genes 
# IgBlast command example (assuming blastDB for the reference gene made): igblastn -
germline_db_V ./rabbit/ref -germline_db_D ./database/human_gl_D -germline_db_J 
./database/human_gl_J -query 1S40seqs_untagged.fna -domain_system imgt -outfmt 3 -
num_alignments_V 47 > results.txt 
# Usage: perl igblast_geneconv.pl igblast-results.txt 
 
use List::MoreUtils 'pairwise'; 
use List::MoreUtils 'firstidx'; 




$infile =~ /(.+)\.txt/; 
$filename=$1; 
open(InFile,$infile) or die "Error opening $infile !\n"; 
open(OutFile,">$filename-scores.txt") or die $!; 







while ($line=<InFile>) { 
 chomp($line); 
  
 if ($line =~ /Query= (.+)/) { 
  $queryname=$1; 
  %ref=(); 
  %refori=(); 
  $sectioncnt=0; 
  %lastsection=(); 
  $printchk=0; 






 # Sectioning is used for accommodating reference sequence (esp. pseudogenes) 
where alignments do not come in until mid-query sequence... 
 if ($line =~ /Query_/) {$sectioncnt++;} 
  
 if ($line =~ /^V\s\s/) { 
  @tmp=split(/\s/,$line); 
  $n=-1; 
  foreach $i (@tmp) { 
   if ($i ne '') { 
     $n++; 
     if ($n==3) {$current=$i;} 
     if ($n==5) {$currentseq=$i;} 
   } 
  } 
   
  if ($current eq $lastname) {next;} 
   
  # The section checking is to ensure proper gapping if the reference aligns 
at mid-query sequence 
  if (($sectioncnt-$lastsection{$current})>1) 
{$refori{$current}=$refori{$current}.'-'x(($sectioncnt-$lastsection{$current}-
1)*70).$currentseq;} 
  else {$refori{$current}=$refori{$current}.$currentseq;} 
  $currentseq =~ tr/\./1/;  
  $currentseq =~ tr/[ATGC-]/0/;  
  if (($sectioncnt-$lastsection{$current})>1) 
{$ref{$current}=$ref{$current}.'0'x(($sectioncnt-$lastsection{$current}-
1)*70).$currentseq;} 
  else {$ref{$current}=$ref{$current}.$currentseq;} 
  $lastsection{$current}=$sectioncnt; 
  $lastname=$current; 
 } 
  
 if (($line =~ /^D\s\s/) && ($printchk==0)) { 
  @arr2=split(//,$ref{$refname}); 
  map { 
   $key=$_; 
   if ($key ne $refname) { 
    @arr1=split(//,$ref{$key}); 
    @score=pairwise{$a-$b} @arr1,@arr2; 




    $startpos=0; 
    $pos=-1; 
    $maxscore=0; 
    $terminatechk=0; 
    foreach $i (@score) { 
    $pos++; 
    $sum=$sum+$i; 
    if ($sum > $maxscore) {$maxscore=$sum;$chk=1;} 
    # $i=1 means matching the non-based ref and $i=-1 means 
matching the based ref 
    if ($i == 1) {$terminatechk=0;} 
    if ($i == -1) { 
     if ($terminatechk==0) {$spcfinalend=$pos-1;} 
     $terminatechk++; 
    } 
    if (($i == -1 && $sum <=1) || $pos+1==@score) { 
     $sum=0; 
     if ($chk==1) { 
      $finalstart=$startpos; 
      if ($terminatechk > 1) 
{$finalend=$spcfinalend;} 
      else {$finalend=$pos-1;} 
      $chk=0; 
     } 
     $startpos=$pos+1; 
    } 
    } 
    if ($maxscore > 1) { 
    $base=substr($refori{$refname},$finalstart,$finalend-
$finalstart+1); 
    $winner=substr($refori{$key},$finalstart,$finalend-
$finalstart+1); 
    $basegap=$base=~tr/-/-/; 
    $winnergap=$winner=~tr/-/-/; 
    $shortstart=firstidx {$_ == 1} 
@score[$finalstart..$finalend]; 
    $shortend=lastidx {$_ == 1} 
@score[$finalstart..$finalend]; 
    $shortstart=$finalstart+$shortstart; 




    print OutFile 
"$queryname\t$key\t$maxscore\t$finalstart\t$finalend\t$basegap\t$winnergap\t$shortstar
t\t$shortend\n"; 
    } 
   } 
  } sort keys (%ref); 
  # The printchk here is to prevent multiple output of the results when 
multiple D-gene results were present from the igblast results; 
  # When reports started, printchk will be 1 and will stop generating results 











GENE CONVERSION PERMUTATION (PYTHON) 
#!/usr/bin/python 
#This is a script that processes the gene conversion scores files and IgBlast results to give 
p-values to the scores 
#This will shuffle the nucleotides of the baseref germline and the Gene_Conversion 
germline [trimming about 15 nucleotides from both ends; i.e. the primer regions] 
#Then uses the scoring system to find a score iteratively with the specified number of 
repeats 
#If the score is greater or equal than the current score, it will be counted towards the p-
value for randomly generating a score higher or as high as the one observed 
#Note: the start stop position is based on python index at 0 




from collections import defaultdict 
from random import randrange 




baseref=raw_input("What is your base reference gene (case sensitive)?") 
#This is how many iterations needed to generate the p-values; it can be changed 





with open(sys.argv[1]) as f: 
 for line in f: 
  if "Query\tReference\t" in line: 
   continue 
  line=line.replace("\r\n",'') 
  tmp=line.split("\t") 
  input[tmp[0]]=tmp 










with open(sys.argv[2]) as f: 
 for line in f: 
  #Checking to see whether the section should begin or not by using the 
section flag 
  if section==0: 
   m=re.search(r"Query=\s(.+)",line) 
   if m and (m.group(1) in querylist): 
    query=m.group(1) 
    section=1 #Allowing to begin checking for blocks to be 
extracted 
    proceed=0 #This would be the flag to signal when to start 
extracting sequences 
    tempmat=defaultdict(str) 
    print "Working on %s ..."%query 
  if section==1: 
   tmp=line.split(' ') 
   tmp=[x for x in tmp if x] 
   if 'Query_' in tmp[0]: 
    proceed=1 
   #Check when to start extracting the sequence 
   if 'V' in tmp[0] and proceed==1: 
    if tmp[3]==baseref: 
     tempmat[baseref]+=tmp[5] 
    if tmp[3]==input[query][1]: 
     tempmat[input[query][1]]+=tmp[5] 
   if tmp[0]=='D' or tmp[0]=='J': 
    #Start permutation/shuffling analysis 
    proceed=0 
    #making sure the extracted lengths are the same 
    while 
len(tempmat[baseref])>len(tempmat[input[query][1]]): 
     tempmat[input[query][1]]+='-' 
    while 
len(tempmat[baseref])<len(tempmat[input[query][1]]): 
     tempmat[baseref]+='-' 
    #Trimming the sequences by 15 nucleotides on both ends 
   
 tempmat[baseref]=tempmat[baseref][15:len(tempmat[baseref])-15] 
   
 tempmat[input[query][1]]=tempmat[input[query][1]][15:len(tempmat[input[query
][1]])-15] 




    tempmat[baseref]=re.sub(r'[ATGC-]','0',tempmat[baseref]) 
    tempmat[baseref]=re.sub(r'\.','1',tempmat[baseref]) 
    tempmat[input[query][1]]=re.sub(r'[ATGCN-
]','0',tempmat[input[query][1]]) 
   
 tempmat[input[query][1]]=re.sub(r'\.','1',tempmat[input[query][1]]) 
    scoremat=defaultdict(list) 
    scoremat[baseref]=[int(c) for c in tempmat[baseref]] 
    scoremat[input[query][1]]=[int(c) for c in 
tempmat[input[query][1]]] 
    #Generating the position Numpy array 
    pos=range(len(scoremat[baseref])) 
    pos=np.array(pos) 
    count=0 
    for i in range(iterations): 
     np.random.shuffle(pos) 
     randmat=defaultdict(list) 
     for p in pos: 
     
 randmat[baseref].append(scoremat[baseref][p]) 
     
 randmat[input[query][1]].append(scoremat[input[query][1]][p]) 
     a=np.array(randmat[input[query][1]]) 
     b=np.array(randmat[baseref]) 
     c=a-b 
     sum=0 
     maxscore=0 
     currentpos=-1 
     for s in c: 
      currentpos+=1 
      sum+=s 
      if sum>maxscore: 
       maxscore=sum 
      if (s==-1 and sum<=1) or 
currentpos+1==len(c): 
       sum=0 
     #print "%s\t\t\t%d"%(input[query][2],maxscore) 
     if maxscore>=int(input[query][2]): 
      count+=1 
    for q in range(9): 
     print >>fout,"%s\t"%input[query][q], 




    print >>fout,"%d\t%.6f"%(count,pval) 









SEED-BASED CIRCLE SEQUENCING SAMPLE PROCESSING (PYTHON) 
#!/usr/bin/python 
 
# Note: when generating the k-mer hash table; the primers were used to split the sequence 
into chunks and the chunks were used to build the hash table and no linkage between the 
chunks 
# 
# Note: it generates FASTQ output 
# 
# Function: This program is to process the raw Illumina MiSeq sequences (R1 & R2) 
# using the algorithm similar to the Inchworm Algorithm to re-create the transcript 
#sequence based on repeats 
# 
# Motivation: This is intended to filter out the PCR-mediated recombination problem 
#where short reads were generated within a cluster causing Sequencing Adaptor polluting 
#the read quality in subsequent repeats 
# 
# Output: Fastq file with the quality score expanded, sequence improved by repeats and  
# removed of adaptor contaminants  
# 
# Usage: python kmer-adapt-filter-primer.py [-h] [-k] [-q] MiSeq_R1.fastq 
#MiSeq_R2.fastq 
 
from argparse import ArgumentParser 
from Bio import SeqIO 
from Bio.Alphabet import generic_dna 
from Bio.Seq import Seq 
from collections import defaultdict 




# The following function will process the R1,R2 reads of the sequence 
# to generate the combined kmer hashtables and usage list and quality score hashtables 
# **** Note: The primers were used to split the sequence into chunks and no linkage 
between the chunks 








 # Splitting the sequence into chunks; using the CCS 3' primer to uncouple the 
3'end-5'end linkage 
 inseq1chunks=re.split(r"GTCTCCTGTGAGAATTCCCCGTT",inseq1) 
 if len(inseq1chunks)==1: 
  inseq1chunks=re.split(r"AACGGGGAATTCTCACAGGAGAC",inseq1) 
 # Generate list equivalent of inseq1chunks for the quality scores 
 # Remove leadning or trailing primer exact match 
 if inseq1chunks[0]=='': 
  inqual1=inqual1[23:] 
 if inseq1chunks[-1]=='': 
  inqual1=inqual1[:-23] 
 inseq1chunks=[i for i in inseq1chunks if i != ''] 
 # Start extracting the quality list 
 inqual1chunks=[] 
 for i in inseq1chunks: 
  inqual1chunks.append(inqual1[0:len(i)]) 
  if len(i)+23<=len(inqual1): 
   inqual1=inqual1[len(i)+23:] 
 for n in range(len(inseq1chunks)): 
  inseq1=inseq1chunks[n] 
  inqual1=inqual1chunks[n] 
  while inseq1: 
   if len(inseq1)>=ksize: 
    tempqual=inqual1[0:ksize] 
    # Checking to see if 80% of bases in the kmer is worse than 
the specified error rates 
    # If it is the case, simply bypass that kmer and not store in 
the hashtables 
    #  
    if sum([1 if i > pcutoffs else 0 for i in 
tempqual])>int(ksize*0.80): 
     inseq1=inseq1[1:] 
     inqual1=inqual1[1:] 
    else: 
     seqdict[inseq1[0:ksize]]+=1 
     if inseq1[0:ksize] in qualdict: 
      qualdict[inseq1[0:ksize]]=[a*b for a,b in 
zip(qualdict[inseq1[0:ksize]],tempqual)] 
     else: 
      qualdict[inseq1[0:ksize]]=tempqual 
     inseq1=inseq1[1:] 




   else: 
    break 
  
 # Splitting the sequence into chunks; using the CCS 3' primer to uncouple the 
3'end-5'end linkage 
 inseq2chunks=re.split(r"GTCTCCTGTGAGAATTCCCCGTT",inseq2) 
 if len(inseq2chunks)==1: 
  inseq2chunks=re.split(r"AACGGGGAATTCTCACAGGAGAC",inseq2) 
 # Generate list equivalent of inseq1chunks for the quality scores 
 # Remove leadning or trailing primer exact match 
 if inseq2chunks[0]=='': 
  inqual2=inqual2[23:] 
 if inseq2chunks[-1]=='': 
  inqual2=inqual2[:-23] 
 inseq2chunks=[i for i in inseq2chunks if i != ''] 
 # Start extracting the quality list 
 inqual2chunks=[] 
 for i in inseq2chunks: 
  inqual2chunks.append(inqual2[0:len(i)]) 
  if len(i)+23<=len(inqual2): 
   inqual2=inqual2[len(i)+23:] 
 for n in range(len(inseq2chunks)): 
  inseq2=inseq2chunks[n] 
  inqual2=inqual2chunks[n] 
  while inseq2: 
   if len(inseq2)>=ksize: 
    tempqual=inqual2[0:ksize] 
    if sum([1 if i > pcutoffs else 0 for i in 
tempqual])>int(ksize*0.8): 
     inseq2=inseq2[1:] 
     inqual2=inqual2[1:] 
    else: 
     seqdict[inseq2[0:ksize]]+=1 
     if inseq2[0:ksize] in qualdict: 
      qualdict[inseq2[0:ksize]]=[a*b for a,b in 
zip(qualdict[inseq2[0:ksize]],tempqual)] 
     else: 
      qualdict[inseq2[0:ksize]]=tempqual 
     inseq2=inseq2[1:] 
     inqual2=inqual2[1:] 
   else: 




     seqlist.append(s) 
    return seqdict,seqlist,qualdict 
 
 
# The following function will grow the contig/transcript using seqdict,seqlist,qualdict 







 # Extend right 
 while chk==1: 
  countlist=[0,0,0,0] 
  for n in range(4): 
   if finalseq[-(ksize-1):]+nuclist[n] in seqlist and finalseq[-(ksize-
1):]+nuclist[n] not in usedlist: 
    countlist[n]=seqdict[finalseq[-(ksize-1):]+nuclist[n]] 
    usedlist.append(finalseq[-(ksize-1):]+nuclist[n]) 
  if sum(countlist)==0: 
   chk=0 
  elif countlist.count(max(countlist))>1: 
   maxlist=[] 
   for n in range(4): 
    if countlist[n]==max(countlist): 




  else: 
   qual=qual+[qualdict[finalseq[-(ksize-
1):]+nuclist[countlist.index(max(countlist))]][-1]] 




 # Extend left 
 while chk==1: 
  countlist=[0,0,0,0] 




   if nuclist[n]+finalseq[0:(ksize-1)] in seqlist and 
nuclist[n]+finalseq[0:(ksize-1)] not in usedlist: 
    countlist[n]=seqdict[nuclist[n]+finalseq[0:(ksize-1)]] 
    usedlist.append(nuclist[n]+finalseq[0:(ksize-1)]) 
  if sum(countlist)==0: 
   chk=0 
  elif countlist.count(max(countlist))>1: 
   maxlist=[] 
   for n in range(4): 
    if countlist[n]==max(countlist): 








   finalseq=nuclist[countlist.index(max(countlist))]+finalseq 
 return finalseq,qual 
 
 
# The following function will perform the branch off comparison and return final results 
until cumulative max is found 
# Or, no absolute max is found so contigs growth is terminated [Conservative measure] 






 if extdirection==0: 
  while True: 
   # Build a list of 1 nt extended k-mer from the branches 
   for i in maxlist: 
    for j in range(4): 
     branchlist.append(i+nuclist[j]) 
     branchcount.append(0) 
   for n in range(len(branchlist)): 
    if seed[-(ksize-len(branchlist[n])):]+branchlist[n] in seqlist 




     branchcount[n]=seqdict[seed[-(ksize-
len(branchlist[n])):]+branchlist[n]] 
     usedlist.append(seed[-(ksize-
len(branchlist[n])):]+branchlist[n]) 
   # If no matching k-mer found, report previously found seed as 
finalseq 
   if sum(branchcount)==0: 
    finalseq=seed 
    qual=seedqual 
    return finalseq,usedlist,qual 
   elif branchcount.count(max(branchcount))>1: 
    passmaxlist=[] 
    for n in range(len(branchcount)): 
     if branchcount[n]==max(branchcount): 
      passmaxlist.append(branchlist[n]) 
    # Loop back with updated maxlist and reset the branches 
variables 
    maxlist=passmaxlist 
    branchlist=[] 
    branchcount=[] 
   else: 
    # Report values when absolute max is found 
   
 lenextend=len(branchlist[branchcount.index(max(branchcount))]) 
    # Note the quality of the extension should be a list already; 
therefore no need to convert it to list as in the single extension case 
    qual=seedqual+qualdict[seed[-(ksize-
lenextend):]+branchlist[branchcount.index(max(branchcount))]][-lenextend:] 
   
 finalseq=seed+branchlist[branchcount.index(max(branchcount))] 
    return finalseq,usedlist,qual 
 
 if extdirection==1: 
  while True: 
   for i in maxlist: 
    for j in range(4): 
     branchlist.append(nuclist[j]+i) 
     branchcount.append(0) 
   for n in range(len(branchlist)): 
    if branchlist[n]+seed[0:(ksize-len(branchlist[n]))] in seqlist 




    
 branchcount[n]=seqdict[branchlist[n]+seed[0:(ksize-len(branchlist[n]))]] 
     usedlist.append(branchlist[n]+seed[0:(ksize-
len(branchlist[n]))]) 
   if sum(branchcount)==0: 
    finalseq=seed 
    qual=seedqual 
    return finalseq,usedlist,qual 
   elif branchcount.count(max(branchcount))>1: 
    passmaxlist=[] 
    for n in range(len(branchcount)): 
     if branchcount[n]==max(branchcount): 
      passmaxlist.append(branchlist[n]) 
    maxlist=passmaxlist 
    branchlist=[] 
    branchcount=[] 
   else: 
   
 lenextend=len(branchlist[branchcount.index(max(branchcount))]) 
   
 qual=qualdict[branchlist[branchcount.index(max(branchcount))]+seed[0:(ksize-
lenextend)]][0:lenextend]+seedqual 
   
 finalseq=branchlist[branchcount.index(max(branchcount))]+seed 





# Main function starts here # 
############################# 
 
# Arguments parsing 
parser=ArgumentParser() 
parser.add_argument("-k","--kmersize",type=int,default=11,help='k-mer size (Default: 
11; Recommend odd kmer)') 
parser.add_argument("-q","--qscoremin",type=int,default=1,help='Quality score minimal 
for 4/5 of bases to be considered a k-mer (Default: 1; Essentially imposing no 
thredshold)') 
parser.add_argument("R1",help='Illumina R1 fastq reads (.fastq)') 
































 r2qual=r2qual[::-1] # reversing the order of quality score to match the reverse 
complemented sequence 
 # convert the phred score to probability 
 r1qual=[10**-(i*1.0/10) for i in r1qual] 
 r2qual=[10**-(i*1.0/10) for i in r2qual] 
 # Filtering out short reads 
 if len(r1seq)<4*ksize or len(r2seq)<4*ksize: 
  continue 
 seqdict,seqlist,qualdict=process_seq(r1seq,r2seq,r1qual,r2qual) 
 # Provide proper error message if quality score was set too high resulting in no 
qualified kmer list 
 if len(seqlist)==0: 
  #sys.exit("ERROR: The minimal quality score is too strict! No kmer is 
qualifiied.") 




  continue 
 finalseq,qual=extend_seq(seqdict,seqlist,qualdict) 
 # Convert P to quality score then to ASCII code Illumina V1.8 (Ascii based 33) 
 # Limiting quality score to max out at 93 ASCII code is '~' 
 qual=[chr(int(-10*log10(i)+33)) if i>5.1e-10 else '~' for i in qual] 
 qual=''.join(qual) 
 print >>fout,"@%s\n%s\n+\n%s"%(seqheader,finalseq,qual) 
 totlen+=len(finalseq) 
 
# Reporting some basic info 
fout2=open("%s-k%dq%d-log.txt"%(filename,ksize,args.qscoremin),"w") 
print >>fout2,"Total number of sequences analyzed: %d"%seqcount 
print >>fout2,"Average length: %.4f"%((totlen*1.0)/seqcount) 
print >>fout2,"Number of sequences discarded due to strict requirements: 
%d"%unbuiltseq 
 










LIST OF ADDITIONAL SCRIPTS 
 
Due to the limited space in this dissertation, the list below describes some more scripts 
created for most projects throughout author’s graduate program. Please send request to 
author for these scripts. Note: this is not a complete list and please contact author as other 
practical scripts might have been created that can serve your needs in handling NGS data 
or visualization purposes. Also, some scripts were deposited on Appsoma.com under the 
tag Immunogrep. 
 
Data I/O /pre-processing/data conversion: 
 
- Split FASTA: splitting FASTA file into batches of different number of sequences 
 
- Split FASTQ: splitting FASTQ file into batches of different number of sequences 
 
- FASTQ to FASTA: converting FASTQ format into FASTA format 
 




- IMGT parsing scripts: various versions that transform IMGT outputs into unique 
antibody output 
 
- Clonotype: combining Usearch program and IMGT V gene assignment for clonotyping 
antibody sequences 
 
- Protease related scripts: analyze enrichment from protease data 
 
- Isotyping script: analyzing antibody sequences to extract and categorize isotypes based 




- Variability plot: tool to process sequencing data and plot the Kabat-Wu variability plot 
 
- Hydropathy plot: tool to process sequencing data and plot the Eisenberg scale 
hydropathy plot 
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